0001944048 12/28 2025 Q3 FALSE P6Y0M0D xbrli:shares iso4217:USD iso4217:USD xbrli:shares kvue:Segment xbrli:pure utr:sqft kvue:transitionService kvue:board_seat 0001944048 2024-12-30 2025-09-28 0001944048 2025-10-28 0001944048 2025-09-28 0001944048 2024-12-29 0001944048 2025-06-30 2025-09-28 0001944048 2024-07-01 2024-09-29 0001944048 2024-01-01 2024-09-29 0001944048 us-gaap:CommonStockMember 2025-06-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2025-06-29 0001944048 us-gaap:TreasuryStockCommonMember 2025-06-29 0001944048 us-gaap:RetainedEarningsMember 2025-06-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-29 0001944048 2025-06-29 0001944048 us-gaap:RetainedEarningsMember 2025-06-30 2025-09-28 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 2025-09-28 0001944048 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 2025-09-28 0001944048 us-gaap:CommonStockMember 2025-06-30 2025-09-28 0001944048 us-gaap:TreasuryStockCommonMember 2025-06-30 2025-09-28 0001944048 us-gaap:CommonStockMember 2025-09-28 0001944048 us-gaap:AdditionalPaidInCapitalMember 2025-09-28 0001944048 us-gaap:TreasuryStockCommonMember 2025-09-28 0001944048 us-gaap:RetainedEarningsMember 2025-09-28 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-28 0001944048 us-gaap:CommonStockMember 2024-06-30 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001944048 us-gaap:TreasuryStockCommonMember 2024-06-30 0001944048 us-gaap:RetainedEarningsMember 2024-06-30 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001944048 2024-06-30 0001944048 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-29 0001944048 us-gaap:CommonStockMember 2024-07-01 2024-09-29 0001944048 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-29 0001944048 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-29 0001944048 us-gaap:CommonStockMember 2024-09-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-09-29 0001944048 us-gaap:TreasuryStockCommonMember 2024-09-29 0001944048 us-gaap:RetainedEarningsMember 2024-09-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-29 0001944048 2024-09-29 0001944048 us-gaap:CommonStockMember 2024-12-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-12-29 0001944048 us-gaap:TreasuryStockCommonMember 2024-12-29 0001944048 us-gaap:RetainedEarningsMember 2024-12-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0001944048 us-gaap:RetainedEarningsMember 2024-12-30 2025-09-28 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-30 2025-09-28 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-12-30 2025-09-28 0001944048 us-gaap:CommonStockMember 2024-12-30 2025-09-28 0001944048 us-gaap:TreasuryStockCommonMember 2024-12-30 2025-09-28 0001944048 us-gaap:CommonStockMember 2023-12-31 0001944048 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001944048 us-gaap:TreasuryStockCommonMember 2023-12-31 0001944048 us-gaap:RetainedEarningsMember 2023-12-31 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001944048 2023-12-31 0001944048 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-29 0001944048 us-gaap:CommonStockMember 2024-01-01 2024-09-29 0001944048 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-29 0001944048 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-29 0001944048 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2024-09-29 0001944048 kvue:CloudComputingArrangementsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2024-09-29 0001944048 kvue:CloudComputingArrangementsMember srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2024-01-01 2024-09-29 0001944048 kvue:Dr.CiLaboAssetImpairmentMember 2024-01-01 2024-09-29 0001944048 kvue:SkillmanFixedAssetImpairmentMember 2024-01-01 2024-09-29 0001944048 kvue:Dr.CiLaboAssetImpairmentMember 2024-04-01 2024-06-30 0001944048 us-gaap:FiniteLivedIntangibleAssetsMember kvue:Dr.CiLaboAssetImpairmentMember 2024-04-01 2024-06-30 0001944048 kvue:Dr.CiLaboAssetImpairmentMember us-gaap:PropertyPlantAndEquipmentMember 2024-04-01 2024-06-30 0001944048 kvue:Dr.CiLaboAssetImpairmentMember 2024-06-30 0001944048 srt:MinimumMember us-gaap:TrademarksMember 2024-06-30 0001944048 srt:MaximumMember us-gaap:TrademarksMember 2024-06-30 0001944048 us-gaap:MeasurementInputDiscountRateMember 2024-06-30 0001944048 kvue:SkillmanFixedAssetImpairmentMember 2024-01-01 2024-03-31 0001944048 2023-04-20 0001944048 kvue:InformationTechnologyAndOtherMember 2025-06-30 2025-09-28 0001944048 kvue:InformationTechnologyAndOtherMember 2024-07-01 2024-09-29 0001944048 kvue:InformationTechnologyAndOtherMember 2024-12-30 2025-09-28 0001944048 kvue:InformationTechnologyAndOtherMember 2024-01-01 2024-09-29 0001944048 kvue:LegalEntityNameChangeMember 2025-06-30 2025-09-28 0001944048 kvue:LegalEntityNameChangeMember 2024-07-01 2024-09-29 0001944048 kvue:LegalEntityNameChangeMember 2024-12-30 2025-09-28 0001944048 kvue:LegalEntityNameChangeMember 2024-01-01 2024-09-29 0001944048 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-09-28 0001944048 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-12-29 0001944048 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-06-30 2025-09-28 0001944048 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-07-01 2024-09-29 0001944048 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-12-30 2025-09-28 0001944048 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-01-01 2024-09-29 0001944048 kvue:NetEconomicBenefitArrangementsMember us-gaap:ParentMember 2025-09-28 0001944048 kvue:NetEconomicBenefitArrangementsMember us-gaap:ParentMember 2024-12-29 0001944048 kvue:NetEconomicBenefitArrangementsMember us-gaap:ParentMember 2025-06-30 2025-09-28 0001944048 kvue:NetEconomicBenefitArrangementsMember us-gaap:ParentMember 2024-07-01 2024-09-29 0001944048 kvue:NetEconomicBenefitArrangementsMember us-gaap:ParentMember 2024-12-30 2025-09-28 0001944048 kvue:NetEconomicBenefitArrangementsMember us-gaap:ParentMember 2024-01-01 2024-09-29 0001944048 kvue:PatentsAndTrademarksMember 2025-09-28 0001944048 kvue:PatentsAndTrademarksMember 2024-12-29 0001944048 us-gaap:CustomerRelationshipsMember 2025-09-28 0001944048 us-gaap:CustomerRelationshipsMember 2024-12-29 0001944048 us-gaap:OtherIntangibleAssetsMember 2025-09-28 0001944048 us-gaap:OtherIntangibleAssetsMember 2024-12-29 0001944048 us-gaap:TrademarksMember 2025-09-28 0001944048 us-gaap:TrademarksMember 2024-12-29 0001944048 us-gaap:OtherIntangibleAssetsMember 2025-09-28 0001944048 us-gaap:OtherIntangibleAssetsMember 2024-12-29 0001944048 us-gaap:FiniteLivedIntangibleAssetsMember kvue:Dr.CiLaboAssetImpairmentMember 2024-01-01 2024-09-29 0001944048 kvue:SelfCareMember 2024-12-29 0001944048 kvue:SkinHealthAndBeautyMember 2024-12-29 0001944048 kvue:EssentialHealthMember 2024-12-29 0001944048 kvue:SelfCareMember 2024-12-30 2025-09-28 0001944048 kvue:SkinHealthAndBeautyMember 2024-12-30 2025-09-28 0001944048 kvue:EssentialHealthMember 2024-12-30 2025-09-28 0001944048 kvue:SelfCareMember 2025-09-28 0001944048 kvue:SkinHealthAndBeautyMember 2025-09-28 0001944048 kvue:EssentialHealthMember 2025-09-28 0001944048 kvue:SkinHealthAndBeautyMember 2025-09-28 0001944048 kvue:A550NotesDue2025Member 2025-09-28 0001944048 kvue:A550NotesDue2025Member 2024-12-29 0001944048 kvue:A535NotesDue2026Member 2025-09-28 0001944048 kvue:A535NotesDue2026Member 2024-12-29 0001944048 kvue:A505NotesDue2028Member 2025-09-28 0001944048 kvue:A505NotesDue2028Member 2024-12-29 0001944048 kvue:A500NotesDue2030Member 2025-09-28 0001944048 kvue:A500NotesDue2030Member 2024-12-29 0001944048 kvue:A4.85NotesDue2032Member 2025-09-28 0001944048 kvue:A4.85NotesDue2032Member 2024-12-29 0001944048 kvue:A490NotesDue2033Member 2025-09-28 0001944048 kvue:A490NotesDue2033Member 2024-12-29 0001944048 kvue:A510NotesDue2043Member 2025-09-28 0001944048 kvue:A510NotesDue2043Member 2024-12-29 0001944048 kvue:A505NotesDue2053Member 2025-09-28 0001944048 kvue:A505NotesDue2053Member 2024-12-29 0001944048 kvue:A520NotesDue2063Member 2025-09-28 0001944048 kvue:A520NotesDue2063Member 2024-12-29 0001944048 us-gaap:OtherDebtSecuritiesMember 2025-09-28 0001944048 us-gaap:OtherDebtSecuritiesMember 2024-12-29 0001944048 kvue:A4.85NotesDue2032Member us-gaap:SeniorNotesMember 2025-05-22 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2025-06-29 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-06-29 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2025-06-29 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2025-06-30 2025-09-28 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-06-30 2025-09-28 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2025-06-30 2025-09-28 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2025-09-28 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-09-28 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2025-09-28 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-30 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2024-06-30 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-01 2024-09-29 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-07-01 2024-09-29 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2024-07-01 2024-09-29 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-29 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-29 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2024-09-29 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-29 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-29 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2024-12-29 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-30 2025-09-28 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-30 2025-09-28 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2024-12-30 2025-09-28 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2023-12-31 0001944048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-29 0001944048 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-09-29 0001944048 kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember 2024-01-01 2024-09-29 0001944048 us-gaap:CostOfSalesMember 2025-06-30 2025-09-28 0001944048 us-gaap:CostOfSalesMember 2024-07-01 2024-09-29 0001944048 us-gaap:CostOfSalesMember 2024-12-30 2025-09-28 0001944048 us-gaap:CostOfSalesMember 2024-01-01 2024-09-29 0001944048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-06-30 2025-09-28 0001944048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-29 0001944048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-12-30 2025-09-28 0001944048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-29 0001944048 kvue:JohnsonJohnsonMember 2025-09-28 0001944048 kvue:JohnsonJohnsonMember 2024-12-29 0001944048 kvue:JohnsonJohnsonMember 2025-06-30 2025-09-28 0001944048 kvue:JohnsonJohnsonMember 2024-07-01 2024-09-29 0001944048 kvue:JohnsonJohnsonMember 2024-12-30 2025-09-28 0001944048 kvue:JohnsonJohnsonMember 2024-01-01 2024-09-29 0001944048 kvue:JohnsonJohnsonMember 2025-04-01 2025-04-30 0001944048 us-gaap:ForeignExchangeContractMember 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0001944048 us-gaap:FairValueInputsLevel1Member 2025-09-28 0001944048 us-gaap:FairValueInputsLevel2Member 2025-09-28 0001944048 us-gaap:FairValueInputsLevel3Member 2025-09-28 0001944048 us-gaap:FairValueInputsLevel1Member 2024-12-29 0001944048 us-gaap:FairValueInputsLevel2Member 2024-12-29 0001944048 us-gaap:FairValueInputsLevel3Member 2024-12-29 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2025-09-28 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2025-09-28 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2025-09-28 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2025-09-28 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-12-29 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0001944048 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0001944048 us-gaap:AccountsPayableMember 2025-09-28 0001944048 us-gaap:AccountsPayableMember us-gaap:FairValueInputsLevel1Member 2025-09-28 0001944048 us-gaap:AccountsPayableMember us-gaap:FairValueInputsLevel2Member 2025-09-28 0001944048 us-gaap:AccountsPayableMember us-gaap:FairValueInputsLevel3Member 2025-09-28 0001944048 us-gaap:AccountsPayableMember 2024-12-29 0001944048 us-gaap:AccountsPayableMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0001944048 us-gaap:AccountsPayableMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0001944048 us-gaap:AccountsPayableMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0001944048 us-gaap:OtherAssetsMember 2025-09-28 0001944048 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member 2025-09-28 0001944048 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member 2025-09-28 0001944048 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member 2025-09-28 0001944048 us-gaap:OtherAssetsMember 2024-12-29 0001944048 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0001944048 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0001944048 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0001944048 us-gaap:OtherLiabilitiesMember 2025-09-28 0001944048 us-gaap:OtherLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2025-09-28 0001944048 us-gaap:OtherLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2025-09-28 0001944048 us-gaap:OtherLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2025-09-28 0001944048 us-gaap:OtherLiabilitiesMember 2024-12-29 0001944048 us-gaap:OtherLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0001944048 us-gaap:OtherLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0001944048 us-gaap:OtherLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-28 0001944048 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-29 0001944048 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2025-09-28 0001944048 us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2024-12-29 0001944048 us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2025-09-28 0001944048 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2024-12-29 0001944048 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-09-28 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2025-09-28 0001944048 us-gaap:NondesignatedMember 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-29 0001944048 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2024-12-29 0001944048 us-gaap:NondesignatedMember 2024-12-29 0001944048 us-gaap:ForeignExchangeContractMember srt:MinimumMember 2024-12-30 2025-09-28 0001944048 us-gaap:ForeignExchangeContractMember srt:MaximumMember 2024-12-30 2025-09-28 0001944048 us-gaap:ForeignExchangeForwardMember 2025-06-30 2025-09-28 0001944048 us-gaap:ForeignExchangeForwardMember 2024-07-01 2024-09-29 0001944048 us-gaap:ForeignExchangeForwardMember 2024-12-30 2025-09-28 0001944048 us-gaap:ForeignExchangeForwardMember 2024-01-01 2024-09-29 0001944048 kvue:NetSalesMember 2025-06-30 2025-09-28 0001944048 kvue:OtherIncomeExpenseNetMember 2025-06-30 2025-09-28 0001944048 kvue:NetSalesMember 2024-07-01 2024-09-29 0001944048 kvue:OtherIncomeExpenseNetMember 2024-07-01 2024-09-29 0001944048 kvue:NetSalesMember 2024-12-30 2025-09-28 0001944048 kvue:OtherIncomeExpenseNetMember 2024-12-30 2025-09-28 0001944048 kvue:NetSalesMember 2024-01-01 2024-09-29 0001944048 kvue:OtherIncomeExpenseNetMember 2024-01-01 2024-09-29 0001944048 us-gaap:InterestRateSwapMember 2024-12-30 2025-09-28 0001944048 us-gaap:CurrencySwapMember 2025-06-30 2025-09-28 0001944048 us-gaap:CurrencySwapMember 2024-07-01 2024-09-29 0001944048 us-gaap:CurrencySwapMember 2024-12-30 2025-09-28 0001944048 us-gaap:CurrencySwapMember 2024-01-01 2024-09-29 0001944048 kvue:CoughColdAndAllergyMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2025-06-30 2025-09-28 0001944048 kvue:CoughColdAndAllergyMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-07-01 2024-09-29 0001944048 kvue:CoughColdAndAllergyMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-12-30 2025-09-28 0001944048 kvue:CoughColdAndAllergyMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-01-01 2024-09-29 0001944048 kvue:PainCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2025-06-30 2025-09-28 0001944048 kvue:PainCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-07-01 2024-09-29 0001944048 kvue:PainCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-12-30 2025-09-28 0001944048 kvue:PainCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-01-01 2024-09-29 0001944048 kvue:OtherSelfCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2025-06-30 2025-09-28 0001944048 kvue:OtherSelfCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-07-01 2024-09-29 0001944048 kvue:OtherSelfCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-12-30 2025-09-28 0001944048 kvue:OtherSelfCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SelfCareMember 2024-01-01 2024-09-29 0001944048 kvue:FaceAndBodyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2025-06-30 2025-09-28 0001944048 kvue:FaceAndBodyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2024-07-01 2024-09-29 0001944048 kvue:FaceAndBodyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2024-12-30 2025-09-28 0001944048 kvue:FaceAndBodyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2024-01-01 2024-09-29 0001944048 kvue:HairSunAndOtherMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2025-06-30 2025-09-28 0001944048 kvue:HairSunAndOtherMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2024-07-01 2024-09-29 0001944048 kvue:HairSunAndOtherMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2024-12-30 2025-09-28 0001944048 kvue:HairSunAndOtherMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:SkinHealthAndBeautyMember 2024-01-01 2024-09-29 0001944048 kvue:OralCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2025-06-30 2025-09-28 0001944048 kvue:OralCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-07-01 2024-09-29 0001944048 kvue:OralCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-12-30 2025-09-28 0001944048 kvue:OralCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-01-01 2024-09-29 0001944048 kvue:BabyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2025-06-30 2025-09-28 0001944048 kvue:BabyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-07-01 2024-09-29 0001944048 kvue:BabyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-12-30 2025-09-28 0001944048 kvue:BabyCareMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-01-01 2024-09-29 0001944048 kvue:OtherEssentialHealthMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2025-06-30 2025-09-28 0001944048 kvue:OtherEssentialHealthMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-07-01 2024-09-29 0001944048 kvue:OtherEssentialHealthMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-12-30 2025-09-28 0001944048 kvue:OtherEssentialHealthMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember kvue:EssentialHealthMember 2024-01-01 2024-09-29 0001944048 kvue:SelfCareMember 2025-06-30 2025-09-28 0001944048 kvue:SkinHealthAndBeautyMember 2025-06-30 2025-09-28 0001944048 kvue:EssentialHealthMember 2025-06-30 2025-09-28 0001944048 kvue:SelfCareMember 2024-07-01 2024-09-29 0001944048 kvue:SkinHealthAndBeautyMember 2024-07-01 2024-09-29 0001944048 kvue:EssentialHealthMember 2024-07-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember kvue:SelfCareMember 2025-06-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember kvue:SkinHealthAndBeautyMember 2025-06-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember kvue:EssentialHealthMember 2025-06-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember 2025-06-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember kvue:SelfCareMember 2024-07-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember kvue:SkinHealthAndBeautyMember 2024-07-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember kvue:EssentialHealthMember 2024-07-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember 2024-07-01 2024-09-29 0001944048 kvue:SelfCareMember 2024-01-01 2024-09-29 0001944048 kvue:SkinHealthAndBeautyMember 2024-01-01 2024-09-29 0001944048 kvue:EssentialHealthMember 2024-01-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember kvue:SelfCareMember 2024-12-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember kvue:SkinHealthAndBeautyMember 2024-12-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember kvue:EssentialHealthMember 2024-12-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember 2024-12-30 2025-09-28 0001944048 us-gaap:OperatingSegmentsMember kvue:SelfCareMember 2024-01-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember kvue:SkinHealthAndBeautyMember 2024-01-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember kvue:EssentialHealthMember 2024-01-01 2024-09-29 0001944048 us-gaap:OperatingSegmentsMember 2024-01-01 2024-09-29 0001944048 2024-04-01 2024-06-30 0001944048 2024-05-06 0001944048 kvue:ITAndProjectRelatedCostsMember 2024-05-06 2024-05-06 0001944048 us-gaap:EmployeeSeveranceMember 2024-05-06 2024-05-06 0001944048 us-gaap:OtherRestructuringMember 2024-05-06 2024-05-06 0001944048 kvue:A2024MultiYearRestructuringInitiativeMember 2025-06-30 2025-09-28 0001944048 kvue:A2024MultiYearRestructuringInitiativeMember 2024-07-01 2024-09-29 0001944048 kvue:A2024MultiYearRestructuringInitiativeMember 2024-12-30 2025-09-28 0001944048 kvue:A2024MultiYearRestructuringInitiativeMember 2024-01-01 2024-09-29 0001944048 us-gaap:EmployeeSeveranceMember kvue:A2024MultiYearRestructuringInitiativeMember 2025-06-30 2025-09-28 0001944048 us-gaap:EmployeeSeveranceMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-07-01 2024-09-29 0001944048 us-gaap:EmployeeSeveranceMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-12-30 2025-09-28 0001944048 us-gaap:EmployeeSeveranceMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-01-01 2024-09-29 0001944048 us-gaap:EmployeeSeveranceMember kvue:A2024MultiYearRestructuringInitiativeMember 2025-09-28 0001944048 kvue:ITAndProjectRelatedCostsMember kvue:A2024MultiYearRestructuringInitiativeMember 2025-06-30 2025-09-28 0001944048 kvue:ITAndProjectRelatedCostsMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-07-01 2024-09-29 0001944048 kvue:ITAndProjectRelatedCostsMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-12-30 2025-09-28 0001944048 kvue:ITAndProjectRelatedCostsMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-01-01 2024-09-29 0001944048 kvue:ITAndProjectRelatedCostsMember kvue:A2024MultiYearRestructuringInitiativeMember 2025-09-28 0001944048 us-gaap:OtherRestructuringMember kvue:A2024MultiYearRestructuringInitiativeMember 2025-06-30 2025-09-28 0001944048 us-gaap:OtherRestructuringMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-07-01 2024-09-29 0001944048 us-gaap:OtherRestructuringMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-12-30 2025-09-28 0001944048 us-gaap:OtherRestructuringMember kvue:A2024MultiYearRestructuringInitiativeMember 2024-01-01 2024-09-29 0001944048 us-gaap:OtherRestructuringMember kvue:A2024MultiYearRestructuringInitiativeMember 2025-09-28 0001944048 kvue:A2024MultiYearRestructuringInitiativeMember 2025-09-28 0001944048 us-gaap:EmployeeSeveranceMember 2024-12-29 0001944048 kvue:ITAndProjectRelatedCostsMember 2024-12-29 0001944048 us-gaap:OtherRestructuringMember 2024-12-29 0001944048 us-gaap:EmployeeSeveranceMember 2024-12-30 2025-09-28 0001944048 kvue:ITAndProjectRelatedCostsMember 2024-12-30 2025-09-28 0001944048 us-gaap:OtherRestructuringMember 2024-12-30 2025-09-28 0001944048 us-gaap:EmployeeSeveranceMember 2025-09-28 0001944048 kvue:ITAndProjectRelatedCostsMember 2025-09-28 0001944048 us-gaap:OtherRestructuringMember 2025-09-28 0001944048 kvue:KenvueInc.Member kvue:KimberlyClarkCorporationMember us-gaap:SubsequentEventMember 2025-11-02 2025-11-02 0001944048 kvue:KenvueInc.Member kvue:KimberlyClarkCorporationMember us-gaap:SubsequentEventMember 2025-11-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☑ |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|  | For the quarterly period ended September 28, 2025

or

☐ |  | TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|  | For the transition period from to

Commission File Number: 001-41697

Kenvue Inc.
(Exact name of registrant as specified in its charter)

Delaware |  | 88-1032011
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

1 Kenvue Way Summit, New Jersey |  | 07901
(Address of principal executive offices) |  | (Zip Code)

(908) 874-1200
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, Par Value $0.01 |  | KVUE |  | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large accelerated filer | ☑ | Accelerated filer | ☐
| Non-accelerated filer | ☐ | Smaller reporting company | ☐
|  |  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No
On October 28, 2025, 1,915,802,170 shares of Common Stock, $0.01 par value, were outstanding.

TABLE OF CONTENTS

|  |  |  | Page
|  |  |  | No.
|  | Cautionary Note Regarding Forward-Looking Statements |  | 3
|  | Part I—Financial Information |  |
Item 1. |  | Financial Statements (unaudited) |  | 5
|  | Condensed Consolidated Balance Sheets |  | 5
|  | Condensed Consolidated Statements of Operations |  | 6
|  | Condensed Consolidated Statements of Comprehensive Income |  | 7
|  | Condensed Consolidated Statements of Stockholders’ Equity |  | 8
|  | Condensed Consolidated Statements of Cash Flows |  | 10
|  | Notes to Condensed Consolidated Financial Statements |  | 11
Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 40
Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 59
Item 4. |  | Controls and Procedures |  | 59
|  | Part II—Other Information |  |
Item 1. |  | Legal Proceedings |  | 60
Item 1A. |  | Risk Factors |  | 60
Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 63
Item 5. |  | Other Information |  | 63
Item 6. |  | Exhibits |  | 64
|  | Signatures |  | 65

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and Kenvue Inc.’s other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives, and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth and cost savings; product development activities; regulatory approvals; market position; expenditures; the effects of the Separation (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Description of the Company and Business Segments,” to the Condensed Consolidated Financial Statements included herein) on our business; and our proposed Transaction (as defined in Note 16, “Subsequent Events,” to the Condensed Consolidated Financial Statements included herein).
As used in this Quarterly Report on Form 10-Q, “Kenvue,” the “Company,” “we,” “us,” “our,” and similar terms include Kenvue Inc. and its subsidiaries, unless the context indicates otherwise.
Because forward-looking statements are based on current beliefs, expectations, and assumptions regarding future events, they are subject to risks, uncertainties, and changes that are difficult to predict and many of which are outside of our control. You should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements. The forward-looking statements in this report, other than the statements regarding the proposed Transaction with Kimberly-Clark, do not assume the consummation of the proposed Transaction unless specifically stated otherwise. Risks and uncertainties include but are not limited to:
•Our ability to expand globally, implement our digital strategy, and respond appropriately to competitive pressure, including from private-label brands and generic non-branded products, market trends, increased costs, and customer and consumer preferences;
•The rapidly changing retail landscape, including our dependence on key retailers, policies of our customers, the emergence of e-commerce and other alternative retail channels, and challenges with innovation and research and development;
•Product reliability, safety, and/or efficacy concerns, whether or not based on scientific or factual evidence, potentially resulting in governmental investigations, regulatory action (including, but not limited to, the shutdown of manufacturing facilities, product relabeling, or withdrawal of product from the market), private claims and lawsuits, significant remediation and related costs, safety alerts, product shortages, product recalls, declining sales, reputational damage, and share price impact;
•The potential that the expected benefits and opportunities from our strategic review process, the 2024 Multi-Year Restructuring Initiative (as defined in Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein) or any other planned or completed restructuring, cost-saving, or other strategic initiative, acquisition, or divestiture, including the proposed Transaction, may not be realized or may take longer to realize than expected;
•Our ability to establish, maintain, protect, and enforce intellectual property rights, as well as address the threats of counterfeit and other unauthorized versions of our products;
•Allegations that we or our products infringe the intellectual property rights of third parties;
•The impact of negative publicity and failed marketing efforts;
•Difficulties and delays in manufacturing, internally or within the supply chain, which may lead to business interruptions, product shortages, withdrawals, or suspensions of products from the market, and potential regulatory action;
•Our reliance on third-party relationships, global supply chains, and production and distribution processes, which may adversely affect manufacturing operations, supply, sourcing, and pricing of materials used in our products, and impact our ability to forecast product demand;
•Interruptions, breakdowns, invasions, corruptions, destruction, and breaches of our information technology or operational technology systems or those of a third party;
•The development, deployment, use, and regulation of artificial intelligence in our internal processes, manufacturing operations, products and services, as well as our business more broadly;
3

•The potential for labor disputes, strikes, work stoppages, and similar labor relations matters, and the impact of minimum wage increases;
•Our ability to attract and retain talented, highly skilled employees and to implement succession plans for our senior management;
•Climate change, extreme weather, and natural disasters, or legal, regulatory, or market measures to address climate change;
•The impact of increasing scrutiny, emerging legal and regulatory requirements, and rapidly evolving expectations from stakeholders regarding environmental, social, and governance matters;
•The potential for insurance to be unavailable or insufficient to cover losses we may incur;
•Legal proceedings related to talc or talc-containing products, such as Johnson’s® Baby Powder, sold outside the United States and Canada, and other risks and uncertainties related to talc or talc-containing products, including the ability of our former parent Johnson & Johnson (“J&J”) to fully satisfy its obligation to indemnify us in the United States and Canada for the Talc-Related Liabilities (as defined in Note 13, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein);
•The impact of legal proceedings and the uncertainty of their outcome, whether or not we believe they have merit;
•Changes to applicable laws, regulations, policies, and related interpretations;
•Potential changes in export/import and trade laws, regulations, and policies, such as new or increased tariffs, sanctions, quotas, or trade barriers;
•Changes in tax laws and regulations, increased audit scrutiny by tax authorities and exposures to additional tax liabilities potentially in excess of existing reserves;
•The impact of inflation and fluctuations in interest rates and currency exchange rates;
•The impact of a natural disaster, catastrophe, epidemic, pandemic, and global tension, including armed conflict, or other event;
•The impact of impairment of our goodwill and other intangible assets;
•Our ability to maintain satisfactory credit ratings and access credit markets;
•Our ability to achieve the expected benefits of the Separation from J&J and related transactions;
•Restrictions on our business, potential tax and indemnification liabilities and substantial charges in connection with the Separation and related transactions;
•Failure of our rebranding efforts in connection with the Separation to achieve market acceptance, and the impact of our continued use of legacy J&J branding, including the “Johnson’s®” brand;
•Our substantial indebtedness, including the restrictions and covenants in our debt agreements; and
•Our ability to complete the proposed Transaction and uncertainties related to the proposed Transaction generally, including, among others, those related to the ability of the combined company (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Proposed Transaction with Kimberly-Clark,” to the Condensed Consolidated Financial Statements included herein) to identify and realize any benefits that the Transaction may offer, consideration our shareholders may receive, the ability of our shareholders to influence the future combined company, the possibility of future litigation related to the Transaction, and the receipt of regulatory approvals and satisfaction of other customary closing conditions necessary for the Transaction to be consummated.
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found under the section titled “Cautionary Note Regarding Forward-Looking Statements” and Part I, Item 1A,“Risk Factors,” in our Annual Report on Form 10-K for the fiscal twelve months ended December 29, 2024 filed on February 24, 2025 with the U.S. Securities and Exchange Commission (the “SEC”), in Part II, Item 1A, “Risk Factors,” included herein, and in our other filings with the SEC. You should understand that it is not possible to predict or identify all such factors, and you should not consider the risks described above to be a complete statement of all potential risks and uncertainties. We do not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments, except as required by law.
4

PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
KENVUE INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; Dollars in Millions, Except Per Share Data; Shares in Thousands)

|  | September 28, 2025 |  | December 29, 2024
Assets |  |  |  |
Current assets |  |  |  |
Cash and cash equivalents |  | $ | 1,139 |  |  | $ | 1,070 |
Trade receivables, less allowances for credit losses ($25 and $26 as of September 28, 2025 and December 29, 2024, respectively) |  | 2,416 |  |  | 2,165 |
Inventories |  | 1,794 |  |  | 1,591 |
Prepaid expenses and other receivables |  | 531 |  |  | 494 |
Other current assets |  | 152 |  |  | 205 |
Total current assets |  | 6,032 |  |  | 5,525 |
Property, plant, and equipment, net |  | 2,092 |  |  | 1,849 |
Intangible assets, net |  | 8,716 |  |  | 8,474 |
Goodwill |  | 9,441 |  |  | 8,843 |
Deferred taxes on income |  | 237 |  |  | 184 |
Other assets |  | 730 |  |  | 726 |
Total Assets |  | $ | 27,248 |  |  | $ | 25,601 |
Liabilities and Stockholders’ Equity |  |  |  |
Current liabilities |  |  |  |
Loans and notes payable |  | $ | 1,913 |  |  | $ | 1,552 |
Accounts payable |  | 2,445 |  |  | 2,254 |
Accrued liabilities |  | 958 |  |  | 1,132 |
Accrued rebates, returns, and promotions |  | 737 |  |  | 727 |
Accrued taxes on income |  | 103 |  |  | 74 |
Total current liabilities |  | 6,156 |  |  | 5,739 |
Long-term debt |  | 7,060 |  |  | 7,055 |
Deferred taxes on income |  | 2,425 |  |  | 2,261 |
Employee-related obligations |  | 373 |  |  | 342 |
Other liabilities |  | 600 |  |  | 536 |
Total liabilities |  | 16,614 |  |  | 15,933 |
Commitments and contingencies (Note 13) |  |  |  |
Stockholders’ Equity |  |  |  |
Preferred stock, $0.01 par value, 750,000 shares authorized; no shares issued and outstanding as of September 28, 2025 and December 29, 2024 |  | — |  |  | — |
Common stock, $0.01 par value, 12,500,000 shares authorized; 1,936,118 and 1,915,731 shares issued and outstanding as of September 28, 2025, respectively; 1,924,977 and 1,913,768 shares issued and outstanding as of December 29, 2024, respectively |  | 19 |  |  | 19 |
Additional paid-in capital |  | 16,320 |  |  | 16,130 |
Treasury stock, 20,387 and 11,208 shares at cost as of September 28, 2025 and December 29, 2024, respectively |  | (439) |  |  | (242) |
Accumulated deficit |  | (136) |  |  | (93) |
Accumulated other comprehensive loss |  | (5,130) |  |  | (6,146) |
Total stockholders’ equity |  | 10,634 |  |  | 9,668 |
Total Liabilities and Stockholders’ Equity |  | $ | 27,248 |  |  | $ | 25,601 |

See accompanying Notes to Condensed Consolidated Financial Statements.
5

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; Dollars in Millions, Except Per Share Data; Shares in Millions)

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
|  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Net sales |  | $ | 3,764 |  |  | $ | 3,899 |  |  | $ | 11,344 |  |  | $ | 11,793 |  |  |
Cost of sales |  | 1,538 |  |  | 1,617 |  |  | 4,689 |  |  | 4,904 |  |  |
Gross profit |  | 2,226 |  |  | 2,282 |  |  | 6,655 |  |  | 6,889 |  |  |
Selling, general, and administrative expenses |  | 1,512 |  |  | 1,590 |  |  | 4,553 |  |  | 4,804 |  |  |
Restructuring expenses |  | 84 |  |  | 31 |  |  | 204 |  |  | 120 |  |  |
Impairment charges |  | — |  |  | — |  |  | — |  |  | 578 |  |  |
Other operating expense, net |  | 1 |  |  | 7 |  |  | 19 |  |  | 29 |  |  |
Operating income |  | 629 |  |  | 654 |  |  | 1,879 |  |  | 1,358 |  |  |
Other expense (income), net |  | 10 |  |  | (19) |  |  | 26 |  |  | 6 |  |  |
Interest expense, net |  | 93 |  |  | 96 |  |  | 281 |  |  | 283 |  |  |
Income before taxes |  | 526 |  |  | 577 |  |  | 1,572 |  |  | 1,069 |  |  |
Provision for taxes |  | 128 |  |  | 194 |  |  | 432 |  |  | 332 |  |  |
Net income |  | $ | 398 |  |  | $ | 383 |  |  | $ | 1,140 |  |  | $ | 737 |  |  |
Net income per share |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.21 |  |  | $ | 0.20 |  |  | $ | 0.59 |  |  | $ | 0.38 |  |  |
Diluted |  | $ | 0.21 |  |  | $ | 0.20 |  |  | $ | 0.59 |  |  | $ | 0.38 |  |  |
Weighted-average number of shares outstanding |  |  |  |  |  |  |  |  |  |
Basic |  | 1,918 |  | 1,915 |  | 1,917 |  | 1,915 |  |
Diluted |  | 1,923 |  | 1,924 |  | 1,925 |  | 1,921 |  |

See accompanying Notes to Condensed Consolidated Financial Statements.
6

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited; Dollars in Millions)

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
|  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024
Net income |  | $ | 398 |  |  | $ | 383 |  |  | $ | 1,140 |  |  | $ | 737 |
Other comprehensive (loss) income, net of taxes |  |  |  |  |  |  |  |
Foreign currency translation |  | (65) |  |  | 473 |  |  | 1,000 |  |  | 41 |
Employee benefit plans |  | 7 |  |  | (7) |  |  | (1) |  |  | (1) |
Derivatives and hedges |  | — |  |  | 10 |  |  | 17 |  |  | (22) |
Other comprehensive (loss) income |  | (58) |  |  | 476 |  |  | 1,016 |  |  | 18 |
Comprehensive income |  | $ | 340 |  |  | $ | 859 |  |  | $ | 2,156 |  |  | $ | 755 |

See accompanying Notes to Condensed Consolidated Financial Statements.
7

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited; Dollars in Millions, Except Per Share Data; Shares in Thousands)

|  | Fiscal Three Months Ended September 28, 2025
|  | Common Stock |  | Additional Paid-In Capital |  | Treasury Stock |  | Accumulated Deficit |  |  |  | Accumulated Other Comprehensive Loss |  | Total Stockholders’ Equity
|  | Shares |  | Amount |  |  | Shares |  | Amount |  |  |  |
June 29, 2025 |  | 1,918,837 |  |  | $ | 19 |  |  | $ | 16,288 |  |  | 16,874 |  |  | $ | (369) |  |  | $ | (136) |  |  |  |  | $ | (5,072) |  |  | $ | 10,730 |
Net income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 398 |  |  |  |  | — |  |  | 398 |
Other comprehensive loss |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | (58) |  |  | (58) |
Cash dividends on common stock ($0.2075 per share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (398) |  |  |  |  | — |  |  | (398) |
Stock-based compensation |  | — |  |  | — |  |  | 25 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 25 |
Issuance of common stock under the Kenvue 2023 Plan, net |  | 407 |  |  | — |  |  | 7 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 7 |
Purchase of treasury stock |  | (3,513) |  |  | — |  |  | — |  |  | 3,513 |  |  | (70) |  |  | — |  |  |  |  | — |  |  | (70) |
September 28, 2025 |  | 1,915,731 |  |  | $ | 19 |  |  | $ | 16,320 |  |  | 20,387 |  |  | $ | (439) |  |  | $ | (136) |  |  |  |  | $ | (5,130) |  |  | $ | 10,634 |

|  | Fiscal Three Months Ended September 29, 2024
|  | Common Stock |  | Additional Paid-In Capital |  | Treasury Stock |  | Retained Earnings |  |  |  | Accumulated Other Comprehensive Loss |  | Total Stockholders’ Equity
|  | Shares |  | Amount |  |  | Shares |  | Amount |  |  |  |
June 30, 2024 |  | 1,915,064 |  |  | $ | 19 |  |  | $ | 16,075 |  |  | 4,950 |  |  | $ | (98) |  |  | $ | 17 |  |  |  |  | $ | (5,835) |  |  | $ | 10,178 |
Net income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 383 |  |  |  |  | — |  |  | 383 |
Other comprehensive income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 476 |  |  | 476 |
Cash dividends on common stock ($0.205 per share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (393) |  |  |  |  | — |  |  | (393) |
Stock-based compensation |  | — |  |  | — |  |  | 58 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 58 |
Issuance of common stock under the Kenvue 2023 Plan, net |  | 2,314 |  |  | — |  |  | 41 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 41 |
Purchase of treasury stock |  | (1,100) |  |  | — |  |  | — |  |  | 1,100 |  |  | (23) |  |  | — |  |  |  |  | — |  |  | (23) |
Separation-related adjustments |  | — |  |  | — |  |  | (76) |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (76) |
September 29, 2024 |  | 1,916,278 |  |  | $ | 19 |  |  | $ | 16,098 |  |  | 6,050 |  |  | $ | (121) |  |  | $ | 7 |  |  |  |  | $ | (5,359) |  |  | $ | 10,644 |

|  | Fiscal Nine Months Ended September 28, 2025
|  | Common Stock |  | Additional Paid-In Capital |  | Treasury Stock |  | Accumulated Deficit |  |  |  | Accumulated Other Comprehensive Loss |  | Total Stockholders’ Equity
|  | Shares |  | Amount |  |  | Shares |  | Amount |  |  |  |
December 29, 2024 |  | 1,913,768 |  |  | $ | 19 |  |  | $ | 16,130 |  |  | 11,208 |  |  | $ | (242) |  |  | $ | (93) |  |  |  |  | $ | (6,146) |  |  | $ | 9,668 |
Net income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,140 |  |  |  |  | — |  |  | 1,140 |
Other comprehensive income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 1,016 |  |  | 1,016 |
Cash dividends on common stock ($0.6175 per share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,183) |  |  |  |  | — |  |  | (1,183) |
Stock-based compensation |  | — |  |  | — |  |  | 106 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 106 |
Issuance of common stock under the Kenvue 2023 Plan, net |  | 11,142 |  |  | — |  |  | 84 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 84 |
Purchase of treasury stock |  | (9,179) |  |  | — |  |  | — |  |  | 9,179 |  |  | (197) |  |  | — |  |  |  |  | — |  |  | (197) |
September 28, 2025 |  | 1,915,731 |  |  | $ | 19 |  |  | $ | 16,320 |  |  | 20,387 |  |  | $ | (439) |  |  | $ | (136) |  |  |  |  | $ | (5,130) |  |  | $ | 10,634 |

8

|  | Fiscal Nine Months Ended September 29, 2024
|  | Common Stock |  | Additional Paid-In Capital |  | Treasury Stock |  | Retained Earnings |  |  |  | Accumulated Other Comprehensive Loss |  | Total Stockholders’ Equity
|  | Shares |  | Amount |  |  | Shares |  | Amount |  |  |  |
December 31, 2023 |  | 1,915,057 |  |  | $ | 19 |  |  | $ | 16,147 |  |  | 350 |  |  | $ | (7) |  |  | $ | 429 |  |  |  |  | $ | (5,377) |  |  | $ | 11,211 |
Net income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 737 |  |  |  |  | — |  |  | 737 |
Other comprehensive income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 18 |  |  | 18 |
Cash dividends on common stock ($0.605 per share) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,159) |  |  |  |  | — |  |  | (1,159) |
Stock-based compensation |  | — |  |  | — |  |  | 200 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 200 |
Issuance of common stock under the Kenvue 2023 Plan, net |  | 6,921 |  |  | — |  |  | 35 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 35 |
Purchase of treasury stock |  | (5,700) |  |  | — |  |  | — |  |  | 5,700 |  |  | (114) |  |  | — |  |  |  |  | — |  |  | (114) |
Separation-related adjustments |  | — |  |  | — |  |  | (284) |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (284) |
September 29, 2024 |  | 1,916,278 |  |  | $ | 19 |  |  | $ | 16,098 |  |  | 6,050 |  |  | $ | (121) |  |  | $ | 7 |  |  |  |  | $ | (5,359) |  |  | $ | 10,644 |

See accompanying Notes to Condensed Consolidated Financial Statements.
9

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in Millions)

|  |  |  |  |  | Fiscal Nine Months Ended
|  |  |  |  |  | September 28, 2025 |  |  |  | September 29, 2024 |  |
Cash flows from operating activities |  |  |  |  |  |  |  |  |  |  |  |
Net income |  |  |  |  |  | $ | 1,140 |  |  |  |  | $ | 737 |  |  |
Adjustments to reconcile net income to cash flows from operating activities |  |  |  |  |  |  |  |  |  |  |  |
Depreciation and amortization |  |  |  |  |  | 419 |  |  |  |  | 472 |  |  |
Stock-based compensation |  |  |  |  |  | 106 |  |  |  |  | 200 |  |  |
Deferred income taxes |  |  |  |  |  | (11) |  |  |  |  | (245) |  |  |
Impairment charges |  |  |  |  |  | — |  |  |  |  | 578 |  |  |
Losses on investments |  |  |  |  |  | — |  |  |  |  | 31 |  |  |
Other |  |  |  |  |  | 54 |  |  |  |  | 36 |  |  |
Net changes in assets and liabilities |  |  |  |  |  |  |  |  |  |  |  |
Trade receivables |  |  |  |  |  | (147) |  |  |  |  | (343) |  |  |
Inventories |  |  |  |  |  | (144) |  |  |  |  | 13 |  |  |
Other current and non-current assets |  |  |  |  |  | 147 |  |  |  |  | 29 |  |  |
Accounts payable and accrued liabilities |  |  |  |  |  | (89) |  |  |  |  | (573) |  |  |
Employee-related obligations |  |  |  |  |  | 17 |  |  |  |  | 5 |  |  |
Accrued taxes on income |  |  |  |  |  | (80) |  |  |  |  | 9 |  |  |
Other liabilities |  |  |  |  |  | (69) |  |  |  |  | 27 |  |  |
Net cash flows from operating activities |  |  |  |  |  | 1,343 |  |  |  |  | 976 |  |  |
Cash flows used in investing activities |  |  |  |  |  |  |  |  |  |  |  |
Purchases of property, plant, and equipment |  |  |  |  |  | (365) |  |  |  |  | (302) |  |  |
Other investing activities |  |  |  |  |  | 4 |  |  |  |  | 9 |  |  |
Net cash flows used in investing activities |  |  |  |  |  | (361) |  |  |  |  | (293) |  |  |
Cash flows used in financing activities |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from commercial paper program, net of repayments and issuance costs |  |  |  |  |  | 324 |  |  |  |  | 258 |  |  |
Proceeds from issuance of Senior Notes, net of issuance cost |  |  |  |  |  | 746 |  |  |  |  | — |  |  |
Repayment of Senior Notes |  |  |  |  |  | (750) |  |  |  |  | — |  |  |
Dividends paid |  |  |  |  |  | (1,183) |  |  |  |  | (1,159) |  |  |
Purchase of treasury stock |  |  |  |  |  | (197) |  |  |  |  | (114) |  |  |
Other financing activities |  |  |  |  |  | 92 |  |  |  |  | 37 |  |  |
Net cash flows used in financing activities |  |  |  |  |  | (968) |  |  |  |  | (978) |  |  |
Effect of exchange rate changes on cash and cash equivalents |  |  |  |  |  | 55 |  |  |  |  | (30) |  |  |
Cash and cash equivalents, beginning of period |  |  |  |  |  | 1,070 |  |  |  |  | 1,382 |  |  |
Net increase (decrease) in cash and cash equivalents |  |  |  |  |  | 69 |  |  |  |  | (325) |  |  |
Cash and cash equivalents, end of period |  |  |  |  |  | $ | 1,139 |  |  |  |  | $ | 1,057 |  |  |

See accompanying Notes to Condensed Consolidated Financial Statements.
10

KENVUE INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Description of the Company and Summary of Significant Accounting Policies
Description of the Company and Business Segments
Kenvue Inc. (“Kenvue” or the “Company”) is a pure-play consumer health company with iconic brands including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®. The Company is organized into three reportable business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes a broad product range such as cough, cold, and allergy; pain care; digestive health; smoking cessation; eye care; and other products. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products.
Kenvue was initially formed as a wholly owned subsidiary of Johnson & Johnson (“J&J”). In November 2021, J&J announced its intention to separate its Consumer Health segment (the “Consumer Health Business”) into a new, publicly traded company (the “Separation”). On April 4, 2023, in connection with the Separation, J&J completed in all material respects the transfer of the assets and liabilities of the Consumer Health Business to the Company and its subsidiaries, other than the transfer of certain Deferred Local Businesses (as defined below in “—Variable Interest Entities and Net Economic Benefit Arrangements”).
On May 3, 2023, the registration statement related to the initial public offering of Kenvue’s common stock was declared effective, and on May 4, 2023, Kenvue’s common stock began trading on the New York Stock Exchange under the ticker symbol “KVUE” (the “Kenvue IPO”).
On July 24, 2023, J&J announced an exchange offer (the “Exchange Offer”) under which its shareholders could exchange shares of J&J common stock for shares of Kenvue common stock owned by J&J. On August 23, 2023, J&J completed the Exchange Offer, and as a result, Kenvue became a fully independent company.
On May 17, 2024, J&J completed an additional exchange offer (the “Debt-for-Equity Exchange”) through which J&J exchanged indebtedness of J&J for shares of Kenvue common stock owned by J&J. Following the completion of the Debt-for-Equity Exchange, J&J did not own any shares of Kenvue common stock.
Proposed Transaction with Kimberly-Clark
On November 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kimberly-Clark Corporation, a Delaware corporation (“K-C” or, with reference to the post-closing period, the “combined company”), Vesta Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of K-C (“First Merger Sub”), and Vesta Sub II, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of K-C (“Second Merger Sub”). The Merger Agreement provides for the combination of the Company and K-C upon the terms and subject to the conditions set forth therein, as described in Note 16, “Subsequent Events.”
Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the Condensed Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations, and cash flows for the periods indicated. These financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures for the fiscal twelve months ended December 29, 2024 included in the Company’s Annual Report on Form 10-K filed on February 24, 2025 with the SEC.
Intercompany balances and transactions have been eliminated. The Condensed Consolidated Financial Statements include the accounts of the Company and its affiliates and entities consolidated under the variable interest and voting models.
During the fiscal nine months ended September 29, 2024, the Company recorded out-of-period adjustments primarily related to the Separation, which corrected an overstatement in Additional paid-in capital of $284 million, including $94 million ($71
11

million net of tax) related to certain cloud computing arrangements described below. This amount did not have an impact on the operating results for the fiscal nine months ended September 29, 2024. The Company concluded that these adjustments were not material to the Condensed Consolidated Financial Statements for the prior period.
As of September 29, 2024, the Condensed Consolidated Balance Sheet reflects an adjustment for a change in classification from Property, plant, and equipment, net of $300 million to Other assets and Additional paid-in capital of $171 million and $94 million, respectively, related to certain cloud computing arrangements, net of amortization of $35 million. The Company concluded that this adjustment was not material to the Condensed Consolidated Financial Statements for the prior period.
Reclassifications
Certain prior period amounts have been reclassified to conform to current fiscal year presentation.
Use of Estimates
The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenue and expenses during the periods reported. Estimates are used when accounting for, among other things, sales discounts, trade promotions, rebates, allowances and incentives, product liabilities, income taxes and related valuation allowances, withholding taxes, pensions, postretirement benefits, fair value of financial instruments, stock-based compensation assumptions, depreciation, amortization, employee benefits, contingencies, and the valuation of goodwill, intangible assets, and liabilities. Actual results may or may not differ from those estimates.
Impairment Charges
No impairments were recognized for both the fiscal three and nine months ended September 28, 2025 and the fiscal three months ended September 29, 2024.
Impairment charges for the fiscal nine months ended September 29, 2024 consisted of:

|  |  |  |  |  | Fiscal Nine Months Ended
(Dollars in Millions) |  |  |  |  |  |  |  | September 29, 2024 |  |
Dr.Ci:Labo® asset impairment(1) |  |  |  |  |  |  |  | $ | 488 |  |  |
Skillman fixed asset impairment(2) |  |  |  |  |  |  |  | 68 |  |  |
Other asset impairment(3) |  |  |  |  |  |  |  | 22 |  |  |
Total impairment charges |  |  |  |  |  |  |  | $ | 578 |  |  |

(1) Represents the impairment charge recognized during the fiscal three months ended June 30, 2024 in relation to Dr.Ci:Labo® long-lived assets. See “—Dr.Ci:Labo® Asset Impairment” below and Note 3, “Intangible Assets and Goodwill,” for more information.
(2) Represents the impairment charge recorded during the fiscal three months ended March 31, 2024 on the held for sale asset associated with the Company’s former corporate headquarters in Skillman, New Jersey. See “—Assets Held for Sale” below.
(3) Represents the impairment charge recognized during the fiscal three months ended June 30, 2024 related to certain software development assets.
Dr.Ci:Labo® Asset Impairment
During the fiscal three months ended June 30, 2024, there was a significant change in the senior leadership of the Dr.Ci:Labo® business, resulting in a new strategic plan with a key focus on increased expenses related to brand support designed to allow the brand to reach more consumers and appropriately address evolving market dynamics, including shifts in consumer sentiment in China as well as changing shopping patterns in the region. Following the change to the Company’s strategy for the brand, the Company made revisions to the internal forecasts relating to the Dr.Ci:Labo® asset group and concluded that the changes in circumstances, which impacted the forecasted cash flows in relation to this business, resulted in a triggering event, requiring an interim impairment review of the Dr.Ci:Labo® asset group. As a result of the interim impairment test, the Company concluded that the carrying value of long-lived assets of the asset group, consisting primarily of intangible assets, including trademarks and other intangibles, and property, plant, and equipment, exceeded their estimated fair value, resulting in impairment charges of $488 million recognized in the fiscal three months ended June 30, 2024, of which $463 million related to definite-lived intangible assets and $25 million related to property, plant, and equipment. Following the impairment charge, the carrying value of the Dr.Ci:Labo® asset group was $118 million.
12

The Company estimated the fair value of the definite-lived intangible assets within the Dr.Ci:Labo® asset group based on an income approach using the relief-from-royalty method. This valuation required significant judgments and estimates by management regarding several key inputs, including future cash flows consistent with management’s plans, sales growth rates, the selection of royalty rates, and a discount rate. The Company selected the assumptions used in the financial forecasts of cash flows specific to the remaining useful lives of the trademarks ranging from six to 15 years using historical data, supplemented by current and anticipated market conditions and estimated growth rates. The Company utilized a discount rate of 8%. As the fair value measurements were based on significant inputs not observable in the market, they represented Level 3 measurements within the fair value hierarchy.
Assets Held for Sale
On February 21, 2024, the Company listed its former corporate headquarters in Skillman, New Jersey for sale, which met the criteria to be classified as held for sale at that date. The Skillman, New Jersey facility continues to meet the criteria for held for sale classification as of September 28, 2025. The held for sale asset is measured at the lower of the carrying amount or the fair value less costs to sell.
The results of the impairment test performed upon classification as held for sale indicated that the carrying value of the Skillman, New Jersey facility exceeded its estimated fair value less costs to sell by $68 million. As a result, the Company recorded an impairment charge equivalent to that amount within Impairment charges in the Condensed Consolidated Statement of Operations for the fiscal three months ended March 31, 2024. The fair value of the held for sale asset was determined utilizing third-party sales pricing as an input. The inputs utilized in the analysis are classified as Level 3 inputs within the fair value hierarchy.
The Company recorded the remaining asset held for sale balance related to the Skillman, New Jersey facility within Other current assets on the Condensed Consolidated Balance Sheets as of both September 28, 2025 and December 29, 2024.
Global and North America Headquarters Lease
On April 20, 2023, the Company entered into a long-term lease for a newly renovated global and North America corporate headquarters building and a newly constructed research and development building in Summit, New Jersey (the “Global and North America Headquarters Lease”). In March 2025, the Company began operating out of the new global and North America corporate headquarters. The relocation to this new campus from multiple U.S.-based locations will continue through 2026 when the new research and development building is expected to be complete. When construction is completed, the campus will encompass approximately 290,000 square feet. The Global and North America Headquarters Lease collectively includes the lease associated with the global and North America corporate headquarters building, the lease associated with the land where the research and development building is under construction, and the lease associated with land used for amenities (the “Amenities Lease”). The Amenities Lease commenced in October 2025.
Separation-Related Costs
The Company is incurring certain non-recurring separation-related costs in connection with the establishment of Kenvue as a standalone public company (“Separation-related costs”), which are included in Cost of sales and Selling, general, and administrative expenses in the Condensed Consolidated Statements of Operations. Separation-related costs associated with information technology and other activities, primarily related to the disentanglement of systems and the discontinuance of
13

certain information technology assets, are substantially completed. However, costs related to legal entity name changes and certain other separation-related activities are expected to continue for a longer period than originally anticipated.
Separation-related costs for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 consisted of:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Information technology and other(1) |  | $ | 12 |  |  | $ | 75 |  |  | $ | 63 |  |  | $ | 203 |  |  |
Legal entity name change |  | 5 |  |  | 10 |  |  | 16 |  |  | 28 |  |  |
Total Separation-related costs |  | $ | 17 |  |  | $ | 85 |  |  | $ | 79 |  |  | $ | 231 |  |  |

(1) Primarily related to the disentanglement of systems and the costs associated with the discontinuation of certain information technology assets. These costs also include depreciation expense on Separation-related assets for the fiscal three and nine months ended September 29, 2024.
Research and Development
Research and development expenses are expensed as incurred and included in Selling, general, and administrative expenses in the Condensed Consolidated Statements of Operations. Research and development expenses were $94 million and $97 million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, and $284 million and $302 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively.
Supplier Finance Program
As of September 28, 2025 and December 29, 2024, the Company’s Accounts payable balances included $252 million and $260 million, respectively, related to invoices from suppliers participating in the supplier finance program.
Variable Interest Entities and Net Economic Benefit Arrangements
When the Company makes an initial investment in or establishes other variable interests in an entity, the entity is first evaluated to determine if it is a Variable Interest Entity (“VIE”) and if the Company is the primary beneficiary of the VIE, and therefore subject to consolidation regardless of percentage ownership. The primary beneficiary of a VIE is a party that meets both of the following criteria: 1) it has the power to direct the activities that most significantly impact the economic performance of the VIE; and 2) it has the obligation to absorb losses or the right to receive benefits that could be potentially significant to the VIE. Periodically, the Company assesses whether any change in its interest in or relationship with the entity affects the determination as to whether the entity is a VIE, and, if so, whether the Company is the primary beneficiary.
In connection with the Separation, J&J and Kenvue entered into a separation agreement (the “Separation Agreement”) on May 3, 2023. Under the Separation Agreement, transfer of certain assets and liabilities of the Consumer Health Business in certain jurisdictions (each, a “Deferred Local Business”) was not completed prior to the Kenvue IPO and was deferred due to certain precedent conditions, which include ensuring compliance with applicable law and obtaining necessary governmental approvals and other consents, and for other business reasons. At the Kenvue IPO and until the Deferred Local Business transfers to the Company, J&J 1) holds and operates the Deferred Local Businesses on behalf of and for the benefit of the Company, and 2) will use reasonable best efforts to treat and operate, insofar as reasonably practicable and to the extent permitted by applicable law, each such Deferred Local Business in the ordinary course of business in all material respects consistent with past practice. The benefits and costs related to these Deferred Local Businesses will be assumed by the Company (see below “—Net Economic Benefit Arrangements”). In addition, the Company and J&J will use reasonable best efforts to take all actions to transfer each Deferred Local Business as promptly as reasonably practicable. When the precedent conditions are met, the Deferred Local Businesses will be transferred as per the terms of the arrangement with J&J.
The Company determined that certain Deferred Local Businesses that are legal entities (“Deferred Legal Entities”) are VIEs for which Kenvue is the primary beneficiary, since Kenvue has the power to direct the activities that most significantly impact such Deferred Legal Entities’ economic performance, as well as to obtain all the economic benefits and losses of such entities. These significant activities include, but are not limited to, product pricing, marketing and sales strategy, supply chain strategy, material supply and vendor management, budget planning, and labor and overhead management. Accordingly, the assets and liabilities of these entities are recognized on the Condensed Consolidated Balance Sheets at their historical carrying amounts as of the date when the Company entered into the arrangement, since the primary beneficiary of the VIEs and the VIEs themselves
14

were under common control. Additionally, the results of the operations and cash flows are included within the Condensed Consolidated Financial Statements.
All Deferred Legal Entities are exposed to similar operational risks and are therefore monitored and evaluated on a similar basis by management. Accordingly, the financial information for Deferred Legal Entities has been aggregated and the following table summarizes the consolidated assets and liabilities of these entities on the Condensed Consolidated Balance Sheets as of September 28, 2025 and December 29, 2024. The amounts represented in this table are only those assets of the VIEs that can be used to settle only the VIE’s obligations and the VIE’s creditors (or beneficial interest holders) have no recourse against the general credit of the primary beneficiary.

(Dollars in Millions) |  |  |  |  |  | September 28, 2025 |  | December 29, 2024
Assets |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  |  |  |  |  | $ | 126 |  |  | $ | 99 |
Trade receivables, less allowances for credit losses |  |  |  |  |  | 79 |  |  | 70 |
Inventories |  |  |  |  |  | 28 |  |  | 16 |
Prepaid expenses and other receivables |  |  |  |  |  | 5 |  |  | 3 |
Total current assets |  |  |  |  |  | 238 |  |  | 188 |
Property, plant, and equipment, net |  |  |  |  |  | 3 |  |  | 3 |
Deferred taxes on income |  |  |  |  |  | 5 |  |  | 3 |
Other assets |  |  |  |  |  | 5 |  |  | — |
Total assets |  |  |  |  |  | $ | 251 |  |  | $ | 194 |
Liabilities |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |
Accounts payable |  |  |  |  |  | $ | 4 |  |  | $ | 3 |
Accrued liabilities |  |  |  |  |  | 11 |  |  | 11 |
Accrued rebates, returns, and promotions |  |  |  |  |  | 19 |  |  | 16 |
Total current liabilities |  |  |  |  |  | 34 |  |  | 30 |
Other liabilities |  |  |  |  |  | 3 |  |  | — |
Total liabilities |  |  |  |  |  | $ | 37 |  |  | $ | 30 |

The Company recognized Net income of $9 million and $6 million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, and $14 million and $12 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, related to the Deferred Legal Entities in the Condensed Consolidated Statements of Operations.
Net Economic Benefit Arrangements
With respect to certain Deferred Legal Entities and the Deferred Local Businesses that are not legal entities (“Deferred Markets”), the Company and J&J entered into net economic benefit arrangements effective on April 4, 2023, pursuant to which, among other things, J&J will transfer to the Company the net profits from the operations of each of the Deferred Markets (or, in the event the operations of any such Deferred Markets result in net losses to J&J, the Company will reimburse J&J for the amount of such net losses).
The Company had a net liability to J&J of $25 million and $23 million as of September 28, 2025 and December 29, 2024, respectively, in relation to the net economic benefit arrangements on the Condensed Consolidated Balance Sheets. The Company recognized Net income of $4 million and $7 million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, and $26 million and $40 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, in relation to the net economic benefit arrangements in the Condensed Consolidated Statements of Operations.
15

Recent Accounting Standards Not Yet Adopted
Accounting Standards Update (“ASU”) 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures
In December 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 enhances the transparency of income tax disclosures, primarily by requiring public business entities to disclose 1) consistent categories and greater disaggregation of information in the rate reconciliations and 2) the disclosure of income taxes paid disaggregated by jurisdiction, among other requirements. This guidance is effective for public business entities for the fiscal years beginning after December 15, 2024. The Company expects to adopt the amendments on a prospective basis. The Company is currently evaluating this guidance and expects that adoption will result in changes to the annual income tax disclosures, including, but not limited to, greater disaggregation of information related to rate reconciliations and income taxes paid.
ASU 2024-03—Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses
In November 2024, the FASB issued ASU 2024-03—Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). Among other various new disclosures, ASU 2024-03 requires public business entities to disaggregate operating expenses included in certain expense captions presented on the face of the income statement into specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) to provide enhanced transparency into the nature of expenses. This guidance is effective for public business entities for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Companies are required to apply the amendments either 1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or 2) retrospectively to all periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating this guidance and the impact on its disclosures.
ASU 2025-06—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software
In September 2025, the FASB issued ASU 2025-06—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”). ASU 2025-06 simplifies capitalization guidance by removing all references to software development project stages so that the guidance is neutral to different software development methods. The amendment requires entities to start capitalizing software costs when both of the following occur: 1) management has authorized and committed to funding the software project and 2) it is probable that the project will be completed and the software will be used to perform the function intended. This guidance is effective for all entities for fiscal years beginning after December 15, 2027, and for interim periods within those fiscal years. Companies are permitted to apply the amendments using a prospective, retrospective, or modified transition approach. Early adoption is permitted. The Company is currently evaluating this guidance and the impact on its financial statements and related disclosures.
No other new accounting standards that were issued or became effective during the fiscal nine months ended September 28, 2025 had, or are expected to have, a significant impact on the Condensed Consolidated Financial Statements.
2. Inventories
As of September 28, 2025 and December 29, 2024, Inventories consisted of:

(Dollars in Millions) |  | September 28, 2025 |  | December 29, 2024
Raw materials and supplies |  | $ | 308 |  |  | $ | 274 |
Goods in process |  | 89 |  |  | 101 |
Finished goods |  | 1,397 |  |  | 1,216 |
Total inventories |  | $ | 1,794 |  |  | $ | 1,591 |

16

3. Intangible Assets and Goodwill
As of September 28, 2025 and December 29, 2024, the gross and net amounts of intangible assets were:

|  |  |  |  |  | September 28, 2025 |  | December 29, 2024
(Dollars in Millions) |  |  |  |  |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Definite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Patents and trademarks |  |  |  |  |  | $ | 4,468 |  |  | $ | (2,065) |  |  | $ | 2,403 |  |  | $ | 4,110 |  |  | $ | (1,780) |  |  | $ | 2,330 |
Customer relationships |  |  |  |  |  | 2,040 |  |  | (1,169) |  |  | 871 |  |  | 1,933 |  |  | (1,074) |  |  | 859 |
Other intangibles |  |  |  |  |  | 1,322 |  |  | (746) |  |  | 576 |  |  | 1,276 |  |  | (694) |  |  | 582 |
Total definite-lived intangible assets |  |  |  |  |  | $ | 7,830 |  |  | $ | (3,980) |  |  | $ | 3,850 |  |  | $ | 7,319 |  |  | $ | (3,548) |  |  | $ | 3,771 |
Indefinite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks |  |  |  |  |  | $ | 4,804 |  |  | $ | — |  |  | $ | 4,804 |  |  | $ | 4,648 |  |  | $ | — |  |  | $ | 4,648 |
Other |  |  |  |  |  | 62 |  |  | — |  |  | 62 |  |  | 55 |  |  | — |  |  | 55 |
Total intangible assets, net |  |  |  |  |  | $ | 12,696 |  |  | $ | (3,980) |  |  | $ | 8,716 |  |  | $ | 12,022 |  |  | $ | (3,548) |  |  | $ | 8,474 |

Gross carrying amount changes for the fiscal nine months ended September 28, 2025 were driven by the impact of currency translations.
No intangible asset impairments were recognized for both the fiscal three and nine months ended September 28, 2025 and the fiscal three months ended September 29, 2024.
For the fiscal nine months ended September 29, 2024, the Company recognized $479 million in intangible asset impairments, of which $463 million related to impairment charges recognized in relation to Dr.Ci:Labo® definite-lived intangible assets, including trademarks and other intangibles, as described in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment Charges.”
Amortization expense for the Company’s amortizable assets, which is included in Cost of sales, was $66 million for both the fiscal three months ended September 28, 2025 and September 29, 2024, and $193 million and $212 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively.
The following table summarizes the changes in the carrying amount of goodwill by reportable business segment during the fiscal nine months ended September 28, 2025:

(Dollars in Millions) |  |  |  |  |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total Goodwill
December 29, 2024 |  |  |  |  |  | $ | 5,054 |  |  | $ | 2,185 |  |  | $ | 1,604 |  |  | $ | 8,843 |
Currency translation |  |  |  |  |  | 425 |  |  | 103 |  |  | 70 |  |  | 598 |
September 28, 2025 |  |  |  |  |  | $ | 5,479 |  |  | $ | 2,288 |  |  | $ | 1,674 |  |  | $ | 9,441 |

During the fiscal three months ended September 28, 2025, there was a reassessment of the long-term outlook for the Skin Health and Beauty business. The revised outlook aimed to address slower growth in the broader skincare categories, as well as the recent decline in profitability of the Skin Health and Beauty reporting unit. Management revised the internal forecasts to reflect the updated outlook. These changes in circumstances were determined to be a triggering event, which resulted in a quantitative interim impairment assessment of the fair value of the Skin Health and Beauty reporting unit.
The Company estimates the fair value of a reporting unit using a combination of a discounted cash flow model and a market-based approach. The discounted cash flow model relies on assumptions regarding revenue and net income growth rates, projected working capital needs, capital expenditures, and discount rates. Forecasted cash flows are discounted to present value to estimate the fair value. Under the market-based approach, the Company utilizes the guideline public company method and market transaction method. These methods utilize valuation multiples derived from comparable publicly traded companies and relevant industry transactions, which are then applied to the reporting unit’s operating performance metrics. Based on the results of the assessment, the estimated fair value of the Skin Health and Beauty reporting unit exceeded the carrying value by approximately 10%; therefore, no impairment charge was recorded for the fiscal three months ended September 28, 2025. If all
17

other assumptions were held constant, an increase of approximately 100 basis points in the selected discount rate would have resulted in an impairment charge.
A decline in forecasted Net sales or net income, or adverse macroeconomic developments such as rising interest rates, could significantly reduce the excess between fair value and carrying value. Management will continue to monitor the performance of the Skin Health and Beauty business; however, further deterioration of market conditions or an inability of the Company to execute on its strategies could lead to an impairment charge of the goodwill associated with the Skin Health and Beauty reporting unit in the future.
4. Borrowings
The components of the Company’s debt as of September 28, 2025 and December 29, 2024 were as follows:

(Dollars in Millions) |  |  |  |  |  |  |  | September 28, 2025 |  | December 29, 2024
Senior Notes |  |  |  |  |  |  |  |  |  |
5.50% Senior Notes due 2025 |  |  |  |  |  |  |  | $ | — |  |  | $ | 750 |
5.35% Senior Notes due 2026 |  |  |  |  |  |  |  | 750 |  |  | 750 |
5.05% Senior Notes due 2028 |  |  |  |  |  |  |  | 1,000 |  |  | 1,000 |
5.00% Senior Notes due 2030 |  |  |  |  |  |  |  | 1,000 |  |  | 1,000 |
4.85% Senior Notes due 2032 |  |  |  |  |  |  |  | 750 |  |  | — |
4.90% Senior Notes due 2033 |  |  |  |  |  |  |  | 1,250 |  |  | 1,250 |
5.10% Senior Notes due 2043 |  |  |  |  |  |  |  | 750 |  |  | 750 |
5.05% Senior Notes due 2053 |  |  |  |  |  |  |  | 1,500 |  |  | 1,500 |
5.20% Senior Notes due 2063 |  |  |  |  |  |  |  | 750 |  |  | 750 |
Other(1) |  |  |  |  |  |  |  | 125 |  |  | 119 |
Discounts and debt issuance costs |  |  |  |  |  |  |  | (65) |  |  | (64) |
Total |  |  |  |  |  |  |  | 7,810 |  |  | 7,805 |
Less: Current portion of long-term debt—principal amount, net of discounts and debt issuance costs |  |  |  |  |  |  |  | (750) |  |  | (750) |
Total long-term debt |  |  |  |  |  |  |  | 7,060 |  |  | 7,055 |
Current portion of long-term debt—principal amount |  |  |  |  |  |  |  | 750 |  |  | 750 |
Commercial paper |  |  |  |  |  |  |  | 1,160 |  |  | 800 |
Discounts and debt issuance costs |  |  |  |  |  |  |  | (3) |  |  | (3) |
Other |  |  |  |  |  |  |  | 6 |  |  | 5 |
Total loans and notes payable |  |  |  |  |  |  |  | 1,913 |  |  | 1,552 |
Total debt |  |  |  |  |  |  |  | $ | 8,973 |  |  | $ | 8,607 |

(1) Other consists primarily of finance lease liabilities.
Senior Notes
On May 22, 2025, the Company issued a series of senior unsecured notes maturing in 2032 in an aggregate principal amount of $750 million, which bear an interest rate of 4.850% per annum. The interest payments are due on May 22 and November 22 of each year, and commence on November 22, 2025. These notes, collectively with the series of senior unsecured notes issued on March 22, 2023, are referred to as the “Senior Notes.”
18

Interest Expense, Net
The amount included in Interest expense, net in the Condensed Consolidated Statements of Operations for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 consisted of the following:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024
Interest expense |  | $ | 107 |  |  | $ | 108 |  |  | $ | 321 |  |  | $ | 323 |
Interest income |  | (14) |  |  | (12) |  |  | (40) |  |  | (40) |
Interest expense, net |  | $ | 93 |  |  | $ | 96 |  |  | $ | 281 |  |  | $ | 283 |

Fair Value of Debt
The Company’s debt was recorded at the carrying amount. The estimated fair value of the Company’s Senior Notes was $7.6 billion and $7.5 billion as of September 28, 2025 and December 29, 2024, respectively. Fair value was estimated based upon quoted market prices in active markets which would be considered Level 2 in the fair value hierarchy. The carrying value of the commercial paper notes approximated the fair value as of September 28, 2025 and December 29, 2024 due to the nature and short-term duration of the instrument.
5. Accrued and Other Liabilities
As of September 28, 2025 and December 29, 2024, Accrued liabilities and Other liabilities, respectively, consisted of:

(Dollars in Millions) |  | September 28, 2025 |  | December 29, 2024
Accrued expenses |  | $ | 432 |  |  | $ | 368 |
Accrued compensation and benefits |  | 282 |  |  | 325 |
Operating lease liabilities |  | 38 |  |  | 36 |
Tax indemnification liability(1) |  | 23 |  |  | 82 |
Other accrued liabilities |  | 183 |  |  | 321 |
Total accrued liabilities |  | $ | 958 |  |  | $ | 1,132 |

(Dollars in Millions) |  | September 28, 2025 |  | December 29, 2024
Accrued income taxes |  | $ | 213 |  |  | $ | 185 |
Operating lease liabilities |  | 98 |  |  | 76 |
Tax indemnification liability(1) |  | 151 |  |  | 143 |
Other accrued liabilities |  | 138 |  |  | 132 |
Total other liabilities |  | $ | 600 |  |  | $ | 536 |

(1) The balances primarily relate to the Tax Matters Agreement (as defined in Note 8, “Relationship with J&J—Tax Indemnification”) entered into with J&J on May 3, 2023 that governs the parties’ respective rights, responsibilities, and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and other matters regarding taxes. See Note 8, “Relationship with J&J—Tax Indemnification,” for more information.
19

6. Accumulated Other Comprehensive Loss
The following tables summarize the changes in the accumulated balances for each component of Accumulated other comprehensive loss during the fiscal three and nine months ended September 28, 2025 and September 29, 2024:

(Dollars in Millions) |  | Foreign Currency Translation |  | Employee Benefit Plans |  | Gain on Derivatives and Hedges(1) |  |  |  | Total Accumulated Other Comprehensive Loss
June 29, 2025 |  | $ | (4,975) |  |  | $ | (138) |  |  | $ | 41 |  |  |  |  | $ | (5,072) |
Other comprehensive (loss) income before reclassifications |  | (65) |  |  | — |  |  | 9 |  |  |  |  | (56) |
Amounts reclassified to the Condensed Consolidated Statement of Operations |  | — |  |  | 7 |  |  | (9) |  |  |  |  | (2) |
Net current period Other comprehensive (loss) income |  | (65) |  |  | 7 |  |  | — |  |  |  |  | (58) |
September 28, 2025 |  | $ | (5,040) |  |  | $ | (131) |  |  | $ | 41 |  |  |  |  | $ | (5,130) |
June 30, 2024 |  | $ | (5,689) |  |  | $ | (161) |  |  | $ | 15 |  |  |  |  | $ | (5,835) |
Other comprehensive income (loss) before reclassifications |  | 473 |  | (8) |  | 12 |  |  |  |  | 477 |
Amounts reclassified to the Condensed Consolidated Statement of Operations |  | — |  |  | 1 |  |  | (2) |  |  |  |  | (1) |
Net current period Other comprehensive income (loss) |  | 473 |  |  | (7) |  |  | 10 |  |  |  |  | 476 |
September 29, 2024 |  | $ | (5,216) |  |  | $ | (168) |  |  | $ | 25 |  |  |  |  | $ | (5,359) |

(1) For the fiscal three months ended September 28, 2025 and September 29, 2024, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $0 million and $11 million, respectively, related to its cash flow hedge portfolio.
20

(Dollars in Millions) |  | Foreign Currency Translation |  | Employee Benefit Plans |  | Gain on Derivatives and Hedges(1) |  |  |  | Total Accumulated Other Comprehensive Loss
December 29, 2024 |  | $ | (6,040) |  |  | $ | (130) |  |  | $ | 24 |  |  |  |  | $ | (6,146) |
Other comprehensive income (loss) before reclassifications |  | 1,000 |  |  | (10) |  |  | 41 |  |  |  |  | 1,031 |
Amounts reclassified to the Condensed Consolidated Statement of Operations |  | — |  |  | 9 |  |  | (24) |  |  |  |  | (15) |
Net current period Other comprehensive income (loss) |  | 1,000 |  |  | (1) |  |  | 17 |  |  |  |  | 1,016 |
September 28, 2025 |  | $ | (5,040) |  |  | $ | (131) |  |  | $ | 41 |  |  |  |  | $ | (5,130) |
December 31, 2023 |  | $ | (5,257) |  |  | $ | (167) |  |  | $ | 47 |  |  |  |  | $ | (5,377) |
Other comprehensive income (loss) before reclassifications |  | 41 |  |  | (4) |  |  | (12) |  |  |  |  | 25 |
Amounts reclassified to the Condensed Consolidated Statement of Operations |  | — |  |  | 3 |  |  | (10) |  |  |  |  | (7) |
Net current period Other comprehensive income (loss) |  | 41 |  |  | (1) |  |  | (22) |  |  |  |  | 18 |
September 29, 2024 |  | $ | (5,216) |  |  | $ | (168) |  |  | $ | 25 |  |  |  |  | $ | (5,359) |

(1) For the fiscal nine months ended September 28, 2025 and September 29, 2024, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $17 million and $(22) million, respectively, related to its cash flow hedge portfolio.
Amounts in Accumulated other comprehensive loss are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international operations. For additional details on comprehensive income, see the Condensed Consolidated Statements of Comprehensive Income.
The provision (benefit) for taxes allocated to the components of Accumulated other comprehensive loss before reclassification for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 was as follows:

|  | Fiscal Three Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  | September 28, 2025 |  | September 29, 2024 |  |
Foreign currency translation |  | $ | 8 |  |  | $ | (7) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (15) |  |  | $ | (12) |  |  |
Employee benefit plans |  | 1 |  |  | — |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (3) |  |  | — |  |  |
Gain on derivatives and hedges |  | 2 |  |  | — |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 |  |  | 11 |  |  |
Total provision (benefit) for taxes recognized in Accumulated other comprehensive loss |  | $ | 11 |  |  | $ | (7) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (10) |  |  | $ | (1) |  |  |

The provision (benefit) for taxes allocated to the reclassifications from Accumulated other comprehensive loss to the Condensed Consolidated Statements of Operations was not significant for the fiscal three and nine months ended September 28, 2025 and September 29, 2024.
21

7. Stock-Based Compensation
The classification of stock-based compensation expense for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 was as follows:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Cost of sales(1) |  | $ | 6 |  |  | $ | 26 |  |  | $ | 21 |  |  | $ | 89 |  |  |
Selling, general, and administrative expenses(1) |  | 19 |  |  | 32 |  |  | 85 |  |  | 111 |  |  |
Total stock-based compensation expense(2) |  | $ | 25 |  |  | $ | 58 |  |  | $ | 106 |  |  | $ | 200 |  |  |

(1) During the fiscal three months ended March 30, 2025, the Company made a refinement to the methodology of its stock-based compensation expense allocations, which resulted in a reduction to Cost of sales and an increase to Selling, general, and administrative expenses for the fiscal three and nine months ended September 28, 2025 as compared to the fiscal three and nine months ended September 29, 2024.
(2) The decrease in stock-based compensation expense during the fiscal three and nine months ended September 28, 2025 as compared to the fiscal three and nine months ended September 29, 2024 was driven primarily by forfeitures of unvested stock-based awards. The decrease in stock-based compensation expense during the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024 was additionally driven by the vesting of J&J stock-based awards that were converted into Kenvue awards, which had a higher grant date fair value and shorter expense attribution period as compared to stock-based awards outstanding as of September 28, 2025.
Grant activity for the fiscal nine months ended September 28, 2025 primarily relates to stock options, restricted stock units (“RSUs”), and performance stock units (“PSUs”) awarded as part of the annual grant of stock-based awards under the 2023 Long-Term Incentive Plan (the “Kenvue 2023 Plan”) that occurred during the fiscal three months ended March 30, 2025.
There was no significant grant activity during the fiscal three months ended September 28, 2025.
8. Relationship with J&J
On August 23, 2023, Kenvue became a fully independent company upon the completion of the Exchange Offer (see Note 1, “Description of the Company and Summary of Significant Accounting Policies—Description of the Company and Business Segments”), and J&J ceased to be a related party on that date. The Company continues to have material agreements with J&J—see “—Transactions with J&J, Including the Separation Agreement” below for additional details of these material agreements that govern the Company’s relationship with J&J.
Transactions with J&J, Including the Separation Agreement
In connection with the Separation, Kenvue entered into various agreements with J&J which created a framework for the Company’s ongoing relationships with J&J following the completion of the Kenvue IPO. These agreements include, but are not limited to:
•the Separation Agreement, which governs aspects of Kenvue’s relationship with J&J following the Kenvue IPO;
•a tax matters agreeme nt (the “Tax Matters Agreement”), which governs J&J’s and Kenvue’s respective rights, responsibilities, and obligations with respect to all tax matters, including tax liabilities, tax attributes, tax contests, and tax returns (See “—Tax Indemnification” below);
•a transition services agreement (the “Transition Services Agreement”), pursuant to which J&J provides to Kenvue certain services for terms of varying duration following the Kenvue IPO; and
•a transition manufacturing agreement (the “Transition Manufacturing Agreement”), pursuant to which J&J provides to Kenvue certain manufacturing services for terms of varying duration following the Kenvue IPO.
22

The Company had the following balances and transactions with J&J and its affiliates, primarily in connection with the Tax Matters Agreement, Transition Services Agreement, and the Transition Manufacturing Agreement, reported in the Condensed Consolidated Financial Statements:

(Dollars in Millions) |  |  |  |  |  | September 28, 2025 |  | December 29, 2024
Prepaid expenses and other receivables |  |  |  |  |  | $ | 65 |  |  | $ | 109 |
Accounts payable and Accrued liabilities |  |  |  |  |  | $ | 152 |  |  | $ | 270 |
Other assets |  |  |  |  |  | $ | 90 |  |  | $ | 78 |
Other liabilities |  |  |  |  |  | $ | 155 |  |  | $ | 143 |

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Cost of sales |  | $ | 40 |  |  | $ | 44 |  |  | $ | 125 |  |  | $ | 153 |  |  |
Selling, general, and administrative expenses |  | $ | (5) |  |  | $ | 45 |  |  | $ | 12 |  |  | $ | 167 |  |  |

In April 2025, the Company completed its Transitions Services Agreement program. Consistent with the program’s plan, the Company finalized the exit of more than 2,300 transition services.
Tax Indemnification
The Company entered into the Tax Matters Agreement with J&J on May 3, 2023 that governs the parties’ respective rights, responsibilities, and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and other matters regarding taxes.
Allocation of Taxes
With respect to taxes other than those incurred in connection with the Separation and any subsequent distribution or the disposition by J&J of the shares of Kenvue stock owned by J&J following the Kenvue IPO (the “Distribution”), the Tax Matters Agreement provides that Kenvue will generally indemnify J&J for 1) any taxes of Kenvue for all periods after the Distribution and 2) any taxes of Kenvue or J&J for periods prior to the Distribution to the extent attributable to the Consumer Health Business. J&J will generally indemnify Kenvue for 1) any taxes of J&J for all periods after the Distribution and 2) any taxes of Kenvue or J&J for periods prior to the Distribution to the extent attributable to the business and operations conducted by J&J other than the Consumer Health Business. Furthermore, subject to certain exceptions, the Company is required to reimburse J&J for certain tax refunds it receives with respect to taxes paid prior to the effective date of the Tax Matters Agreement.
Preservation of the Intended Tax Treatment of Certain Steps of the Separation and the Distribution
With respect to taxes incurred in connection with the Separation and the Distribution, Kenvue will generally be required to indemnify J&J for any taxes resulting from the failure of certain steps of the Separation and the Distribution to qualify for their intended tax treatment, where such taxes are attributable to actions or omissions by Kenvue. In addition, during the time period ending two years after the date of the Distribution, August 23, 2025, covenants were in place that limited or restricted certain actions, including share issuances, business combinations, sales of assets, and similar transactions by Kenvue. The above covenants did not have a material impact on the Company, and the Company believes that it complied with these requirements through August 23, 2025.
The Company had a net liability to J&J totaling approximately $80 million and $104 million for income and non-income indemnification tax payables and refunds, unrecognized tax benefits, and associated interest due as Prepaid expenses and other receivables and Accrued liabilities for current assets and current liabilities, respectively, and to Other assets and Other liabilities for non-current assets and non-current liabilities, respectively, on the Condensed Consolidated Balance Sheets as of September 28, 2025 and December 29, 2024, respectively.
23

9. Other Operating Expense, Net and Other Expense (Income), Net
Other operating expense, net for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 consisted of:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Royalty income |  | $ | (8) |  |  | $ | (7) |  |  | $ | (26) |  |  | $ | (24) |  |  |
Impact of Deferred Markets(1) |  | 7 |  |  | 11 |  |  | 35 |  |  | 49 |  |  |
Other(2) |  | 2 |  |  | 3 |  |  | 10 |  |  | 4 |  |  |
Total other operating expense, net |  | $ | 1 |  |  | $ | 7 |  |  | $ | 19 |  |  | $ | 29 |  |  |

(1) Includes the provision for taxes, minority interest expense, and service fees to be paid to J&J under the net economic benefit arrangements. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Variable Interest Entities and Net Economic Benefit Arrangements,” for more information regarding Deferred Markets.
(2) Other consists primarily of other miscellaneous operating (income) expenses.
Other expense (income), net for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 consisted of:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Currency losses (gains) on transactions |  | $ | 20 |  |  | $ | 1 |  |  | $ | 37 |  |  | $ | (3) |  |  |
Losses on investments |  | — |  |  | — |  |  | — |  |  | 31 |  |  |
Tax indemnification release(1) |  | — |  |  | (21) |  |  | — |  |  | (21) |  |  |
Other(2) |  | (10) |  |  | 1 |  |  | (11) |  |  | (1) |  |  |
Total other expense (income), net |  | $ | 10 |  |  | $ | (19) |  |  | $ | 26 |  |  | $ | 6 |  |  |

(1) Includes the release of tax indemnification reserves that were no longer considered to be probable.
(2) Other consists primarily of net periodic benefit costs other than service cost components and miscellaneous non-operating (income) expenses. Other also includes the receipt of a government subsidy for the fiscal three and nine months ended September 28, 2025.
10. Income Taxes
For interim financial statement purposes, U.S. GAAP provision (benefit) for taxes related to ordinary income is determined by applying an estimated annual effective income tax rate against a company’s ordinary income, subject to certain limitations on the benefit of losses. Provision (benefit) for taxes related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company’s income tax provision requires the use of management forecasts and other estimates, the application of statutory income tax rates, and an evaluation of valuation allowances. The Company’s estimated annual effective income tax rate may be revised, if necessary, in each interim period.
The worldwide effective income tax rates were 24.3% and 33.6% for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, and 27.5% and 31.1% for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively. The decrease in the effective tax rate for the fiscal three months ended September 28, 2025 as compared to the fiscal three months ended September 29, 2024 was primarily the result of changes to the jurisdictional mix of income and favorable return-to-provision adjustments. The decrease in the effective tax rate for the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024 was primarily the result of the quarter-to-date effective tax rate impacts discussed above, as well as a windfall on stock-based compensation recorded during the fiscal nine months ended September 28, 2025 as compared to a shortfall on stock-based compensation recorded during the fiscal nine months ended September 29, 2024. The decrease was partially offset by income tax benefits recognized during the fiscal nine months ended September 29, 2024 resulting from the impairment to the Dr.Ci:Labo® skin health business and the corresponding reversal of a deferred tax liability at the higher Japanese rate, the remeasurement of the state deferred tax liability recognized during the fiscal nine months ended September 29, 2024 as a result of a change in the Company’s state tax rate, and reduced
24

income tax benefits derived from fewer releases of income tax reserves due to the expiration of certain statutes of limitations during the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024.
As of September 28, 2025, the Company had approximately $205 million of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries. With respect to the United States, per the Tax Matters Agreement between J&J and the Company, J&J remains liable for all liabilities related to the final settlement of any U.S. federal income tax audits in which the Company was part of J&J’s federal consolidated tax return. In other major jurisdictions where the Company conducts business, the years that are under tax audit or remain open to tax audits range from 2014 and forward.
The Company has included the impact of enacted legislation related to the Organization for Economic Co-operation Development’s (the “OECD”) Pillar Two Inclusive Framework (“Pillar Two”) in its provision for taxes beginning in fiscal year 2024. While the impact of currently enacted laws for Pillar Two is not significant, it is possible that further administrative guidance from the OECD or new legislation in countries where the Company operates could have a material effect on the Company’s provision for taxes in the future. In addition, in January 2025, the United States issued an executive order expressing disagreement with certain aspects of Pillar Two. In June 2025, the Group of Seven (“G7”) issued a statement supporting the exclusion of U.S. parented groups from certain aspects of Pillar Two in exchange for the United States not imposing certain retaliatory taxes. The executive order and G7 statement do not have a binding effect. The Company will continue to monitor any changes to Pillar Two and any enacted Pillar Two legislation resulting from these negotiations.
On July 4, 2025, the reconciliation bill commonly referred to as the One Big Beautiful Bill Act (the “OBBBA”) was signed into law. The OBBBA made a number of changes to U.S. federal income tax law, including the permanent suspension of the requirement to capitalize and amortize domestic research and experimental expenditures, changes to certain deductions available for deemed inclusions, and a permanent extension of certain corporate international income tax provisions. The enactment of the OBBBA is not expected to have a material impact on the Company’s current fiscal year effective tax rate. Further guidance is expected with respect to the OBBBA, and the Company will continue to assess the impact on its financial statements.
11. Net Income Per Share
The Company had 1,936,118,014 shares of common stock issued and 1,915,731,292 shares of common stock outstanding as of September 28, 2025.
Diluted net income per share is computed by giving effect to all potentially dilutive equity instruments or equity awards that are outstanding during the period. The following table summarizes the shares held by the Company that were determined to be anti-dilutive under the treasury stock method and therefore excluded from the diluted net income per share calculation during the fiscal three and nine months ended September 28, 2025 and September 29, 2024:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Shares in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Anti-dilutive shares(1) |  | 50 |  |  | 52 |  |  | 46 |  |  | 60 |  |  |

(1) For both the fiscal three and nine months ended September 28, 2025 and both the fiscal three and nine months ended September 29, 2024, the majority of anti-dilutive shares related to stock options.
25

Net income per share for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 was calculated as follows:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(In Millions, Except Per Share Data) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Net income |  | $ | 398 |  |  | $ | 383 |  |  | $ | 1,140 |  |  | $ | 737 |  |  |
Basic weighted-average number of shares outstanding |  | 1,918 |  |  | 1,915 |  |  | 1,917 |  |  | 1,915 |  |  |
Dilutive effects of stock-based awards |  | 5 |  |  | 9 |  |  | 8 |  |  | 6 |  |  |
Diluted weighted-average number of shares outstanding |  | 1,923 |  |  | 1,924 |  |  | 1,925 |  |  | 1,921 |  |  |
Net income per share: |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.21 |  |  | $ | 0.20 |  |  | $ | 0.59 |  |  | $ | 0.38 |  |  |
Diluted |  | $ | 0.21 |  |  | $ | 0.20 |  |  | $ | 0.59 |  |  | $ | 0.38 |  |  |

12. Fair Value Measurements
Fair value measurements are estimated based on valuation techniques and inputs categorized as follows:
•Level 1—Quoted prices in active markets for identical assets or liabilities
•Level 2—Significant other observable inputs
•Level 3—Significant unobservable inputs
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
26

The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 28, 2025 and December 29, 2024:

|  |  |  |  |  | September 28, 2025 |  | December 29, 2024
(Dollars in Millions) |  |  |  |  |  | Carrying Value |  | Level 1 |  | Level 2 |  | Level 3 |  | Carrying Value |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  |  |  |  |  | $ | 92 |  |  | $ | — |  |  | $ | 92 |  |  | $ | — |  |  | $ | 81 |  |  | $ | — |  |  | $ | 81 |  |  | $ | — |
Cross currency swap contracts |  |  |  |  |  | 15 |  |  | — |  |  | 15 |  |  | — |  |  | 71 |  |  | — |  |  | 71 |  |  | — |
Total assets |  |  |  |  |  | $ | 107 |  |  | $ | — |  |  | $ | 107 |  |  | $ | — |  |  | $ | 152 |  |  | $ | — |  |  | $ | 152 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  |  |  |  |  | $ | (66) |  |  | $ | — |  |  | $ | (66) |  |  | $ | — |  |  | $ | (76) |  |  | $ | — |  |  | $ | (76) |  |  | $ | — |
Cross currency swap contracts |  |  |  |  |  | (106) |  |  | — |  |  | (106) |  |  | — |  |  | (1) |  |  | — |  |  | (1) |  |  | — |
Total liabilities |  |  |  |  |  | $ | (172) |  |  | $ | — |  |  | $ | (172) |  |  | $ | — |  |  | $ | (77) |  |  | $ | — |  |  | $ | (77) |  |  | $ | — |
Net amount presented in Prepaid expenses and other receivables: |  |  |  |  |  | $ | 24 |  |  | $ | — |  |  | $ | 24 |  |  | $ | — |  |  | $ | 52 |  |  | $ | — |  |  | $ | 52 |  |  | $ | — |
Net amount presented in Accounts payable: |  |  |  |  |  | $ | (42) |  |  | $ | — |  |  | $ | (42) |  |  | $ | — |  |  | $ | (13) |  |  | $ | — |  |  | $ | (13) |  |  | $ | — |
Net amount presented in Other assets: |  |  |  |  |  | $ | 1 |  |  | $ | — |  |  | $ | 1 |  |  | $ | — |  |  | $ | 36 |  |  | $ | — |  |  | $ | 36 |  |  | $ | — |
Net amount presented in Other liabilities: |  |  |  |  |  | $ | (48) |  |  | $ | — |  |  | $ | (48) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |

As of September 28, 2025 and December 29, 2024, cash equivalents were $145 million and $118 million, respectively, which were primarily composed of time deposits and money market funds.
The carrying amount of Cash and cash equivalents, Trade receivables, Prepaid expenses and other receivables, and Loans and notes payable approximated fair value as of September 28, 2025 and December 29, 2024. The fair value of forward foreign exchange contracts is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. dollar at the current spot foreign exchange rate. The cross currency swap contracts are each recorded at fair value derived from observable market data, including foreign exchange rates and yield curves.
There were no transfers between Level 1, Level 2, or Level 3 during the fiscal three and nine months ended September 28, 2025 and the fiscal twelve months ended December 29, 2024.
The following table sets forth the notional amounts of the Company’s outstanding derivative instruments as of September 28, 2025 and December 29, 2024:

|  |  |  |  |  | September 28, 2025 |  | December 29, 2024
(Dollars in Millions) |  |  |  |  |  | Forward Foreign Exchange Contracts |  |  |  | Cross Currency Swap Contracts |  | Total Notional Amount |  | Forward Foreign Exchange Contracts |  |  |  | Cross Currency Swap Contracts |  | Total Notional Amount
Cash flow hedges |  |  |  |  |  | $ | 4,536 |  |  |  |  | $ | — |  |  | $ | 4,536 |  |  | $ | 3,570 |  |  |  |  | $ | — |  |  | $ | 3,570 |
Fair value hedges |  |  |  |  |  | $ | 297 |  |  |  |  | $ | 61 |  |  | $ | 358 |  |  | $ | 30 |  |  |  |  | $ | — |  |  | $ | 30 |
Net investment hedges |  |  |  |  |  | $ | — |  |  |  |  | $ | 2,000 |  |  | $ | 2,000 |  |  | $ | — |  |  |  |  | $ | 1,900 |  |  | $ | 1,900 |
Undesignated hedging instruments |  |  |  |  |  | $ | 565 |  |  |  |  | $ | — |  |  | $ | 565 |  |  | $ | 574 |  |  |  |  | $ | — |  |  | $ | 574 |

Cash Flow Hedges
For the fiscal three and nine months ended September 28, 2025, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $0 million and $17 million, respectively, related to its cash flow hedge portfolio. For the fiscal
27

three and nine months ended September 29, 2024, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $11 million and $(22) million, respectively, related to its cash flow hedge portfolio.
Forward Foreign Exchange Contracts
In certain jurisdictions, the Company uses forward foreign exchange contracts to manage its exposure to the variability of foreign exchange rates. Changes in the fair value of derivatives are recorded each period in earnings or Other comprehensive (loss) income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
The Company enters into forward foreign exchange contracts to hedge a portion of forecasted cash flows denominated in foreign currency. The terms of these contracts are generally no longer than 12 to 18 months. These contracts are designated as cash flow hedging relationships at the date of contract inception, in accordance with the appropriate accounting guidance. At inception, all designated hedging relationships are expected to be highly effective. These contracts are accounted for using the forward method, and all gains/losses associated with these contracts are recorded in Other comprehensive (loss) income. The Company reclassifies the gains and losses related to these contracts at the time the inventory is sold to the customer into Net sales or Cost of sales and Other expense (income), net in the Condensed Consolidated Statements of Operations, as applicable.
The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transactional exposure is 18 months. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
The following table summarizes the gains and losses recognized on forward foreign exchange contracts designated as cash flow hedges within Other comprehensive (loss) income and the gains and losses reclassified into earnings for the fiscal three and nine months ended September 28, 2025 and September 29, 2024:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended |
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |
Gain (loss) recognized in Other comprehensive (loss) income |  | $ | 11 |  |  | $ | 14 |  |  | $ | 42 |  |  | $ | (1) |  |
Gain reclassified from Other comprehensive (loss) income into earnings |  | $ | 10 |  |  | $ | — |  |  | $ | 23 |  |  | $ | 7 |  |

28

The following tables summarize the gains and losses reclassified from Other comprehensive (loss) income into earnings related to the forward foreign exchange contracts designated as cash flows hedges for the fiscal three and nine months ended September 28, 2025 and September 29, 2024:

|  | Fiscal Three Months Ended
|  | September 28, 2025 |  | September 29, 2024
(Dollars in Millions) |  | Net Sales |  | Cost of Sales |  | Other Expense (Income), Net |  | Net Sales |  | Cost of Sales |  | Other Expense (Income), Net
Gain (loss) reclassified from Other comprehensive (loss) income into earnings |  | $ | 1 |  |  | $ | 13 |  |  | $ | (4) |  |  | $ | (1) |  |  | $ | — |  |  | $ | 1 |

|  | Fiscal Nine Months Ended |
|  | September 28, 2025 |  | September 29, 2024 |
(Dollars in Millions) |  | Net Sales |  | Cost of Sales |  | Other Expense (Income), Net |  | Net Sales |  | Cost of Sales |  | Other Expense (Income), Net |
Gain (loss) reclassified from Other comprehensive (loss) income into earnings |  | $ | 1 |  |  | $ | 15 |  |  | $ | 7 |  |  | $ | (1) |  |  | $ | 12 |  |  | $ | (4) |  |

Forward Starting Interest Rate Swaps
The Company enters into forward starting interest rate swaps to manage future interest rate exposure related to changes in the benchmark rate on forecasted debt issuances. These contracts are designated as cash flow hedging relationships at the date of contract inception, in accordance with the appropriate accounting guidance. During the fiscal nine months ended September 28, 2025, the Company recorded a gain of $7 million in Accumulated other comprehensive loss related to the settlement of its forward starting interest rate swaps upon the issuance of long-term debt. The gain in Accumulated other comprehensive loss will be amortized and recorded in Interest expense, net in the Condensed Consolidated Statements of Operations as the hedged item impacts earnings. For the fiscal three and nine months ended September 28, 2025 and September 29, 2024, the amounts reclassified from Other comprehensive (loss) income to the Condensed Consolidated Statements of Operations were not significant.
Fair Value Hedges
Forward Foreign Exchange Contracts
The Company entered into forward foreign exchange contracts beginning in the fiscal three months ended March 31, 2024 to hedge against the risk of changes in the fair value of foreign-denominated intercompany debt attributable to foreign exchange rate fluctuations. These contracts are designated as fair value hedging relationships at the date of contract inception, in accordance with the appropriate accounting guidance. At inception, all designated fair value hedging relationships are expected to be highly effective. The contracts are accounted for using the spot method with changes in the fair value of the contract attributable to the changes in spot rates recorded within Other expense (income), net in the Condensed Consolidated Statements of Operations. The Company has elected to exclude the changes in the fair value attributable to the difference between the spot price and the forward price, as well as any cross currency basis spread, from the assessment of hedge effectiveness (the “Excluded Components”). The value of the Excluded Components was not significant to the Condensed Consolidated Financial Statements in the current fiscal period or prior fiscal period. The changes in fair value attributable to the Excluded Components are recorded in Accumulated other comprehensive loss and are recognized in Other expense (income), net in the Condensed Consolidated Statements of Operations on a systematic and rational basis over the life of the hedging instrument.
29

Net Investment Hedges
Cross Currency Swap Contracts
Beginning in the fiscal three months ended December 31, 2023, the Company entered into cross currency swap contracts to hedge exposure in foreign subsidiaries with local functional currencies. These contracts are designated as net investment hedges at the date of contract inception, in accordance with the appropriate accounting guidance. These contracts are accounted for using the spot method with changes in the fair value of the contracts attributable to changes in spot rates recorded within Cumulative Translation Adjustments (“CTA”) as a component of Other comprehensive (loss) income and will remain there until the hedged net investments are sold or substantially liquidated. The Company has elected to exclude the changes in the fair value attributable to time value and spot-forward rate differences (the “Excluded Net Investment Hedge Components on Cross Currency Swap Contracts”) from the assessment of the hedge effectiveness. The value of the Excluded Net Investment Hedge Components on Cross Currency Swap Contracts was not significant to the Condensed Consolidated Financial Statements in the current fiscal period or prior fiscal period. The changes in fair value attributable to the Excluded Net Investment Hedge Components on Cross Currency Swap Contracts are recognized into Interest expense, net in the Condensed Consolidated Statements of Operations on a systematic and rational basis through the swap accrual over the life of the hedging instrument.
The following table summarizes the gains and losses recognized within Other comprehensive (loss) income related to the cross currency swap contracts designated as net investment hedges for the fiscal three and nine months ended September 28, 2025 and September 29, 2024:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended |
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |  |
Gain (loss) recognized in CTA within Other comprehensive (loss) income |  | $ | 12 |  |  | $ | (76) |  |  | $ | (167) |  |  | $ | 4 |  |  |  |

Other than amounts excluded from effectiveness testing, the Company did not reclassify any gains or losses from CTA within Other comprehensive (loss) income to earnings during the fiscal three and nine months ended September 28, 2025 and September 29, 2024 related to the cross currency swap contracts designated as net investment hedges.
Undesignated Hedging Instruments
Undesignated Forward Foreign Exchange Contracts
The Company enters into forward foreign exchange contracts to offset the foreign currency exposure related to the monetary assets and liabilities in non-functional currencies. These contracts are not designated as cash flow hedging relationships, and the net allocated gains and losses related to these contracts are recognized within Other expense (income), net in the Condensed Consolidated Statements of Operations. As of September 28, 2025 and December 29, 2024, the Company held forward foreign exchange contracts that were not designated in cash flow hedging relationships with a fair value of $1 million and $0 million, respectively.
The following table summarizes the gains and losses recognized within Other expense (income), net related to the undesignated forward foreign exchange contracts for the fiscal three and nine months ended September 28, 2025 and September 29, 2024:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |  |
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |  |  |  |  |  |  |  |  |
Gain (loss) recognized in Other expense (income), net |  | $ | 1 |  |  | $ | 2 |  |  | $ | 1 |  |  | $ | (4) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Effectiveness
On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. When a derivative is no longer expected to be highly effective, hedge accounting is discontinued.
30

Statement of Cash Flows
Cash flows from derivatives designated in hedging relationships are reflected in the Condensed Consolidated Statements of Cash Flows consistent with the presentation of the hedged item. Cash flows from derivatives that were not accounted for as designated hedging relationships reflect the classification of the cash flows associated with the activities being economically hedged.
Credit Risk
The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is the Company’s policy to contract with diverse, creditworthy counterparties based upon both strong credit ratings and other credit considerations. The Company has negotiated International Swaps and Derivatives Association, Inc. master agreements with its counterparties, which contain master netting provisions providing the legal right and ability to offset exposures across trades with each counterparty. Given the rights provided by these contracts, the Company presents derivative balances based on its “net” counterparty exposure. These agreements do not require the posting of collateral.
13. Commitments and Contingencies
The Company and/or certain of its subsidiaries are involved from time to time in various lawsuits and claims relating to product liability, labeling, marketing, advertising, pricing, intellectual property, commercial contracts, foreign exchange controls, antitrust and trade regulation, labor and employment, indemnification, information technology systems, data privacy and cybersecurity, environmental, health and safety, tax matters, governmental investigations, and other legal proceedings that arise in the ordinary course of their business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. As of September 28, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accordingly accrued for those contingent liabilities and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments. Accrued liabilities related to litigation matters are included in Accrued liabilities and Other liabilities on the Condensed Consolidated Balance Sheets. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including whether, among other things, damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has commenced or is complete; proceedings are in early stages; matters present legal uncertainties; significant facts are in dispute; procedural or jurisdictional issues exist; the number of potential claims is certain or predictable; comprehensive multi-party settlements are achievable; there are complex related cross-claims and counterclaims; and/or there are numerous parties involved.
In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued on the Condensed Consolidated Balance Sheets, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.
Product Liability
The Company and/or certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive or exemplary damages or legal fees. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company may accrue an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company may accrue additional amounts such as estimated costs associated with settlements, damages, and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.
31

Claims for personal injury have been made against the Company’s subsidiary Johnson & Johnson Consumer Inc., now known as Kenvue Brands LLC (“JJCI”), along with other third-party sellers of acetaminophen-containing products, in federal court alleging that in utero exposure to acetaminophen (the active ingredient in Tylenol®, an over-the-counter (“OTC”) pain medication) is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder in children. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the U.S. District Court for the Southern District of New York. In February 2024, the court entered final judgment in favor of JJCI and the other sellers of acetaminophen-containing products and dismissed the majority of cases then pending in the multi-district litigation. A Notice of Appeal was filed for those cases in March 2024. In August 2024, all remaining cases then pending in the multi-district litigation were dismissed. As of December 2024, all cases were on appeal. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. In addition, lawsuits have been filed in state court against JJCI, the Company, and J&J. Lawsuits have also been filed in Canada against the Company’s subsidiary Johnson & Johnson Inc. (Canadian affiliate) (“JJI”) and J&J. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.
In October 2025, the State of Texas filed a petition in the District Court of Panola County, Texas, against the Company, Kenvue Brands LLC (formerly known as Johnson & Johnson Consumer Inc.) and J&J, alleging violations of the Texas Deceptive Trade Practices-Consumer Protection Act and the Texas Uniform Fraudulent Transfer Act relating to allegations that prenatal and early-childhood exposure to acetaminophen is associated with autism spectrum disorder and attention-deficit/hyperactivity disorder in children. The complaint seeks injunctive relief, civil penalties, disgorgement of assets, and other remedies. The Company awaits formal service, and at this stage in these proceedings, the Company is unable to reasonably estimate the likelihood or magnitude of potential liability arising from this matter.
In October 2025, claims for personal injury and, in some cases, consequential death, were brought in the Business and Property Courts in Manchester (Circuit Commercial Court, KBD) against Kenvue UK Limited, J&J, and J&J’s subsidiary, Johnson & Johnson Management Limited, in respect of Johnson’s® Baby Powder. The claimants allege they developed mesothelioma, ovarian cancer, lung granulomata, lung fibrosis, and/or uterine fibroids as a result of exposure to Johnson’s® Baby Powder. The claimants claim that the defendants are liable for negligence and the tort of deceit. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims.
General Litigation
In 2006, J&J acquired Pfizer’s OTC business including the U.S. rights to OTC Zantac, which were on-sold to Boehringer Ingelheim (“BI”) as a condition to merger control approval such that BI assumed product liability risk for U.S. sales from and after December 2006. J&J received indemnification from BI and gave Pfizer indemnification in connection with the transfer of the Zantac business to BI from Pfizer, through J&J. In November 2019, J&J received a demand for indemnification from Pfizer, pursuant to the 2006 Stock and Asset Purchase Agreement between J&J and Pfizer. In January 2020, J&J received a demand for indemnification from BI, pursuant to the 2006 Asset Purchase Agreement among J&J, Pfizer, and BI. Pursuant to the agreements, Pfizer and BI have asserted indemnification claims against J&J ostensibly related to Zantac sales by Pfizer. In November 2022, J&J received a demand for indemnification from GlaxoSmithKline LLC, pursuant to the 2006 Stock and Asset Purchase Agreement between J&J and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to OTC Zantac (ranitidine) products. Plaintiffs in the underlying actions allege that Zantac and other OTC medications that contain ranitidine may degrade and result in unsafe levels of NDMA (N-nitrosodimethylamine) and can cause or have caused various cancers in individuals using the products and seek declaratory and monetary relief. J&J has rejected all the demands for indemnification relating to the underlying actions. No J&J entity sold Zantac in the United States.
In 2016, JJI sold the Canadian Zantac business to Sanofi Consumer Health, Inc. (“Sanofi”). Under the 2016 Asset Purchase Agreement between JJI and Sanofi (the “2016 Purchase Agreement”), Sanofi assumed certain liabilities including those pertaining to Zantac (ranitidine) product sold by Sanofi after closing and losses arising from or relating to recalls, withdrawals, replacements, or related market actions or post-sale warning in respect of products sold by Sanofi after the closing, and JJI is required to indemnify Sanofi for certain other excluded liabilities. In November 2019, JJI received a notice reserving rights to claim indemnification from Sanofi pursuant to the 2016 Purchase Agreement. The notice refers to indemnification for legal claims in class actions and various individual personal injury actions with similar allegations to the U.S. litigation related to OTC Zantac (ranitidine) products.
Beginning in 2019, multiple putative class actions naming J&J and/or JJI were filed in Canada with similar allegations regarding Zantac or ranitidine use. JJI is named in one of the two outstanding putative class actions. The outstanding putative
32

class action naming JJI has been stayed in the Quebec Superior Court. The Ontario Superior Court of Justice action, which named J&J and JJI and was previously pending, was discontinued by court order in May 2025. JJI was also named as a defendant, along with other manufacturers, in various personal injury actions in Canada related to Zantac products. JJI has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Purchase Agreement related to the class actions and personal injury actions. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.
In September 2023, the Nonprescription Drugs Advisory Committee (the “NDAC”) of the U.S. Food and Drug Administration (the “FDA”) met to discuss new data on the effectiveness of orally administered phenylephrine (“PE”) and concluded that the current scientific data do not support that the recommended dosage of orally administered PE is effective as a nasal decongestant. Neither the FDA nor the NDAC raised concerns about safety issues with use of oral PE at the recommended dose. In November 2024, the FDA issued a proposed order to remove the ingredient from the OTC monograph. Beginning in September 2023, following the NDAC vote, putative class actions were filed against the Company and its affiliates, along with other third-party sellers and manufacturers of PE-containing products, asserting various causes of action including violation of consumer protection statutes, negligence, and unjust enrichment. The complaints seek damages and injunctive relief. In December 2023, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the U.S. District Court for the Eastern District of New York. In November 2024, the U.S. District Court for the Eastern District of New York dismissed plaintiffs’ streamlined complaint, and a Notice of Appeal was filed in December 2024. Separately, putative Canadian class actions were filed beginning in September 2023 against the Company’s affiliates, along with other third-party sellers and manufacturers of PE-containing products, alleging false, misleading representations, and seeking damages and declaratory relief based on similar causes of action. In December 2024, a representative action was filed in the Federal Court of Australia, Victoria Registry, against the Company’s subsidiary Johnson & Johnson Pacific Pty Limited alleging contraventions of the consumer guarantees regime and seeking damages and associated relief based on broadly similar causes of action to those in the United States. In February 2025, a representative action was filed in the High Court of New Zealand, Auckland Registry against Johnson & Johnson (New Zealand) Limited and the Company’s subsidiaries JNTL Consumer Health (New Zealand) Limited and Johnson & Johnson Pacific Pty Limited, alleging breaches of the Fair Trading Act 1986 and the Consumer Guarantees Act 1993.
Additionally, beginning in October 2023, two putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain of its officers, among other defendants. In December 2023, the two cases were consolidated as In re Kenvue Inc. Securities Litigation and a lead plaintiff was appointed. In March 2024, a consolidated amended complaint was filed that named the Company’s directors as defendants in addition to the defendants named in the initial complaints. The consolidated amended complaint brings claims under the Securities Act of 1933, as amended. It alleges that the Company’s registration statements and prospectuses filed with the SEC in connection with the Kenvue IPO on Form S-1 and the Exchange Offer on Form S-4 contained misleading statements and omissions about PE. It seeks damages for all shareholders who acquired shares pursuant to the Kenvue IPO and the Exchange Offer registration statements and prospectuses.
In January 2024, shareholder derivative complaints were filed in the U.S. District Court for the District of New Jersey against the Company as the nominal defendant and the Company’s directors and certain of its officers as defendants, among other defendants. The derivative complaints allege breaches of fiduciary duties based on disclosures in the Company’s SEC filings regarding PE, and they seek damages and equitable relief. The derivative complaints have been consolidated as In re Kenvue, Inc. Derivative Litigation and have been stayed. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.
In March 2024, following the filing of a Citizen Petition with the FDA by Valisure LLC that included testing results purporting to show that benzoyl peroxide (“BPO”) OTC acne products can degrade into benzene at levels well above the alleged limit of two parts per million, putative class actions were filed against the Company and its affiliates, along with other third-party sellers and manufacturers of BPO-containing acne products, asserting various causes of action including violation of consumer protection statutes, negligence, breach of express and implied warranties, and unjust enrichment. The complaints, pending in the U.S. District Court for the District of New Jersey, seek damages and injunctive relief. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.
JJCI, along with more than 120 other companies, is a defendant in a cost recovery action brought by Occidental Chemical Corporation in June 2018 in the U.S. District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. Certain defendants (not including JJCI) have executed a settlement with the U.S. Environmental Protection Agency and U.S. Department of Justice, which was confirmed through a judicial Consent Decree in
33

December 2024. A Notice of Appeal was filed in January 2025. The case has been administratively closed but can be re-opened upon request.
The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local, or foreign laws in which the primary relief sought is the Company’s agreement to implement environmental investigation and remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing investigation, oversight, or remediation at such sites.
Other
A significant number of personal injury claims alleging that talc causes cancer were made against J&J and certain of its current and former affiliates, including the Company, arising out of the use of body powders containing talc, primarily Johnson’s® Baby Powder. These personal injury suits were and continue to be filed primarily in state and federal courts in the United States and in Canada.
Pursuant to the Separation Agreement, J&J has retained all liabilities on account of or relating to harm arising out of, based upon or resulting from, directly or indirectly, the presence of or exposure to talc or talc-containing products sold by J&J or its affiliates in the United States and Canada (the “Talc-Related Liabilities”) and, as a result, has agreed to indemnify the Company for the Talc-Related Liabilities and any costs associated with resolving such claims, including matters that have commenced in the United States and Canada naming the Company or its affiliates. The Company will, however, remain responsible for all liabilities on account of or relating to harm arising out of, based upon or resulting from, directly or indirectly, the presence of or exposure to talc or talc-containing products sold outside the United States or Canada.
14. Segments of Business
The Company is organized into three reportable business segments: Self Care, Skin Health and Beauty, and Essential Health.
The Company’s Chief Operating Decision Maker (the “CODM”), the Chief Executive Officer, uses Segment adjusted operating income as the measure of profit or loss and to evaluate the performance of the Company’s segments. For each segment, the CODM uses this information to assist in evaluating underlying trends, to monitor budget and forecast versus actual results, to make investment decisions to allocate resources both in total, and between the segments, and to make key segment personnel decisions. Segment profit is based on Operating income, excluding depreciation, amortization of intangible assets, Separation-related costs, restructuring expenses and operating model optimization initiatives, impairment charges, the impact of the conversion of stock-based awards, issuance of Founder Shares (as defined below), Other operating expense, net, and unallocated general corporate administrative expenses (referred to herein as “Segment adjusted operating income”), as the CODM excludes these items in assessing segment financial performance. General corporate/unallocated expenses, which include expenses related to treasury, legal operations, and certain other expenses, along with gains and losses related to the overall management of the Company, are not allocated to the segments. In assessing segment performance and managing operations, the CODM does not review segment assets.
The Company operates the business through the following three reportable business segments based on product categories:

Reportable Segments | Product Categories
Self Care | Cough, Cold, and Allergy
| Pain Care
| Other Self Care (Digestive Health, Smoking Cessation, Eye Care, and Other)
Skin Health and Beauty | Face and Body Care
| Hair, Sun, and Other
Essential Health | Oral Care
| Baby Care
| Other Essential Health (Women’s Health, Wound Care, and Other)

34

The Company’s product categories as a percentage of Net sales for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 were as follows:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
Product Categories |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Cough, Cold, and Allergy |  | 13 | % |  | 13 | % |  | 14 | % |  | 14 | % |  |
Pain Care |  | 13 |  |  | 14 |  |  | 13 |  |  | 13 |  |  |
Other Self Care |  | 16 |  |  | 15 |  |  | 15 |  |  | 15 |  |  |
Face and Body Care |  | 20 |  |  | 20 |  |  | 19 |  |  | 19 |  |  |
Hair, Sun, and Other |  | 8 |  |  | 7 |  |  | 8 |  |  | 9 |  |  |
Oral Care |  | 10 |  |  | 11 |  |  | 11 |  |  | 10 |  |  |
Baby Care |  | 9 |  |  | 9 |  |  | 9 |  |  | 9 |  |  |
Other Essential Health |  | 11 |  |  | 11 |  |  | 11 |  |  | 11 |  |  |
Total |  | 100 | % |  | 100 | % |  | 100 | % |  | 100 | % |  |

Segment Net Sales and Segment Adjusted Operating Income
Segment net sales and Segment adjusted operating income for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 were as follows:

|  | Fiscal Three Months Ended |  |
|  | September 28, 2025 |  | September 29, 2024 |  |
(Dollars in Millions) |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  |  |  |
Net sales |  | $ | 1,564 |  |  | $ | 1,038 |  |  | $ | 1,162 |  |  | $ | 3,764 |  |  | $ | 1,625 |  |  | $ | 1,072 |  |  | $ | 1,202 |  |  | $ | 3,899 |  |  |  |  |
Segment adjusted Cost of sales(1) |  | 546 |  |  | 401 |  |  | 512 |  |  | 1,459 |  |  | 569 |  |  | 421 |  |  | 539 |  |  | 1,529 |  |  |  |  |
Other segment expense items(2) |  | 498 |  |  | 500 |  |  | 343 |  |  | 1,341 |  |  | 499 |  |  | 460 |  |  | 372 |  |  | 1,331 |  |  |  |  |
Segment adjusted operating income |  | $ | 520 |  |  | $ | 137 |  |  | $ | 307 |  |  | $ | 964 |  |  | $ | 557 |  |  | $ | 191 |  |  | $ | 291 |  |  | $ | 1,039 |  |  |  |  |
Reconciliation to Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation(3) |  |  |  |  |  |  |  | 75 |  |  |  |  |  |  |  |  | 94 |  |  |  |  |
Amortization of intangible assets(4) |  |  |  |  |  |  |  | 66 |  |  |  |  |  |  |  |  | 66 |  |  |  |  |
Separation-related costs(5) |  |  |  |  |  |  |  | 17 |  |  |  |  |  |  |  |  | 85 |  |  |  |  |
Restructuring expenses and operating model optimization initiatives(6) |  |  |  |  |  |  |  | 97 |  |  |  |  |  |  |  |  | 38 |  |  |  |  |
Conversion of stock-based awards(8) |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  | 6 |  |  |  |  |
Founder Shares(9) |  |  |  |  |  |  |  | (4) |  |  |  |  |  |  |  |  | 7 |  |  |  |  |
Other operating expense, net |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  | 7 |  |  |  |  |
General corporate/unallocated expenses |  |  |  |  |  |  |  | 82 |  |  |  |  |  |  |  |  | 82 |  |  |  |  |
Operating income |  |  |  |  |  |  |  | $ | 629 |  |  |  |  |  |  |  |  | $ | 654 |  |  |  |  |
Other expense (income), net |  |  |  |  |  |  |  | 10 |  |  |  |  |  |  |  |  | (19) |  |  |  |  |
Interest expense, net |  |  |  |  |  |  |  | 93 |  |  |  |  |  |  |  |  | 96 |  |  |  |  |
Income before taxes |  |  |  |  |  |  |  | $ | 526 |  |  |  |  |  |  |  |  | $ | 577 |  |  |  |  |

35

|  | Fiscal Nine Months Ended |  |  |  |
|  | September 28, 2025 |  | September 29, 2024 |  |  |  |
(Dollars in Millions) |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 4,786 |  |  | $ | 3,074 |  |  | $ | 3,484 |  |  | $ | 11,344 |  |  | $ | 4,958 |  |  | $ | 3,229 |  |  | $ | 3,606 |  |  | $ | 11,793 |  |  |  |  |  |  |  |  |  |  |  |  |
Segment adjusted Cost of sales(1) |  | 1,681 |  |  | 1,236 |  |  | 1,539 |  |  | 4,456 |  |  | 1,693 |  |  | 1,324 |  |  | 1,597 |  |  | 4,614 |  |  |  |  |  |  |  |  |  |  |  |  |
Other segment expense items(2) |  | 1,492 |  |  | 1,460 |  |  | 1,048 |  |  | 4,000 |  |  | 1,573 |  |  | 1,403 |  |  | 1,095 |  |  | 4,071 |  |  |  |  |  |  |  |  |  |  |  |  |
Segment adjusted operating income |  | $ | 1,613 |  |  | $ | 378 |  |  | $ | 897 |  |  | $ | 2,888 |  |  | $ | 1,692 |  |  | $ | 502 |  |  | $ | 914 |  |  | $ | 3,108 |  |  |  |  |  |  |  |  |  |  |  |  |
Reconciliation to Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation(3) |  |  |  |  |  |  |  | 226 |  |  |  |  |  |  |  |  | 238 |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization of intangible assets(4) |  |  |  |  |  |  |  | 193 |  |  |  |  |  |  |  |  | 212 |  |  |  |  |  |  |  |  |  |  |  |  |
Separation-related costs(5) |  |  |  |  |  |  |  | 79 |  |  |  |  |  |  |  |  | 231 |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring expenses and operating model optimization initiatives(6) |  |  |  |  |  |  |  | 232 |  |  |  |  |  |  |  |  | 146 |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment charges(7) |  |  |  |  |  |  |  | — |  |  |  |  |  |  |  |  | 578 |  |  |  |  |  |  |  |  |  |  |  |  |
Conversion of stock-based awards(8) |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  | 34 |  |  |  |  |  |  |  |  |  |  |  |  |
Founder Shares(9) |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |  |  |  |  |  |  |  |
Other operating expense, net |  |  |  |  |  |  |  | 19 |  |  |  |  |  |  |  |  | 29 |  |  |  |  |  |  |  |  |  |  |  |  |
General corporate/unallocated expenses |  |  |  |  |  |  |  | 251 |  |  |  |  |  |  |  |  | 258 |  |  |  |  |  |  |  |  |  |  |  |  |
Operating income |  |  |  |  |  |  |  | $ | 1,879 |  |  |  |  |  |  |  |  | $ | 1,358 |  |  |  |  |  |  |  |  |  |  |  |  |
Other expense, net |  |  |  |  |  |  |  | 26 |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  |  |  |  |  |  | 281 |  |  |  |  |  |  |  |  | 283 |  |  |  |  |  |  |  |  |  |  |  |  |
Income before taxes |  |  |  |  |  |  |  | $ | 1,572 |  |  |  |  |  |  |  |  | $ | 1,069 |  |  |  |  |  |  |  |  |  |  |  |  |

(1) The Company defines Segment adjusted cost of sales as Cost of sales adjusted for amortization of intangible assets, Separation-related costs, conversion of stock-based awards, Founder Shares (as defined below), operating model optimization initiatives, and general corporate/unallocated expenses.
(2) Other segment expense items for each reportable segment include brand support, employee-related costs, shipping and handling costs, research and development costs, and certain other operating expenses (income).
(3) Depreciation consists of depreciation of property, plant, and equipment and amortization of integration and development costs capitalized in connection with cloud computing arrangements.
(4) Relates to the amortization of definite-lived intangible assets (primarily trademarks, trade names, and customer lists) over their estimated useful lives.
(5) Separation-related costs includes depreciation expense on Separation-related assets for the fiscal three and nine months ended September 29, 2024. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Separation-Related Costs,” for additional information regarding Separation-related costs.
(6) Restructuring expenses and operating model optimization initiatives relate to the 2024 Multi-Year Restructuring Initiative (as defined in Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives”). See Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” for additional information.
(7) Impairment charges includes $488 million recognized in the fiscal three months ended June 30, 2024 in relation to Dr.Ci:Labo® long-lived assets, $68 million recognized in the fiscal three months ended March 31, 2024 on the held for sale asset associated with the Company’s former corporate headquarters in Skillman, New Jersey, and $22 million recognized in the fiscal three months ended June 30, 2024 on certain software development assets. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment Charges,” for additional information.
(8) Segment adjusted operating income excludes the impact of the conversion of stock-based awards that occurred on August 23, 2023. The adjustment represents the net impact of the gain on reversal of previously recognized stock-based compensation expense, offset by stock-
36

based compensation expense recognized in the fiscal three and nine months ended September 28, 2025 and September 29, 2024 relating to employee services provided prior to the Separation.
(9) On August 25, 2023, the Company’s Compensation & Human Capital Committee approved equity grants to individuals employed by Kenvue as of October 2, 2023 (the “Founder Shares”). On October 2, 2023, the Founder Shares were granted to all Kenvue employees in the form of stock options and PSUs to executive officers and either stock options and PSUs or RSUs to non-executive individuals.
Depreciation and Amortization
Depreciation and amortization by reportable segment for the fiscal three and nine months ended September 28, 2025 and September 29, 2024 were as follows:

|  | Fiscal Three Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | September 28, 2025 |  | September 29, 2024 |  |
Self Care |  | $ | 52 |  |  | $ | 70 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 154 |  |  | $ | 155 |  |  |
Skin Health and Beauty |  | 32 |  |  | 46 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 94 |  |  | 143 |  |  |
Essential Health |  | 57 |  |  | 66 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 171 |  |  | 174 |  |  |
Total depreciation and amortization(1) |  | $ | 141 |  |  | $ | 182 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 419 |  |  | $ | 472 |  |  |

(1) Depreciation consists of depreciation of property, plant, and equipment and amortization of integration and development costs capitalized in connection with cloud computing arrangements. Amortization relates to the amortization of intangible assets.
15. Restructuring Expenses and Operating Model Optimization Initiatives
As part of the Company’s continued transformation to a fit-for-purpose consumer company, during the fiscal year 2024, the Company began strategic initiatives intended to enhance organizational efficiencies and better position Kenvue for future growth (“Our Vue Forward”). To further Our Vue Forward, on May 6, 2024, the Company’s Board of Directors approved a multi-year initiative (the “2024 Multi-Year Restructuring Initiative”) to build on the Company’s strengths, improve underlying information technology infrastructure, and optimize its cost structure by rebalancing resources to better position the Company for future growth. The 2024 Multi-Year Restructuring Initiative primarily includes global workforce reductions, changes in management structure, and the transition to centralized shared-service functions in lower-cost locations.
The 2024 Multi-Year Restructuring Initiative is expected to result in pre-tax restructuring expenses and other charges totaling approximately $550 million, consisting of information technology and project-related costs (approximately 50%), employee-related costs (approximately 40%), and other implementation costs (approximately 10%). These charges are expected to be funded primarily through cash flows generated from operations. The Company planned to incur approximately $275 million in pre-tax restructuring expenses and other charges in each of fiscal year 2024 and fiscal year 2025. The Company incurred lower than expected spend in fiscal year 2024 due to the shift in timing of certain information technology and project-related costs to fiscal year 2025.
The following table summarizes the classification of pre-tax restructuring expenses and other charges incurred related to the 2024 Multi-Year Restructuring Initiative during the fiscal three and nine months ended September 28, 2025 and September 29, 2024:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |
Restructuring expenses |  | $ | 84 |  |  | $ | 31 |  |  | $ | 204 |  |  | $ | 120 |  |  |
Cost of sales |  | 8 |  |  | 4 |  |  | 20 |  |  | 19 |  |  |
Selling, general, and administrative expenses |  | 5 |  |  | 3 |  |  | 8 |  |  | 7 |  |  |
Total pre-tax restructuring expenses and other charges |  | $ | 97 |  |  | $ | 38 |  |  | $ | 232 |  |  | $ | 146 |  |  |

37

The following table summarizes the pre-tax restructuring expenses and other charges incurred by cost type related to the 2024 Multi-Year Restructuring Initiative during the fiscal three and nine months ended September 28, 2025 and September 29, 2024 and inception-to-date through September 28, 2025:

|  | Fiscal Three Months Ended |  | Fiscal Nine Months Ended |  | Inception-To-Date Through September 28, 2025
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024 |  |  |
Employee-related costs(1) |  | $ | 32 |  |  | $ | 17 |  |  | $ | 78 |  |  | $ | 81 |  |  |  |  | $ | 184 |
Information technology and project-related costs(2) |  | 60 |  |  | 18 |  |  | 147 |  |  | 49 |  |  |  |  | 246 |
Other implementation costs(3) |  | 5 |  |  | 3 |  |  | 7 |  |  | 16 |  |  |  |  | 23 |
Total pre-tax restructuring expenses and other charges |  | $ | 97 |  |  | $ | 38 |  |  | $ | 232 |  |  | $ | 146 |  |  |  |  | $ | 453 |

(1) Employee-related costs primarily include severance and other termination benefits.
(2) Information technology and project-related costs primarily include advisory costs to operationalize the initiative.
(3) Other implementation costs primarily include costs to terminate contracts, impairments of assets, and other associated costs to exit.
The following table summarizes the activity related to accrued restructuring expenses and other charges for the 2024 Multi-Year Restructuring Initiative during the fiscal nine months ended September 28, 2025:

(Dollars in Millions) |  |  |  |  |  | Employee-Related Costs(1) |  | Information Technology and Project-Related Costs(2) |  | Other Implementation Costs(3) |  | Total Accrued Costs
December 29, 2024 |  |  |  |  |  | $ | 25 |  |  | $ | 65 |  |  | $ | 3 |  |  | $ | 93 |
Charges to earnings |  |  |  |  |  | 78 |  |  | 147 |  |  | 7 |  |  | 232 |
Cash payments |  |  |  |  |  | (69) |  |  | (141) |  |  | (4) |  |  | (214) |
Non-cash charges |  |  |  |  |  | — |  |  | — |  |  | (4) |  |  | (4) |
September 28, 2025 |  |  |  |  |  | $ | 34 |  |  | $ | 71 |  |  | $ | 2 |  |  | $ | 107 |

(1) Employee-related costs primarily include severance and other termination benefits.
(2) Information technology and project-related costs primarily include advisory costs to operationalize the initiative.
(3) Other implementation costs primarily include costs to terminate contracts, impairments of assets, and other associated costs to exit.
16. Subsequent Events
On November 2, 2025, the Company entered into the Merger Agreement with K-C, the First Merger Sub, and the Second Merger Sub, pursuant to which, among other things, 1) First Merger Sub shall merge with and into the Company (the “First Merger”), with the Company surviving as a direct wholly owned subsidiary of K-C (the “Initial Surviving Company”) (the time the First Merger becomes effective being the “First Effective Time”), and 2) immediately following the First Merger, and as part of the same overall transaction as the First Merger, the Initial Surviving Company shall merge with and into Second Merger Sub (collectively, the “Transaction”).
At the First Effective Time, pursuant to the terms and subject to the conditions of the Merger Agreement, each share of Company common stock issued and outstanding immediately prior to the First Effective Time (other than shares of Company common stock that (x) are owned by K-C or the Company or any wholly owned subsidiary of K-C or the Company (or are held in treasury by the Company) or (y) are held by any Company stockholder who is entitled to demand and properly demands appraisal of such shares pursuant to, and who complies in all respects with, Section 262 of the General Corporation Law of the State of Delaware) shall be converted into the right to receive 1) 0.14625 shares of K-C common stock, par value $1.25 per share (the “K-C Common Stock” and the shares of K-C Common Stock to be issued in connection with the First Merger, the
38

“Stock Consideration”), plus 2) $3.50 in cash (the “Cash Consideration” and, together with the Stock Consideration, the “Merger Consideration”).
Upon completion of the Transaction, current Company stockholders are expected to own approximately 46% and current K-C stockholders are expected to own approximately 54% of the combined company on a fully diluted basis. K-C has agreed to take all necessary actions to cause, effective as of the First Merger, the K-C Board to consist of three Company designees, with the remainder consisting of existing members of the K-C Board as of immediately prior to the First Merger.
39

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This discussion contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions, and projections about our industry, business, and future financial results. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed in Part I, Item 1A,“Risk Factors,” in our Annual Report on Form 10-K for the fiscal twelve months ended December 29, 2024 filed on February 24, 2025 with the SEC (the “Annual Report”), Part II, Item 1A, “Risk Factors,” included herein, and the section titled “Cautionary Note Regarding Forward-Looking Statements” included herein.
This discussion should be read in conjunction with our accompanying Condensed Consolidated Financial Statements for the fiscal three and nine months ended September 28, 2025, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the SEC for interim financial statements, and our audited consolidated financial statements for the fiscal twelve months ended December 29, 2024, which are included in the Annual Report. In our opinion, the Condensed Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations, and cash flows for the periods indicated. All currency amounts are expressed in U.S. dollars unless otherwise noted.
Unless otherwise defined herein, capitalized terms related to the proposed Transaction used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations have the meanings ascribed to them in the Notes to the Condensed Consolidated Financial Statements included in this Form 10-Q.
Overview
Company Overview
At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.5 billion in Net sales in the fiscal year 2024. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®—is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands.
Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products, allowing us to connect with consumers globally—in their daily rituals and the moments that matter most.
Our global scale and the breadth of our brand portfolio are complemented by our well-developed capabilities and accelerated through our digital strategy, allowing us to dynamically capitalize on and respond to current trends impacting our categories and geographic markets.
With a sole focus on consumer health, our marketing organization operates efficiently by leveraging our precision marketing, e-commerce, and broader digital capabilities to develop unique consumer insights and further enhance the relevance of our brands. Similarly, our research and development organization combines these consumer insights with deep, multi-disciplinary scientific expertise, and engagement with healthcare professionals, to drive innovative new products, solutions, and experiences centered around consumer health.
Our Business Segments
We operate our business through the following three reportable business segments:
•Self Care. Our Self Care product categories include: Cough, Cold, and Allergy; Pain Care; and Other Self Care (Digestive Health, Smoking Cessation, Eye Care, and Other). Major brands in the segment include Tylenol®, Motrin®, Nicorette®, Benadryl®, Zyrtec®, Zarbee’s®, ORSL®, Rhinocort®, and Calpol®.
•Skin Health and Beauty. Our Skin Health and Beauty product categories include: Face and Body Care; and Hair, Sun, and Other. Major brands in the segment include Neutrogena®, Aveeno®, Dr.Ci:Labo®, OGX®, Le Petit Marseillais®, Lubriderm®, and Rogaine®.
40

•Essential Health. Our Essential Health product categories include: Oral Care; Baby Care; and Other Essential Health (Women’s Health, Wound Care, and Other). Major brands in the segment include Listerine®, Johnson’s®, BAND-AID® Brand, Stayfree®, o.b.® tampons, Carefree®, and Desitin®.
For additional information about our three reportable business segments, see Note 14, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein.
Separation from J&J
In November 2021, J&J, our former parent company, announced its intention to separate its Consumer Health segment (the “Consumer Health Business”) into an independent publicly traded company (the “Separation”). Kenvue was incorporated in Delaware in February 2022, as a wholly owned subsidiary of J&J, to serve as the ultimate parent company of J&J’s Consumer Health Business. In April 2023, J&J completed the transfer of substantially all of the assets and liabilities of the Consumer Health Business to us and our subsidiaries. In May 2023, we completed an initial public offering (the “Kenvue IPO”) and began trading on the New York Stock Exchange under the ticker symbol “KVUE.” In July 2023, J&J announced an exchange offer (the “Exchange Offer”) under which its shareholders could exchange shares of J&J common stock for shares of our common stock owned by J&J. In August 2023, J&J completed the Exchange Offer, completing the Separation from J&J and transition to being a fully independent public company. In May 2024, J&J completed an additional exchange offer (the “Debt-for-Equity Exchange”) through which J&J exchanged indebtedness of J&J for shares of our common stock owned by J&J. Following the completion of the Debt-for-Equity Exchange, J&J did not own any shares of our common stock.
We are incurring certain non-recurring separation-related costs in connection with our establishment as a standalone public company (the “Separation-related costs”). Separation-related costs associated with information technology and other activities, primarily related to the disentanglement of systems and the discontinuance of certain information technology assets, are substantially completed. However, costs related to legal entity name changes and certain other separation-related activities are expected to continue for a longer period than originally anticipated. For additional information about the Separation, see Note 1, “Description of the Company and Summary of Significant Accounting Policies,” and Note 8, “Relationship with J&J,” to the Condensed Consolidated Financial Statements included herein.
Relationship with J&J
We entered into the Separation Agreement and various other agreements with J&J for the purpose of effecting the Separation. These agreements provide a framework for our relationship with J&J and govern various interim and ongoing relationships between us and J&J that follow the completion of the Kenvue IPO. See Note 8, “Relationship with J&J,” to the Condensed Consolidated Financial Statements included herein for additional information on these agreements.
Kenvue Global and North America Headquarters
On April 20, 2023, we entered into a long-term lease for a newly renovated global and North America corporate headquarters building and a newly constructed research and development building in Summit, New Jersey (the “Global and North America Headquarters Lease”). In March 2025, we began operating out of the new global and North America corporate headquarters. The relocation to our new campus from multiple U.S.-based locations will continue through 2026 when the new research and development building is expected to be complete. When construction is completed, the campus will encompass approximately 290,000 square feet. The Global and North America Headquarters Lease collectively includes the lease associated with the global and North America corporate headquarters building, the lease associated with the land where the research and development building is under construction, and the lease associated with land used for amenities.
On February 21, 2024, we listed our former corporate headquarters in Skillman, New Jersey for sale, which met the criteria to be classified as held for sale at that date. The Skillman, New Jersey facility continues to meet the criteria for held for sale classification as of September 28, 2025. For the fiscal three months ended March 31, 2024, an impairment charge of $68 million was recorded on the held for sale asset associated with the former corporate headquarters in Skillman. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment Charges—Assets Held for Sale,” to the Condensed Consolidated Financial Statements included herein for more information.
41

Recent Developments
Strategic Review and Proposed Transaction with Kimberly-Clark
In July 2025, we announced that our Board of Directors (our “Board”) had previously initiated a comprehensive review of strategic alternatives and has established a strategic review committee (the “Strategic Review Committee”) to oversee the ongoing process. On November 2, 2025, following our Board’s review of strategic alternatives, our Board unanimously approved the execution of the Merger Agreement pursuant to which K-C will acquire all of the outstanding shares of the Company for a combination of stock and cash in a series of transactions, as described in Note 16, “Subsequent Events,” to the Condensed Consolidated Financial Statements included herein. Pursuant to the terms and subject to the conditions of the Merger Agreement, Company stockholders will receive the Merger Consideration consisting of 1) 0.14625 shares of K-C common stock and 2) $3.50 in cash for each share of the Company they own. Upon completion of the Transaction, current K-C stockholders are expected to own approximately 54%, and current Company stockholders are expected to own approximately 46% of the combined company on a fully diluted basis.
The Merger Agreement contains customary representations, warranties, covenants, and termination rights. The Transaction is expected to close in the second half of 2026 and is conditioned on the approval by the Company’s stockholders of a proposal to adopt the Merger Agreement and by K-C stockholders of a proposal to approve the issuance of K-C common stock in connection with the First Merger, as well as the satisfaction or waiver of other customary closing conditions, including the receipt of antitrust clearance in the United States and a number of foreign regulatory approvals.
Acetaminophen Regulatory Developments
In September 2025, officials in the United States federal government alleged that in utero exposure to acetaminophen (the active ingredient in Tylenol®, an over-the-counter pain medication) may be associated with an increased risk of neurological conditions such as autism spectrum disorder and attention-deficit/hyperactivity disorder in children and cautioned against the use of Tylenol® by pregnant women. The U.S. Food and Drug Administration (“FDA”) also stated it initiated the process for a label change for acetaminophen and issued a notice to physicians. A third party, Informed Consent Action Network, filed a citizen petition regarding safety-related labeling changes for the use of over-the-counter acetaminophen-containing drug products during pregnancy. Our subsidiary, Kenvue Brands LLC, submitted its response to the citizen petition in October 2025, requesting that the FDA deny the petition. The foregoing actions may depress sales of acetaminophen and could result in an increased risk of future litigation containing similar claims. See Note 13, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein for details regarding certain litigation matters that are currently pending related to acetaminophen.
Goodwill
During the fiscal three months ended September 28, 2025, there was a reassessment of the long-term outlook for the Skin Health and Beauty business. The revised outlook aimed to address slower growth in the broader skincare categories, as well as the recent decline in profitability of the Skin Health and Beauty reporting unit. We revised the internal forecasts to reflect the updated outlook. These changes in circumstances were determined to be a triggering event, which resulted in a quantitative interim impairment assessment of the fair value of the Skin Health and Beauty reporting unit.
We estimate the fair value of a reporting unit using a combination of a discounted cash flow model and a market-based approach. The discounted cash flow model relies on assumptions regarding revenue and net income growth rates, projected working capital needs, capital expenditures, and discount rates. Forecasted cash flows are discounted to present value to estimate the fair value. Under the market-based approach, we utilize the guideline public company method and market transaction method. These methods utilize valuation multiples derived from comparable publicly traded companies and relevant industry transactions, which are then applied to the reporting unit’s operating performance metrics. Based on the results of the assessment, the estimated fair value of the Skin Health and Beauty reporting unit exceeded the carrying value by approximately 10%; therefore, no impairment charge was recorded for the fiscal three months ended September 28, 2025. If all other assumptions were held constant, an increase of approximately 100 basis points in the selected discount rate would have resulted in an impairment charge.
A decline in forecasted Net sales or net income, or adverse macroeconomic developments such as rising interest rates, could significantly reduce the excess between fair value and carrying value. We will continue to monitor the performance of the Skin Health and Beauty business; however, further deterioration of market conditions or an inability to execute on our strategies could lead to an impairment charge of the goodwill associated with the Skin Health and Beauty reporting unit in the future.
42

Macroeconomic Developments
Macroeconomic developments, including changes in global trade policies, may adversely affect prevailing economic conditions and our business, results of operations, or financial condition. In 2025, the U.S. government issued executive orders imposing tariffs on goods imported into the United States. These actions, as well as retaliatory tariffs imposed by other countries on U.S. exports, are expected to increase supply chain costs in certain geographies and create economic uncertainty for consumers. While the situation is fluid, based on our preliminary analysis of the effects of the tariffs that have been implemented by the United States and retaliatory measures that are in effect as of the reporting date, we estimate incremental gross tariff exposure of approximately $150 million annualized. We continue to monitor the potential impacts that the increased tariffs and other trade restrictions may have on our business, and we continue to focus on internal mitigating actions to partially offset the impact.
Key Factors Affecting Our Results
We believe that our performance and future success depend on a number of factors that present significant opportunities for us but also pose risks and challenges, including those discussed below, in Part I, Item 1A, “Risk Factors,” in our Annual Report, Part II, Item 1A, “Risk Factors,” included herein, and the section titled “Cautionary Note Regarding Forward-Looking Statements” included herein.
Restructuring
As part of our continued transformation to a fit-for-purpose consumer company, during the fiscal year 2024, we began strategic initiatives intended to enhance organizational efficiencies and better position us for future growth (“Our Vue Forward”). To further Our Vue Forward, on May 6, 2024, our Board approved a multi-year initiative (the “2024 Multi-Year Restructuring Initiative”) to build on our strengths, improve our underlying information technology infrastructure, and optimize our cost structure by rebalancing resources to better position us for future growth. The 2024 Multi-Year Restructuring Initiative primarily includes global workforce reductions, changes in management structure, and the transition to centralized shared-service functions in lower-cost locations. See Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for further information.
Acquisitions and Divestitures
We did not complete any significant acquisitions or divestitures during the fiscal three and nine months ended September 28, 2025 and September 29, 2024.
Legal Proceedings
See Note 13, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein for additional information regarding our current legal proceedings.
43

Results of Operations
Fiscal Three Months Ended September 28, 2025 Compared with Fiscal Three Months Ended September 29, 2024
Our results for the fiscal three months ended September 28, 2025 and September 29, 2024 were as follows:

|  | Fiscal Three Months Ended |  | Change In Fiscal Period
|  | September 28, 2025 |  | September 29, 2024 |  | Change 2024 to 2025
(Dollars in Millions) |  |  |  |  |  | Amount |  | Percent
Net sales |  | $ | 3,764 |  |  | $ | 3,899 |  |  | $ | (135) |  |  | (3.5) | %
Cost of sales |  | 1,538 |  |  | 1,617 |  |  | (79) |  |  | (4.9) |
Gross profit |  | 2,226 |  |  | 2,282 |  |  | (56) |  |  | (2.5) |
Selling, general, and administrative expenses |  | 1,512 |  |  | 1,590 |  |  | (78) |  |  | (4.9) |
Restructuring expenses |  | 84 |  |  | 31 |  |  | 53 |  |  | *
Other operating expense, net |  | 1 |  |  | 7 |  |  | (6) |  |  | (85.7) |
Operating income |  | 629 |  |  | 654 |  |  | (25) |  |  | (3.8) |
Other expense (income), net |  | 10 |  |  | (19) |  |  | 29 |  |  | *
Interest expense, net |  | 93 |  |  | 96 |  |  | (3) |  |  | (3.1) |
Income before taxes |  | 526 |  |  | 577 |  |  | (51) |  |  | (8.8) |
Provision for taxes |  | 128 |  |  | 194 |  |  | (66) |  |  | (34.0) |
Net income |  | $ | 398 |  |  | $ | 383 |  |  | $ | 15 |  |  | 3.9 | %

* Calculation not meaningful.
Net Sales
Net sales were $3.8 billion and $3.9 billion for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $135 million, or 3.5%. Excluding the impact of favorable changes in foreign currency exchange rates of 1.0% and the reduction in Net sales related to divestitures of 0.1%, Organic sales (a non-GAAP financial measure as defined in “Segment Results—Organic Sales Change” below) decreased 4.4% driven by both volume-related decreases of 4.0% and unfavorable value realization (defined as price, including mix) of 0.4%. Volume-related decreases across segments were driven by changes in shipment timing as compared to the prior fiscal period in China and trade inventory reductions driven by retailer inventory management in the United States, as well as lower seasonal incidences impacting pediatric Pain Care and Allergy Care. Unfavorable value realization was driven by strategic price investments, primarily in Skin Health and Beauty. For additional information about the Net sales of our three reportable business segments, see “—Segment Results” below.
The following table presents a reconciliation of the change in U.S. GAAP Net sales to the change in Organic sales for the fiscal three months ended September 28, 2025 as compared to the fiscal three months ended September 29, 2024:

|  |  |  |  |  |  | Fiscal Three Months Ended September 28, 2025 vs. September 29, 2024
|  |  |  |  |  |  | Reported Net Sales Change |  | Impact of Foreign Currency |  | Acquisitions and Divestitures |  | Organic Sales Change
|  |  |  |  |  |  |  |  |  | Total Organic Sales Change |  | Price/Mix(1) |  | Volume
Total |  |  |  |  |  |  | (3.5) | % |  | 1.0 | % |  | (0.1) | % |  | (4.4) | % |  | (0.4) | % |  | (4.0) | %

(1) Also referred to as value realization.
Cost of Sales
Cost of sales were $1.5 billion and $1.6 billion for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $79 million, or 4.9%. Gross profit margin expanded 60 basis points to 59.1% for the fiscal three months ended September 28, 2025 as compared to 58.5% for the fiscal three months ended September 29, 2024. Changes in Cost of sales were primarily due to volume-related Net sales decreases. Changes in both Cost of sales and gross profit margin were also driven by gains attributable to the realization of benefits associated with our supply chain optimization initiatives, partially offset by net input cost inflation and the impact of tariffs imposed on goods imported into the United States. Changes in both Cost of sales and gross profit margin were also impacted by a reduction in stock-based compensation expense
44

attributable to a refinement to the methodology of our stock-based compensation expense allocations and forfeitures of unvested stock-based awards. Gross profit margin was also impacted by unfavorable value realization.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $1.5 billion and $1.6 billion for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $78 million, or 4.9%. Selling, general, and administrative expenses as a percentage of Net sales decreased 60 basis points to 40.2% for the fiscal three months ended September 28, 2025, as compared to 40.8% for the fiscal three months ended September 29, 2024. The decrease in Selling, general, and administrative expenses was primarily attributable to a $62 million decrease in Separation-related costs and savings from Our Vue Forward, partially offset by higher expenses related to brand support. The decrease was also driven by a reduction in stock-based compensation expense attributable to forfeitures of unvested stock-based awards, partially offset by a refinement to the methodology of our stock-based compensation expense allocations.
Restructuring Expenses
Restructuring expenses were $84 million and $31 million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, an increase of $53 million. Restructuring expenses relate to costs incurred under Our Vue Forward and the increase was driven by higher information technology and project-related costs. See Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for additional information.
Other Operating Expense, Net
Other operating expense, net was $1 million and $7 million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $6 million. Other operating expense, net for the fiscal three months ended September 28, 2025 and September 29, 2024 was driven by the $7 million and $11 million impact, respectively, of net economic benefit arrangements with J&J in connection with the Deferred Local Businesses (see Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein for additional information), partially offset by $8 million and $7 million, respectively, of royalty income. See Note 9, “Other Operating Expense, Net and Other Expense (Income), Net,” to the Condensed Consolidated Financial Statements included herein for additional information.
Other Expense (Income), Net
Other expense (income), net was $10 million and $(19) million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a change of $29 million. Other expense (income), net for the fiscal three months ended September 28, 2025 was driven by $20 million of currency losses on transactions. Other expense (income), net for the fiscal three months ended September 29, 2024 was primarily driven by a $21 million gain recognized on the release of tax indemnification reserves that were no longer considered to be probable. See Note 9, “Other Operating Expense, Net and Other Expense (Income), Net,” to the Condensed Consolidated Financial Statements included herein for additional information.
Interest Expense, Net
Interest expense, net was $93 million and $96 million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $3 million. Interest expense, net in both fiscal periods primarily consisted of interest expense, including amortization of discounts and debt issuance costs, recognized on the Senior Notes (as defined in Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein) and notes issued under our commercial paper program. See Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein for additional information.
Provision for Taxes
Provision for taxes was $128 million and $194 million for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $66 million. The decrease in Provision for taxes was primarily due to lower quarter-to-date pre-tax income and favorable return-to-provision adjustments. In addition, the worldwide effective income tax rates for the fiscal three months ended September 28, 2025 and September 29, 2024 were 24.3% and 33.6%, respectively. See Note 10, “Income Taxes,” to the Condensed Consolidated Financial Statements included herein for additional information.
45

Segment Results
Segment profit is based on Operating income, excluding depreciation, amortization of intangible assets, Separation-related costs, restructuring expenses and operating model optimization initiatives, impairment charges, the impact of the conversion of stock-based awards, issuance of Founder Shares (as defined below), Other operating expense, net, and unallocated general corporate administrative expenses (referred to herein as “Segment adjusted operating income”), as the Chief Operating Decision Maker (the “CODM”) excludes these items in assessing segment financial performance. General corporate/unallocated expenses, which include expenses related to treasury, legal operations, and certain other expenses, along with gains and losses related to the overall management of our Company, are not allocated to the segments. In assessing segment performance and managing operations, the CODM does not review segment assets.
See Note 14, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein for additional information.
46

Fiscal Three Months Ended September 28, 2025 Compared with Fiscal Three Months Ended September 29, 2024
The following tables present Segment net sales and Segment adjusted operating income and the period-over-period changes in Segment net sales and Segment adjusted operating income for the fiscal three months ended September 28, 2025 and September 29, 2024. See Note 14, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein for further details regarding Segment net sales and Segment adjusted operating income.

|  | Fiscal Three Months Ended |  | Change In Fiscal Period
|  | September 28, 2025 |  | September 29, 2024 |  | Change 2024 to 2025
(Dollars in Millions) |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Amount |  | Percent
Net sales |  | $ | 1,564 |  |  | $ | 1,038 |  |  | $ | 1,162 |  |  | $ | 3,764 |  |  | $ | 1,625 |  |  | $ | 1,072 |  |  | $ | 1,202 |  |  | $ | 3,899 |  |  | $ | (135) |  |  | (3.5) | %
Segment adjusted Cost of sales(1) |  | 546 |  |  | 401 |  |  | 512 |  |  | 1,459 |  |  | 569 |  |  | 421 |  |  | 539 |  |  | 1,529 |  |  | (70) |  |  | (4.6) |
Other segment expense items(2) |  | 498 |  |  | 500 |  |  | 343 |  |  | 1,341 |  |  | 499 |  |  | 460 |  |  | 372 |  |  | 1,331 |  |  | 10 |  |  | 0.8 |
Segment adjusted operating income |  | $ | 520 |  |  | $ | 137 |  |  | $ | 307 |  |  | $ | 964 |  |  | $ | 557 |  |  | $ | 191 |  |  | $ | 291 |  |  | $ | 1,039 |  |  | $ | (75) |  |  | (7.2) | %
Reconciliation to Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation(3) |  |  |  |  |  |  |  | 75 |  |  |  |  |  |  |  |  | 94 |  |  |  |  |
Amortization of intangible assets(4) |  |  |  |  |  |  |  | 66 |  |  |  |  |  |  |  |  | 66 |  |  |  |  |
Separation-related costs(5) |  |  |  |  |  |  |  | 17 |  |  |  |  |  |  |  |  | 85 |  |  |  |  |
Restructuring expenses and operating model optimization initiatives(6) |  |  |  |  |  |  |  | 97 |  |  |  |  |  |  |  |  | 38 |  |  |  |  |
Conversion of stock-based awards(7) |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  | 6 |  |  |  |  |
Founder Shares(8) |  |  |  |  |  |  |  | (4) |  |  |  |  |  |  |  |  | 7 |  |  |  |  |
Other operating expense, net |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  | 7 |  |  |  |  |
General corporate/unallocated expenses |  |  |  |  |  |  |  | 82 |  |  |  |  |  |  |  |  | 82 |  |  |  |  |
Operating income |  |  |  |  |  |  |  | $ | 629 |  |  |  |  |  |  |  |  | $ | 654 |  |  |  |  |
Other expense (income), net |  |  |  |  |  |  |  | 10 |  |  |  |  |  |  |  |  | (19) |  |  |  |  |
Interest expense, net |  |  |  |  |  |  |  | 93 |  |  |  |  |  |  |  |  | 96 |  |  |  |  |
Income before taxes |  |  |  |  |  |  |  | $ | 526 |  |  |  |  |  |  |  |  | $ | 577 |  |  |  |  |

(1) We define Segment adjusted cost of sales as Cost of sales adjusted for amortization of intangible assets, Separation-related costs, conversion of stock-based awards, Founder Shares (as defined below), operating model optimization initiatives, and general corporate/unallocated expenses.
(2) Other segment expense items for each reportable segment include brand support, employee-related costs, shipping and handling costs, research and development costs, and certain other operating expenses (income).
(3) Depreciation consists of depreciation of property, plant, and equipment and amortization of integration and development costs capitalized in connection with cloud computing arrangements.
47

(4) Relates to the amortization of definite-lived intangible assets (primarily trademarks, trade names, and customer lists) over their estimated useful lives.
(5) Separation-related costs includes depreciation expense on Separation-related assets for the fiscal three months ended September 29, 2024. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Separation-Related Costs,” to the Condensed Consolidated Financial Statements included herein for additional information regarding Separation-related costs.
(6) Restructuring expenses and operating model optimization initiatives relate to the 2024 Multi-Year Restructuring Initiative. See Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for additional information.
(7) Segment adjusted operating income excludes the impact of the conversion of stock-based awards that occurred on August 23, 2023. The adjustment represents the net impact of the gain on reversal of previously recognized stock-based compensation expense, offset by stock-based compensation expense recognized in the fiscal three months ended September 28, 2025 and September 29, 2024 relating to employee services provided prior to the Separation.
(8) On August 25, 2023, our Compensation & Human Capital Committee approved equity grants to individuals employed by Kenvue as of October 2, 2023 (the “Founder Shares”). On October 2, 2023, the Founder Shares were granted to all Kenvue employees in the form of stock options and performance stock units (“PSUs”) to executive officers and either stock options and PSUs or restricted stock units (“RSUs”) to non-executive individuals.

|  | Fiscal Three Months Ended |  | Change in Fiscal Period
|  | September 28, 2025 |  | September 29, 2024 |  | Change 2024 to 2025
(Dollars in Millions) |  | Amount |  | Percent |  | Amount |  | Percent |  | Amount |  | Percent
Segment Net Sales |  |  |  |  |  |  |  |  |  |  |  |
Self Care |  | $ | 1,564 |  |  | 41.5 | % |  | $ | 1,625 |  |  | 41.7 | % |  | $ | (61) |  |  | (3.8) | %
Skin Health and Beauty |  | 1,038 |  |  | 27.6 |  |  | 1,072 |  |  | 27.5 |  |  | (34) |  |  | (3.2) |
Essential Health |  | 1,162 |  |  | 30.9 |  |  | 1,202 |  |  | 30.8 |  |  | (40) |  |  | (3.3) |
Segment net sales |  | $ | 3,764 |  |  | 100.0 | % |  | $ | 3,899 |  |  | 100.0 | % |  | $ | (135) |  |  | (3.5) | %
Self Care |  | $ | 520 |  |  |  |  | $ | 557 |  |  |  |  | $ | (37) |  |  | (6.6) | %
Skin Health and Beauty |  | 137 |  |  |  |  | 191 |  |  |  |  | (54) |  |  | (28.3) |
Essential Health |  | 307 |  |  |  |  | 291 |  |  |  |  | 16 |  |  | 5.5 |
Segment adjusted operating income(1) |  | $ | 964 |  |  |  |  | $ | 1,039 |  |  |  |  | $ | (75) |  |  | (7.2) | %

(1) Refer to the table above for the reconciliation of Segment adjusted operating income to Operating income and Income before taxes in the Condensed Consolidated Financial Statements.
Organic Sales Change
We define Organic sales, a non-GAAP financial measure, as Net sales excluding the impact of changes in foreign currency exchange rates and the impact of acquisitions and divestitures. We assess our Net sales performance by measuring the period-over-period change in Organic sales. Management believes reporting period-over-period changes in Organic sales provides investors with additional, supplemental information that is useful in assessing our results of operations by excluding the impact of certain items that we believe do not directly reflect our underlying operations.
The following table presents a reconciliation of the change in U.S. GAAP Net sales to the change in Organic sales for the fiscal three months ended September 28, 2025 as compared to the fiscal three months ended September 29, 2024:

|  |  |  |  |  |  | Fiscal Three Months Ended September 28, 2025 vs. September 29, 2024
|  |  |  |  |  |  | Reported Net Sales Change |  | Impact of Foreign Currency |  | Acquisitions and Divestitures |  | Organic Sales Change
|  |  |  |  |  |  |  |  |  | Total Organic Sales Change |  | Price/Mix(1) |  | Volume
Self Care |  |  |  |  |  |  | (3.8) | % |  | 1.5 | % |  | — | % |  | (5.3) | % |  | (0.3) | % |  | (5.0) | %
Skin Health and Beauty |  |  |  |  |  |  | (3.2) |  |  | 0.6 |  |  | (0.3) |  |  | (3.5) |  |  | (1.3) |  |  | (2.2) |
Essential Health |  |  |  |  |  |  | (3.3) |  |  | 0.9 |  |  | — |  |  | (4.2) |  |  | 0.1 |  |  | (4.3) |
Total |  |  |  |  |  |  | (3.5) | % |  | 1.0 | % |  | (0.1) | % |  | (4.4) | % |  | (0.4) | % |  | (4.0) | %

(1) Also referred to as value realization.
48

Self Care Segment
Self Care Segment Net Sales
The Self Care Segment Net sales were $1.6 billion for both the fiscal three months ended September 28, 2025 and September 29, 2024. For the fiscal three months ended September 28, 2025, Net sales decreased $61 million, or 3.8%, as compared to the fiscal three months ended September 29, 2024. Excluding the impact of favorable changes in foreign currency exchange rates of 1.5%, Organic sales decreased 5.3% driven by both volume-related decreases of 5.0% and unfavorable value realization of 0.3% attributable to strategic price investments. Volume-related decreases, primarily in China and the United States, were attributable to lower incidences of illnesses affecting pediatric Pain Care products and the impact of a softer season on Allergy Care products coupled with changes in shipment timing as compared to the prior fiscal period due to the impact of lower inventory replenishment following inventory builds in the prior year. Volume-related decreases were further impacted by trade inventory reductions driven by retailer inventory management in the United States.
Self Care Segment Adjusted Operating Income
The Self Care Segment adjusted operating income decreased by $37 million, or 6.6%, to $520 million for the fiscal three months ended September 28, 2025 as compared to the fiscal three months ended September 29, 2024. The decrease was primarily driven by volume-related Net sales decreases, net input cost inflation, and the impact of tariffs imposed on goods imported into the United States, partially offset by the realization of benefits associated with our supply chain optimization initiatives, savings from Our Vue Forward resulting in administrative expense reductions, and lower expenses related to brand support.
Skin Health and Beauty Segment
Skin Health and Beauty Segment Net Sales
The Skin Health and Beauty Segment Net sales were $1.0 billion and $1.1 billion for the fiscal three months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $34 million, or 3.2%. Excluding the impact of favorable changes in foreign currency exchange rates of 0.6% and the reduction in Net sales related to divestitures of 0.3%, Organic sales decreased 3.5% driven by both volume-related decreases of 2.2% and unfavorable value realization of 1.3% attributable to strategic price investments. Volume-related decreases were attributable to changes in shipment timing as compared to the prior fiscal year due to the impact of lower inventory replenishment following inventory builds in the prior year in China. Volume-related decreases were further impacted by trade inventory reductions driven by retailer inventory management in the United States.
Skin Health and Beauty Segment Adjusted Operating Income
The Skin Health and Beauty Segment adjusted operating income decreased by $54 million, or 28.3%, to $137 million for the fiscal three months ended September 28, 2025 as compared to the fiscal three months ended September 29, 2024. The decrease was primarily driven by higher expenses related to brand support, volume-related Net sales decreases, net input cost inflation, unfavorable changes in foreign currency exchange rates, the impact of tariffs imposed on goods imported into the United States, and unfavorable value realization, partially offset by the realization of benefits associated with our supply chain optimization initiatives and savings from Our Vue Forward resulting in administrative expense reductions.
Essential Health Segment
Essential Health Segment Net Sales
The Essential Health Segment Net sales were $1.2 billion for both the fiscal three months ended September 28, 2025 and September 29, 2024. For the fiscal three months ended September 28, 2025, Net sales decreased $40 million, or 3.3%, as compared to the fiscal three months ended September 29, 2024. Excluding the impact of favorable changes in foreign currency exchange rates of 0.9%, Organic sales decreased 4.2% driven by both volume-related decreases of 4.3% and favorable value realization of 0.1%. Volume-related decreases were attributable to changes in shipment timing as compared to the prior fiscal period in North America and Asia Pacific, which included impacts from the timing of promotions in Oral Care in the United States. Volume-related decreases were further impacted by competitive pressures in Oral Care and trade inventory reductions driven by retailer inventory management in the United States.
49

Essential Health Segment Adjusted Operating Income
The Essential Health Segment adjusted operating income increased by $16 million, or 5.5%, to $307 million for the fiscal three months ended September 28, 2025 as compared to the fiscal three months ended September 29, 2024. The increase was primarily driven by lower expenses related to brand support, the realization of benefits associated with our supply chain optimization initiatives, and savings from Our Vue Forward resulting in administrative expense reductions, partially offset by volume-related Net sales decreases, net input cost inflation, unfavorable changes in foreign currency exchange rates, and the impact of tariffs imposed on goods imported into the United States.
Results of Operations
Fiscal Nine Months Ended September 28, 2025 Compared with Fiscal Nine Months Ended September 29, 2024
Our results for the fiscal nine months ended September 28, 2025 and September 29, 2024 were as follows:

|  | Fiscal Nine Months Ended |  | Change In Fiscal Period
|  | September 28, 2025 |  | September 29, 2024 |  | Change 2024 to 2025
(Dollars in Millions) |  |  |  |  |  | Amount |  | Percent
Net sales |  | $ | 11,344 |  |  | $ | 11,793 |  |  | $ | (449) |  |  | (3.8) | %
Cost of sales |  | 4,689 |  |  | 4,904 |  |  | (215) |  |  | (4.4) |
Gross profit |  | 6,655 |  |  | 6,889 |  |  | (234) |  |  | (3.4) |
Selling, general, and administrative expenses |  | 4,553 |  |  | 4,804 |  |  | (251) |  |  | (5.2) |
Restructuring expenses |  | 204 |  |  | 120 |  |  | 84 |  |  | 70.0 |
Impairment charges |  | — |  |  | 578 |  |  | (578) |  |  | *
Other operating expense, net |  | 19 |  |  | 29 |  |  | (10) |  |  | (34.5) |
Operating income |  | 1,879 |  |  | 1,358 |  |  | 521 |  |  | 38.4 |
Other expense, net |  | 26 |  |  | 6 |  |  | 20 |  |  | *
Interest expense, net |  | 281 |  |  | 283 |  |  | (2) |  |  | (0.7) |
Income before taxes |  | 1,572 |  |  | 1,069 |  |  | 503 |  |  | 47.1 |
Provision for taxes |  | 432 |  |  | 332 |  |  | 100 |  |  | 30.1 |
Net income |  | $ | 1,140 |  |  | $ | 737 |  |  | $ | 403 |  |  | 54.7 | %

* Calculation not meaningful.
Net Sales
Net sales were $11.3 billion and $11.8 billion for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $449 million, or 3.8%. Excluding the impact of unfavorable changes in foreign currency exchange rates of 0.5%, Organic sales decreased 3.3% driven by both volume-related decreases of 2.7% and unfavorable value realization of 0.6%. Volume-related decreases across segments were driven by changes in shipment timing as compared to the prior fiscal year in China and trade inventory reductions driven by retailer inventory management in the United States, as well as lower seasonal incidences impacting pediatric Pain Care, Allergy Care, and Cough and Cold. Unfavorable value realization was driven by strategic price investments, primarily in Skin Health and Beauty. For additional information about the Net sales of our three reportable business segments, see “—Segment Results” below.
50

The following table presents a reconciliation of the change in U.S. GAAP Net sales to the change in Organic sales for the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024:

|  |  |  |  |  |  | Fiscal Nine Months Ended September 28, 2025 vs. September 29, 2024
|  |  |  |  |  |  | Reported Net Sales Change |  | Impact of Foreign Currency |  |  |  | Organic Sales Change
|  |  |  |  |  |  |  |  |  | Total Organic Sales Change |  | Price/Mix(1) |  | Volume
Total |  |  |  |  |  |  | (3.8) | % |  | (0.5) | % |  |  |  | (3.3) | % |  | (0.6) | % |  | (2.7) | %

(1) Also referred to as value realization.
Cost of Sales
Cost of sales were $4.7 billion and $4.9 billion for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $215 million, or 4.4%. Gross profit margin expanded 30 basis points to 58.7% for the fiscal nine months ended September 28, 2025 as compared to 58.4% for the fiscal nine months ended September 29, 2024. Changes in Cost of sales were primarily due to volume-related Net sales decreases. Changes in both Cost of sales and gross profit margin were also driven by gains attributable to the realization of benefits associated with our supply chain optimization initiatives, partially offset by net input cost inflation. Changes in both Cost of sales and gross profit margin were also impacted by a reduction in stock-based compensation expense attributable to a refinement to the methodology of our stock-based compensation expense allocations, forfeitures of unvested stock-based awards, and the vesting of stock-based awards. Gross profit margin was also impacted by unfavorable value realization.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $4.6 billion and $4.8 billion for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $251 million, or 5.2%. Selling, general, and administrative expenses as a percentage of Net sales decreased 60 basis points to 40.1% for the fiscal nine months ended September 28, 2025, as compared to 40.7% for the fiscal nine months ended September 29, 2024. The decrease in Selling, general, and administrative expenses was primarily attributable to a $138 million decrease in Separation-related costs and savings from Our Vue Forward. The decrease was also driven by a reduction in stock-based compensation expense attributable to forfeitures of unvested stock-based awards as well as the vesting of stock-based awards, partially offset by a refinement to the methodology of our stock-based compensation expense allocations.
Restructuring Expenses
Restructuring expenses were $204 million and $120 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, an increase of $84 million. Restructuring expenses relate to costs incurred under Our Vue Forward and the increase was driven by higher information technology and project-related costs. See Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for additional information.
Impairment Charges
Impairment charges were $578 million for the fiscal nine months ended September 29, 2024, which were driven by a non-cash charge of $488 million ($337 million after-tax) to adjust the carrying value of intangible assets and property, plant, and equipment related to the Dr.Ci:Labo® skin health business. The impairment was due primarily to revisions to internal forecasts for the business as a result of updates in our strategy to reach more consumers and appropriately address evolving market dynamics, including shifts in consumer sentiment in China as well as changing shopping patterns in the region. Impairment charges for the fiscal nine months ended September 29, 2024 were also driven by the impact of a $68 million non-cash impairment charge related to our former corporate headquarters in Skillman, New Jersey, which was classified as held for sale on February 21, 2024. Additionally, we recognized a non-cash impairment charge of $22 million related to certain software development assets. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment Charges,” to the Condensed Consolidated Financial Statements included herein for additional information. There were no impairment charges recognized in the fiscal three months ended September 29, 2024 or in the fiscal nine months ended September 28, 2025.
51

Other Operating Expense, Net
Other operating expense, net was $19 million and $29 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $10 million. Other operating expense, net for the fiscal nine months ended September 28, 2025 and September 29, 2024 was driven by the $35 million and $49 million impact, respectively, of net economic benefit arrangements with J&J in connection with the Deferred Local Businesses (see Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein for additional information), partially offset by $26 million and $24 million, respectively, of royalty income. See Note 9, “Other Operating Expense, Net and Other Expense (Income), Net,” to the Condensed Consolidated Financial Statements included herein for additional information.
Other Expense, Net
Other expense, net was $26 million and $6 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, an increase of $20 million. Other expense, net for the fiscal nine months ended September 28, 2025 was driven by $37 million of currency losses on transactions. Other expense, net for the fiscal nine months ended September 29, 2024 was driven by $31 million in losses on investments, partially offset by a $21 million gain recognized on the release of tax indemnification reserves that were no longer considered to be probable. See Note 9, “Other Operating Expense, Net and Other Expense (Income), Net,” to the Condensed Consolidated Financial Statements included herein for additional information.
Interest Expense, Net
Interest expense, net was $281 million and $283 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $2 million. Interest expense, net in both fiscal periods primarily consisted of interest expense, including amortization of discounts and debt issuance costs, recognized on the Senior Notes (as defined in Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein) and notes issued under our commercial paper program. See Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein for additional information.
Provision for Taxes
Provision for taxes was $432 million and $332 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, an increase of $100 million. The increase in Provision for taxes was primarily due to higher year-to-date pre-tax income, income tax benefits recognized during the fiscal nine months ended September 29, 2024 resulting from the impairment to the Dr.Ci:Labo® skin health business, the remeasurement of our state deferred tax liability recognized during the fiscal nine months ended September 29, 2024 as a result of a change in our state tax rate, and reduced income tax benefits derived from fewer releases of income tax reserves due to the expiration of certain statutes of limitations during the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024. The increase was partially offset by favorable return-to-provision adjustments, as well as a windfall on stock-based compensation recorded during the fiscal nine months ended September 28, 2025 as compared to a shortfall on stock-based compensation recorded during the fiscal nine months ended September 29, 2024. In addition, the worldwide effective income tax rates for the fiscal nine months ended September 28, 2025 and September 29, 2024 were 27.5% and 31.1%, respectively. See Note 10, “Income Taxes,” to the Condensed Consolidated Financial Statements included herein for additional information.
52

Segment Results
Fiscal Nine Months Ended September 28, 2025 Compared with Fiscal Nine Months Ended September 29, 2024
The following tables present Segment net sales and Segment adjusted operating income and the period-over-period changes in Segment net sales and Segment adjusted operating income for the fiscal nine months ended September 28, 2025 and September 29, 2024. See Note 14, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein for further details regarding Segment net sales and Segment adjusted operating income.

|  | Fiscal Nine Months Ended |  | Change In Fiscal Period |  |
|  | September 28, 2025 |  | September 29, 2024 |  | Change 2024 to 2025 |  |
(Dollars in Millions) |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Amount |  | Percent |  |  |  |  |  |  |  |
Net sales |  | $ | 4,786 |  |  | $ | 3,074 |  |  | $ | 3,484 |  |  | $ | 11,344 |  |  | $ | 4,958 |  |  | $ | 3,229 |  |  | $ | 3,606 |  |  | $ | 11,793 |  |  | $ | (449) |  |  | (3.8) | % |  |  |  |  |  |  |  |
Segment adjusted Cost of sales(1) |  | 1,681 |  |  | 1,236 |  |  | 1,539 |  |  | 4,456 |  |  | 1,693 |  |  | 1,324 |  |  | 1,597 |  |  | 4,614 |  |  | (158) |  |  | (3.4) |  |  |  |  |  |  |  |  |
Other segment expense items(2) |  | 1,492 |  |  | 1,460 |  |  | 1,048 |  |  | 4,000 |  |  | 1,573 |  |  | 1,403 |  |  | 1,095 |  |  | 4,071 |  |  | (71) |  |  | (1.7) |  |  |  |  |  |  |  |  |
Segment adjusted operating income |  | $ | 1,613 |  |  | $ | 378 |  |  | $ | 897 |  |  | $ | 2,888 |  |  | $ | 1,692 |  |  | $ | 502 |  |  | $ | 914 |  |  | $ | 3,108 |  |  | $ | (220) |  |  | (7.1) | % |  |  |  |  |  |  |  |
Reconciliation to Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation(3) |  |  |  |  |  |  |  | 226 |  |  |  |  |  |  |  |  | 238 |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization of intangible assets(4) |  |  |  |  |  |  |  | 193 |  |  |  |  |  |  |  |  | 212 |  |  |  |  |  |  |  |  |  |  |  |  |
Separation-related costs(5) |  |  |  |  |  |  |  | 79 |  |  |  |  |  |  |  |  | 231 |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring expenses and operating model optimization initiatives(6) |  |  |  |  |  |  |  | 232 |  |  |  |  |  |  |  |  | 146 |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment charges(7) |  |  |  |  |  |  |  | — |  |  |  |  |  |  |  |  | 578 |  |  |  |  |  |  |  |  |  |  |  |  |
Conversion of stock-based awards(8) |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  | 34 |  |  |  |  |  |  |  |  |  |  |  |  |
Founder Shares(9) |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |  |  |  |  |  |  |  |
Other operating expense, net |  |  |  |  |  |  |  | 19 |  |  |  |  |  |  |  |  | 29 |  |  |  |  |  |  |  |  |  |  |  |  |
General corporate/unallocated expenses |  |  |  |  |  |  |  | 251 |  |  |  |  |  |  |  |  | 258 |  |  |  |  |  |  |  |  |  |  |  |  |
Operating income |  |  |  |  |  |  |  | $ | 1,879 |  |  |  |  |  |  |  |  | $ | 1,358 |  |  |  |  |  |  |  |  |  |  |  |  |
Other expense, net |  |  |  |  |  |  |  | 26 |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  |  |  |  |  |  | 281 |  |  |  |  |  |  |  |  | 283 |  |  |  |  |  |  |  |  |  |  |  |  |
Income before taxes |  |  |  |  |  |  |  | $ | 1,572 |  |  |  |  |  |  |  |  | $ | 1,069 |  |  |  |  |  |  |  |  |  |  |  |  |

(1) We define Segment adjusted cost of sales as Cost of sales adjusted for amortization of intangible assets, Separation-related costs, conversion of stock-based awards, Founder Shares, operating model optimization initiatives, and general corporate/unallocated expenses.
53

(2) Other segment expense items for each reportable segment include brand support, employee-related costs, shipping and handling costs, research and development costs, and certain other operating expenses (income).
(3) Depreciation consists of depreciation of property, plant, and equipment and amortization of integration and development costs capitalized in connection with cloud computing arrangements.
(4) Relates to the amortization of definite-lived intangible assets (primarily trademarks, trade names, and customer lists) over their estimated useful lives.
(5) Separation-related costs includes depreciation expense on Separation-related assets for the fiscal nine months ended September 29, 2024. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Separation-Related Costs,” to the Condensed Consolidated Financial Statements included herein for additional information regarding Separation-related costs.
(6) Restructuring expenses and operating model optimization initiatives relate to the 2024 Multi-Year Restructuring Initiative. See Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for additional information.
(7) Impairment charges for the fiscal nine months ended September 29, 2024 includes $488 million recognized in relation to Dr.Ci:Labo® long-lived assets, $68 million recognized on the held for sale asset associated with the Company’s former corporate headquarters in Skillman, New Jersey, and $22 million recognized on certain software development assets. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment Charges,” to the Condensed Consolidated Financial Statements included herein for additional information.
(8) Segment adjusted operating income excludes the impact of the conversion of stock-based awards that occurred on August 23, 2023. The adjustment represents the net impact of the gain on reversal of previously recognized stock-based compensation expense, offset by stock-based compensation expense recognized in the fiscal nine months ended September 28, 2025 and September 29, 2024 relating to employee services provided prior to the Separation.
(9) On August 25, 2023, our Compensation & Human Capital Committee approved the Founder Shares. On October 2, 2023, the Founder Shares were granted to all Kenvue employees in the form of stock options and PSUs to executive officers and either stock options and PSUs or RSUs to non-executive individuals.

|  | Fiscal Nine Months Ended |  | Change in Fiscal Period
|  | September 28, 2025 |  | September 29, 2024 |  | Change 2024 to 2025
(Dollars in Millions) |  | Amount |  | Percent |  | Amount |  | Percent |  | Amount |  | Percent
Segment Net Sales |  |  |  |  |  |  |  |  |  |  |  |
Self Care |  | $ | 4,786 |  |  | 42.2 | % |  | $ | 4,958 |  |  | 42.0 | % |  | $ | (172) |  |  | (3.5) | %
Skin Health and Beauty |  | 3,074 |  |  | 27.1 |  |  | 3,229 |  |  | 27.4 |  |  | (155) |  |  | (4.8) |
Essential Health |  | 3,484 |  |  | 30.7 |  |  | 3,606 |  |  | 30.6 |  |  | (122) |  |  | (3.4) |
Segment net sales |  | $ | 11,344 |  |  | 100.0 | % |  | $ | 11,793 |  |  | 100.0 | % |  | $ | (449) |  |  | (3.8) | %
Self Care |  | $ | 1,613 |  |  |  |  | $ | 1,692 |  |  |  |  | $ | (79) |  |  | (4.7) | %
Skin Health and Beauty |  | 378 |  |  |  |  | 502 |  |  |  |  | (124) |  |  | (24.7) |
Essential Health |  | 897 |  |  |  |  | 914 |  |  |  |  | (17) |  |  | (1.9) |
Segment adjusted operating income(1) |  | $ | 2,888 |  |  |  |  | $ | 3,108 |  |  |  |  | $ | (220) |  |  | (7.1) | %

(1) Refer to the table above for the reconciliation of Segment adjusted operating income to Operating income and Income before taxes in the Condensed Consolidated Financial Statements.
54

Organic Sales Change
The following table presents a reconciliation of the change in U.S. GAAP Net sales to the change in Organic sales for the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024:

|  |  |  |  |  |  | Fiscal Nine Months Ended September 28, 2025 vs. September 29, 2024
|  |  |  |  |  |  | Reported Net Sales Change |  | Impact of Foreign Currency |  | Acquisitions and Divestitures |  | Organic Sales Change
|  |  |  |  |  |  |  |  |  | Total Organic Sales Change |  | Price/Mix(1) |  | Volume
Self Care |  |  |  |  |  |  | (3.5) | % |  | 0.1 | % |  | — | % |  | (3.6) | % |  | — | % |  | (3.6) | %
Skin Health and Beauty |  |  |  |  |  |  | (4.8) |  |  | (0.6) |  |  | (0.2) |  |  | (4.0) |  |  | (1.9) |  |  | (2.1) |
Essential Health |  |  |  |  |  |  | (3.4) |  |  | (1.2) |  |  | — |  |  | (2.2) |  |  | (0.2) |  |  | (2.0) |
Total |  |  |  |  |  |  | (3.8) | % |  | (0.5) | % |  | — | % |  | (3.3) | % |  | (0.6) | % |  | (2.7) | %

(1) Also referred to as value realization.
Self Care Segment
Self Care Segment Net Sales
The Self Care Segment Net sales were $4.8 billion and $5.0 billion for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $172 million, or 3.5%. Excluding the impact of favorable changes in foreign currency exchange rates of 0.1%, Organic sales decreased 3.6% driven by volume-related decreases of 3.6%, while value realization remained flat. Volume-related decreases, primarily in China and the United States, were primarily attributable to lower incidences of illnesses affecting pediatric Pain Care products, as well as the impact of a softer season on Allergy Care products and the most recent weak cough and cold season on Cough and Cold Products, coupled with changes in shipment timing as compared to the prior fiscal period due to the impact of lower inventory replenishment following inventory builds in the prior year. Volume-related decreases were partially offset by growth in Smoking Cessation in Europe, Middle East, and Africa.
Self Care Segment Adjusted Operating Income
The Self Care Segment adjusted operating income decreased by $79 million, or 4.7%, to $1,613 million for the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024. The decrease was primarily driven by volume-related Net sales decreases, volume deleverage at internal manufacturing sites, unfavorable changes in foreign currency exchange rates, net input cost inflation, and the impact of tariffs imposed on goods imported into the United States, partially offset by the realization of benefits associated with our supply chain optimization initiatives, lower expenses related to brand support, and savings from Our Vue Forward resulting in administrative expense reductions.
Skin Health and Beauty Segment
Skin Health and Beauty Segment Net Sales
The Skin Health and Beauty Segment Net sales were $3.1 billion and $3.2 billion for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $155 million, or 4.8%. Excluding the impact of unfavorable changes in foreign currency exchange rates of 0.6% and the reduction in Net sales related to divestitures of 0.2%, Organic sales decreased 4.0% driven by both volume-related decreases of 2.1% and unfavorable value realization of 1.9% attributable to strategic price investments. Volume-related decreases were attributable to changes in shipment timing as compared to the prior fiscal year due to the impact of lower inventory replenishment following inventory builds in the prior year in China, as well as trade inventory reductions driven by retailer inventory management in the United States. Volume-related decreases were further impacted by a softer sun season in the United States, market softness in Asia Pacific, and current fiscal year competitive pressures resulting in market share losses.
Skin Health and Beauty Segment Adjusted Operating Income
The Skin Health and Beauty Segment adjusted operating income decreased by $124 million, or 24.7%, to $378 million for the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024. The decrease
55

was primarily driven by volume-related Net sales decreases, unfavorable value realization, higher expenses related to brand support, unfavorable changes in foreign currency exchange rates, net input cost inflation, and the impact of tariffs imposed on goods imported into the United States, partially offset by the realization of benefits associated with our supply chain optimization initiatives and savings from Our Vue Forward resulting in administrative expense reductions.
Essential Health Segment
Essential Health Segment Net Sales
The Essential Health Segment Net sales were $3.5 billion and $3.6 billion for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $122 million, or 3.4%. Excluding the impact of unfavorable changes in foreign currency exchange rates of 1.2%, Organic sales decreased 2.2% driven by both volume-related decreases of 2.0% and unfavorable value realization of 0.2% attributable to strategic price investments. Volume-related decreases were attributable to trade inventory reductions driven by retailer inventory management in the United States, primarily in Oral Care and Wound Care, as well as market deceleration in Oral Care in North America and competitive pressures in Oral Care in North America and Baby Care in Asia Pacific, partially offset by growth across product categories in Latin America.
Essential Health Segment Adjusted Operating Income
The Essential Health Segment adjusted operating income decreased by $17 million, or 1.9%, to $897 million for the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024. The decrease was primarily driven by volume-related Net sales decreases, unfavorable changes in foreign currency exchange rates, net input cost inflation, and the impact of tariffs imposed on goods imported into the United States, partially offset by the realization of benefits associated with our supply chain optimization initiatives and lower expenses related to brand support. Segment adjusted operating income margin increased by 0.4% for the fiscal nine months ended September 28, 2025 as compared to the fiscal nine months ended September 29, 2024
Liquidity and Capital Resources
Cash Flows
Summarized cash flow information for the fiscal nine months ended September 28, 2025 and September 29, 2024 were as follows:

|  |  |  |  |  | Change In Fiscal Period
|  | Fiscal Nine Months Ended |  | Change 2024 to 2025
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Amount |  | Percent
Net income |  | $ | 1,140 |  |  | $ | 737 |  |  | $ | 403 |  |  | 54.7 | %
Net changes in assets and liabilities |  | $ | (365) |  |  | $ | (833) |  |  | $ | 468 |  |  | (56.2) | %
Net cash flows from operating activities |  | $ | 1,343 |  |  | $ | 976 |  |  | $ | 367 |  |  | 37.6 | %
Net cash flows used in investing activities |  | $ | (361) |  |  | $ | (293) |  |  | $ | (68) |  |  | 23.2 | %
Net cash flows used in financing activities |  | $ | (968) |  |  | $ | (978) |  |  | $ | 10 |  |  | (1.0) | %

* Calculation not meaningful.
Operating Activities
Net cash flows from operating activities were $1,343 million and $976 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, an increase of $367 million. The increase was primarily attributable to net changes in working capital balances driven by Accounts payable and accrued liabilities due to the timing of payments and Trade receivables due to the timing of sales relative to collections.
Investing Activities
Net cash flows used in investing activities were $361 million and $293 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, an increase of $68 million. Net cash flows used in investing activities were primarily driven by purchases of property, plant, and equipment in both the fiscal nine months ended September 28, 2025 and September 29, 2024.
56

Financing Activities
Net cash flows used in financing activities were $968 million and $978 million for the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively, a decrease of $10 million. Net cash flows used in financing activities for the fiscal nine months ended September 28, 2025 were primarily driven by $1,183 million of dividends paid, the $750 million repayment of the 5.50% Senior Notes due 2025 (as defined in Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein), and $197 million of payments made to purchase treasury stock, partially offset by $746 million of net proceeds from the issuance of the 4.85% Senior Notes due 2032 (as defined in Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein), and $324 million of net proceeds from the issuance of commercial paper under our commercial paper program. Net cash flows used in financing activities for the fiscal nine months ended September 29, 2024 were primarily driven by $1,159 million of dividends paid and $114 million of payments made to purchase treasury stock, partially offset by $258 million of net proceeds from the issuance of commercial paper under our commercial paper program.
Sources of Liquidity
Our primary sources of liquidity are cash on hand, which consisted of Cash and cash equivalents of $1,139 million as of September 28, 2025, cash flows from operations, borrowing capacity under a revolving credit facility of $4.0 billion which expires in March 2029, and authorized commercial paper program issuance of $4.0 billion. Also, on February 24, 2025, we filed a registration statement on Form S-3 with the SEC under which from time to time we may sell securities. On May 22, 2025, we issued a series of senior unsecured notes maturing in 2032 in an aggregate principal amount of $750 million.
As of September 28, 2025, total debt was $8,973 million. As of September 28, 2025, we had $7,685 million of Senior Notes (as defined in Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein) outstanding, net of related discounts and debt issuance costs of $65 million, no amounts outstanding under our revolving credit facility, and $1,158 million of outstanding balances under our commercial paper program, net of a related discount of $2 million.
Our ability to fund our operating needs will depend on our ability to continue to generate positive cash flows from operations and on our ability to obtain debt financing on acceptable terms or to issue additional equity or equity-linked securities. Based upon our history of generating positive cash flows, we believe our existing cash and cash generated from operations will be sufficient to service our current obligations for at least the next 12 months.
Management believes that our cash balances and funds provided by operating activities, along with borrowing capacity and access to capital markets, taken as a whole, provide adequate liquidity to meet all of our current and long-term obligations when due, including third-party debt, adequate liquidity to fund capital expenditures, and flexibility to meet investment opportunities that may arise. However, we cannot assure you that we will be able to obtain additional debt or equity financing on acceptable terms in the future.
Cash and cash equivalents increased by $69 million during the fiscal nine months ended September 28, 2025 to $1,139 million as of September 28, 2025, as compared to $1,070 million as of December 29, 2024. Cash and cash equivalents held by our foreign subsidiaries was $1,120 million and $1,044 million as of September 28, 2025 and December 29, 2024, respectively.
Restructuring
As part of our continued transformation to a fit-for-purpose consumer company, during the fiscal year 2024, we began Our Vue Forward to enhance organizational efficiencies and better position Kenvue for future growth. To further Our Vue Forward, on May 6, 2024, our Board approved the 2024 Multi-Year Restructuring Initiative to build on our strengths, improve our underlying information technology infrastructure, and optimize our cost structure by rebalancing resources to better position us for future growth. The 2024 Multi-Year Restructuring Initiative is expected to result in pre-tax restructuring expenses and other charges totaling approximately $550 million. We planned to incur approximately $275 million in pre-tax restructuring expenses and other charges in each of fiscal year 2024 and fiscal year 2025. We incurred lower than expected spend in fiscal year 2024 due to the shift in timing of certain information technology and project-related costs to fiscal year 2025. Over the life of the initiative, a majority of the pre-tax expenses and other charges are expected to be paid in cash. These charges are expected to be funded primarily through cash flows generated from operations. We began to realize savings resulting from the 2024 Multi-Year Restructuring Initiative in fiscal year 2024, and we expect to realize the full extent of annualized pre-tax gross cost savings of approximately $350 million beginning in fiscal year 2026. In accordance with plan, we have largely reinvested savings realized inception-to-date in association with the 2024 Multi-Year Restructuring Initiative in future growth opportunities, including immediate reinvestment behind advertising, product promotion, and healthcare professional engagement. Our estimates of the costs of the initiative and the expected benefits are preliminary estimates and are subject to a number of
57

assumptions, including local law requirements in various jurisdictions. Actual charges may differ, possibly materially, from the estimates provided above. See Note 15, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for further information.
Dividends
Quarterly dividends have been paid to our shareholders since the Kenvue IPO. A summary of cash dividends per share on the outstanding Kenvue common stock declared to shareholders by our Board and paid during the fiscal nine months ended September 28, 2025 is presented below:

Declaration Date |  | Record Date |  | Payment Date |  | Per Share Amount
January 16, 2025 |  | February 12, 2025 |  | February 26, 2025 |  | $0.205
April 16, 2025 |  | May 14, 2025 |  | May 28, 2025 |  | $0.205
July 30, 2025 |  | August 13, 2025 |  | August 27, 2025 |  | $0.2075

On October 29, 2025, we announced that our Board declared a dividend of $0.2075 per share on our common stock. The dividend is payable on November 26, 2025 to shareholders of record as of the close of business on November 12, 2025.
We expect to continue to pay cash dividends on a quarterly basis. However, the declaration of dividends is subject to the discretion of our Board.
Future Cash Requirements
We expect our future cash requirements will relate to working capital, capital expenditures, restructuring and integration, compensation and benefit-related obligations, interest expense and debt service obligations, litigation costs, the return of capital to shareholders, including through the payment of any dividends, and other contractual obligations that arise in the normal course of business. We may also use cash to enter into business development transactions, such as licensing arrangements or strategic acquisitions.
As of September 28, 2025, we expect our primary cash requirements for fiscal year 2025 to include capital expenditures. We made payments of $365 million for purchases of property, plant, and equipment during the fiscal nine months ended September 28, 2025.
Future Litigation
In the ordinary course of business, we are involved in litigation, claims, government inquiries, investigations, charges, and proceedings. See Note 13, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein for further details regarding certain matters that are currently pending. Our ability to successfully resolve pending and future litigation may adversely impact our financial condition, results of operations, or cash flows.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements (as defined under the rules and regulations of the SEC) or any relationships with unconsolidated entities that have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, Net sales or expenses, results of operations, liquidity, cash requirements, or capital resources.
Other Information
Deferred Markets
Pursuant to the Separation Agreement, in order to ensure compliance with applicable law, to obtain necessary governmental approvals and other consents, and for other business reasons, we and J&J deferred certain transfers of assets and assumptions of liabilities of businesses in certain non-U.S. jurisdictions, including China, Malaysia, and Russia, until after the completion of the Kenvue IPO. On September 11, 2023, J&J transferred the equity interests in the majority of the Deferred Legal Entities (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein) to the Company that previously had been consolidated as Variable Interest
58

Entities in the Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements included herein include businesses in all jurisdictions in which we operate following the completion of the Separation, including any Deferred Local Business (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein). For more information regarding Deferred Local Businesses, see “Risk Factors—Risks Related to Our Relationship with J&J—The transfer of certain assets and liabilities from J&J to us contemplated by the Separation has not been completed and may be significantly delayed or not occur at all” in our Annual Report and Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein.
Provision for Taxes
On December 15, 2022, the European Union (“EU”) Member States formally adopted the EU’s Pillar Two Directive, which g enerally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation Development (“OECD”) Pillar Two Inclusive Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbors that effectively extend certain effective dates to January 1, 2027. The OECD continues to release additional guidance, including guidance on safe harbors for which we may qualify, and many countries have already implemented legislation consistent with the OECD Pillar Two Framework. Due to these new rules, our provision for taxes could be unfavorably impacted as the legislation becomes effective in countries in which we conduct business. However, based on our current analysis, currently enacted laws for Pillar Two do not have a significant impact on the Condensed Consolidated Financial Statements. We are continuing to evaluate the Model Global Anti-Base Erosion Rules for Pillar Two and related legislation, and their potential impact on future periods. In addition, in January 2025, the United States issued an executive order expressing disagreement with certain aspects of the Pillar Two framework. In June 2025, the Group of Seven (“G7”) issued a statement supporting the exclusion of U.S. parented groups from certain aspects of Pillar Two in exchange for the U.S. not imposing certain retaliatory taxes. Although the executive order and G7 statement do not have a binding effect, we will continue to monitor any changes to the OECD Pillar Two framework and enacted Pillar Two legislation resulting from these negotiations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
For quantitative and qualitative disclosures about market risk, see Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” included in our Annual Report.
Item 4. Controls And Procedures
Evaluation of Disclosure Controls and Procedures
As of September 28, 2025, the end of the period covered by this report, the Company’s management evaluated the effectiveness of the design and operation of its disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. The Company’s Chief Executive Officer and Chief Financial Officer reviewed and participated in this evaluation of Kenvue’s disclosure controls and procedures. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of September 28, 2025, the end of the period covered by this report, the Company’s disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
During the fiscal three months ended September 28, 2025, there were no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
During the fiscal three months ended September 29, 2024, the Company began a multi-year implementation of a new global enterprise resource planning (“ERP”) system, which will replace and enhance the Company’s existing operating and financial systems. The ERP system is designed to accurately maintain and enhance the flow of financial information, enhance operational
functionality, and accelerate information reporting to the Company’s management. The implementation is expected to occur in phases over the next several years.
The portion of the new ERP system implementation that has been completed to date did not result in significant changes to the Company’s internal control over financial reporting. As the phased implementation of the new ERP system continues, the Company will continue to assess whether this new ERP system implementation will materially affect, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
59

PART II—OTHER INFORMATION
Item 1. Legal Proceedings
The information called for by this item is incorporated herein by reference to Note 13, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein.
Item 1A. Risk Factors
In addition to the other information set forth in this Quarterly Report on Form 10-Q, the reader should carefully consider the factors in Part I, Item 1A, “Risk Factors,” included in our Annual Report. The following factors are in addition to those set forth in the Annual Report. Unless otherwise defined herein, capitalized terms related to the proposed Transaction used in the following factors have the meanings ascribed to them in the Notes to the Condensed Consolidated Financial Statements included in this Form 10-Q.
The number of shares of K-C common stock issuable in the First Merger in respect of one share of our common stock is fixed and will not be adjusted. Because the market price of K-C common stock may fluctuate, our shareholders cannot be sure of the market value of the stock consideration they will receive in exchange for their shares in connection with the potential Transaction.
At the time the First Merger is completed, each issued and outstanding share of our common stock will be converted into the right to receive the Merger Consideration, which consists of 1) 0.14625 shares of K-C common stock and 2) $3.50 in cash. The exchange ratio is fixed and will not be adjusted to reflect stock price changes of either our common stock or K-C common stock prior to the closing of the First Merger. Accordingly, the market value of the stock consideration that our shareholders will receive in the First Merger will vary based on the price of K-C common stock at the time our shareholders receive the Merger Consideration, and our shareholders cannot be sure of the market value of the share component of the Merger Consideration they will receive upon completion of the First Merger. The market price of K-C common stock is expected to fluctuate from the date hereof through and after the date the Transaction is completed, which could occur a considerable amount of time after the date hereof. Changes in the price of K-C common stock may result from a variety of factors, including general market and economic conditions, changes in K-C’s and our businesses, operations and prospects, changes in market assessments of the likelihood that the Transaction will be completed and/or the value that may be generated by the Transaction, changes with respect to expectations regarding the timing of the Transaction and regulatory considerations. Many of these factors are beyond our and K-C’s control. In addition, the use of cash and incurrence of indebtedness by K-C in connection with the financing of the Transaction may have an adverse impact on K-C’s liquidity, limit K-C’s flexibility in responding to other business opportunities and increase K-C’s vulnerability to adverse economic and industry conditions, each of which could adversely affect the market price of K-C’s common stock prior to closing and that of the combined company following closing.
Failure to complete the Transaction, or a delay in the completion of the Transaction, could negatively impact our business, results of operations, financial condition, and stock price.
The Merger Agreement is subject to a number of conditions that must be fulfilled to complete the Transaction. Those conditions include, among others, the approval by Company shareholders of the Merger Agreement and approval by K-C stockholders of the issuance of K-C Common Stock as Merger Consideration, certain regulatory approvals, the absence of government restraints or prohibitions preventing the completion of the Transaction, the effectiveness of a registration statement to be filed by K-C, the approval of the stock portion of the Merger Consideration for listing on Nasdaq, the continued accuracy of the representations and warranties by both parties, and the performance in all material respects by both parties of their obligations under the Merger Agreement. A number of the conditions are not within our control, and may prevent, delay, or otherwise materially adversely affect the completion of the Transaction. We cannot predict with certainty whether and when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that we will be able to timely consummate the Transaction as currently contemplated under the Merger Agreement or at all. Our business, results of operations, financial condition, or stock price could be adversely affected, potentially in a material way, by the failure to complete the Transaction, or by a delay in the completion of the Transaction, and we may suffer consequences that could adversely affect our business, results of operations, financial condition, and stock price, including the following:
•we may not realize any or all of the potential benefits of the Transaction, including any synergies that could result from combining our financial and business resources with those of K-C;
•we could be required to pay a termination fee of $1,136 million if the Merger Agreement is terminated in certain circumstances;
60

•matters relating to the Transaction will require substantial commitments of time and resources by our management which would otherwise have been devoted to day-to-day operations and other opportunities that may have been beneficial to us as an independent company;
•we have incurred and will incur further substantial expenses in connection with the Transaction, including legal, financial advisory, accounting, consulting and other advisory fees, severance/employee benefit-related costs, public company filing fees and other regulatory fees, and other costs relating to the Transaction regardless of whether the Transaction is consummated;
•we may be subject to legal proceedings related to the potential delay of, or failure to consummate, the Transaction;
•we may experience disruptions to our business resulting from the announcement and pendency of the Transaction, including adverse changes in our relationships with, or loss of, our customers, business partners and employees, which may not be reversible and may continue or even intensify in the event the Transaction is delayed or not consummated;
•under the Merger Agreement, we are subject to certain restrictions on the conduct of our business prior to completing the Transaction, which restrictions could adversely affect our ability to conduct our business as we otherwise would have done if we were not subject to these restrictions;
•we may experience negative reactions to the Transaction from the financial markets, including negative impacts on the market price of our common stock; and
•if the Transaction is not consummated, we may suffer from negative publicity and a negative impression of us in the investment community and a failure to close the Transaction may have a negative impact on the market price of our common stock.
Uncertainties associated with the Transaction may cause a loss of management and other key employees at either of the Company or K-C, which could adversely affect the future business and operations of the combined company following the Transaction.
We depend on the experience and industry knowledge of our management personnel and other key employees to execute our business plans. The success of the combined company after the Transaction will depend in part on its ability to retain or attract key management personnel and other key employees. During the pendency or following the completion of the Transaction, our current and prospective employees may experience uncertainty or have concerns regarding their roles within the combined company, the timing and completion of the Transaction or the operations of the combined company, any of which may have an adverse effect on our ability to retain or attract key management and other key personnel. If we are unable to retain personnel, including our key management, who are critical to the future operations of the combined company, we or the combined company could face disruptions in our operations, loss of existing customers, loss of key information, expertise or know-how and unanticipated additional recruitment and training costs. In addition, the loss of key personnel could diminish the anticipated benefits of the Transaction. No assurance can be given that the combined company, following the Transaction, will be able to retain or attract key management personnel and other key employees of the Company to the same extent that the Company has previously been able to retain or attract its own employees.
Current holders of our common stock will have a significantly reduced ownership and voting interest in the combined company after the Transaction and will therefore have less voting influence over the combined company.
In the Transaction, each of our shareholders will become a holder of common stock of the combined company. Upon completion of the Transaction, current Company stockholders are expected to own approximately 46% and current K-C stockholders are expected to own approximately 54% of the combined company on a fully diluted basis. As a result, the Company’s current shareholders will have less voting influence on the combined company and may have less influence on its management and policies than they now have over the Company.
Litigation against us or K-C, or the members of our or K-C’s board of directors, could prevent or delay the completion of the Transaction.
Our shareholders or K-C’s shareholders may file lawsuits against us, K-C, and/or the board of directors of either company in connection with the Transaction. These legal proceedings could delay or prevent the Transaction from being completed in a timely manner. The existence of litigation related to the Transaction could affect the likelihood of obtaining the required regulatory and stockholder approvals. Moreover, any litigation could be time-consuming and expensive and could divert our and K-C’s management’s attention away from their regular business and their focus on successful integration planning for the two companies. Any lawsuit adversely resolved against us, K-C or members of our respective boards of directors could have a material adverse effect on each company’s business, financial condition and results of operations.
61

The Merger Agreement limits our ability to pursue alternatives to the Transaction and may discourage other companies from trying to acquire us.
The Merger Agreement contains “no shop” covenants that restrict our ability to, directly or indirectly, among other things, solicit proposals relating to any alternative business combination or acquisition transactions and, subject to certain exceptions, enter into any discussions concerning, or provide confidential information in connection with, any such alternative business combination or acquisition transactions. These provisions, which include a $1,136 million termination fee payable under certain circumstances, may discourage a potential third-party acquirer that might have an interest in acquiring all or a significant part of the Company from considering or making such an acquisition proposal.
The need for regulatory approvals may delay the date of completion of the Transaction or may diminish the benefits of the Transaction.
The parties to the Merger Agreement are required to obtain the approvals of certain regulatory agencies before completing the Transaction. Satisfying any requirements of these regulatory agencies may delay the date of completion of the Transaction. The requisite regulatory approvals may not be received on a timely basis, or at all (in which case the Transaction could not be completed), or may contain conditions or restrictions on completion of the Transaction that cannot be satisfied. In addition, any conditions or restrictions imposed could have the effect of imposing additional costs on or limiting the revenues of the combined company following the Transaction, which might have an adverse effect on the combined company following the Transaction. Further, it is possible that, among other things, restrictions on the combined operations of the two companies, including divestitures, may be sought by governmental agencies as a condition to obtaining the required regulatory approvals. This may diminish the benefits of the Transaction to the combined company or otherwise have an adverse effect on the combined company following the Transaction.
If the Transaction is consummated, the combined company may not perform as we or the market expects and may fail to realize the projected benefits and cost savings of the Transaction, which could adversely affect the value of K-C common stock, which our current shareholders will own following the completion of the Transaction.
The success of the Transaction will depend, in part, on K-C’s ability to realize the anticipated benefits and cost savings from combining our and K-C’s respective businesses, including operational and other synergies that we believe the combined company will be able to achieve. The anticipated benefits and cost savings of the Transaction may not be realized fully or at all, may take longer to realize than expected or could have other adverse effects that we do not currently foresee. Risks associated with the combined company following the Transaction include:
•the integration process will require significant time and focus from management following the Transaction and may, for the combined company, result in the loss of key employees, the disruption of ongoing businesses or inconsistencies in standards, controls, procedures, and policies;
•it is possible that key employees might decide not to remain with the combined company after the Transaction is completed, and the loss of key personnel could have a material adverse effect on the resulting entity’s results of operations, financial condition, and growth prospects;
•the results of operations of the combined company and the market price of the combined company’s common stock after the completion of the Transaction may be affected by factors different from those currently affecting the independent results of operations of each of the Company and K-C;
•there could be potential unknown liabilities and unforeseen expenses associated with the Transaction that were not discovered in the course of performing due diligence; and
•the issuance of shares of the K-C Common Stock in the Transaction could depress the market price for the combined company’s common stock.
In addition, in connection with the proposed Transaction, K-C is expected to incur significant additional indebtedness to finance the Cash Consideration and pay fees and expenses relating the proposed Transaction. This increased indebtedness will reduce the amount of cash flow available to service K-C’s debt, including any of our debt assumed by K-C in connection with the proposed Transaction, in future periods. If the combined company’s cash flows and capital resources are insufficient to fund debt service obligations, it could face substantial liquidity problems and could be forced to reduce or delay investments and capital expenditures or to dispose of material assets or operations, seek additional debt or equity capital or restructure or refinance its indebtedness.
62

If the Transaction were to fail to qualify as a “reorganization” within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”), the Company’s shareholders may be required to pay additional U.S. federal income taxes.
The Transaction is intended to qualify as a “reorganization” within the meaning of Section 368(a) of the Code, and the Company and K-C intend to report the Transaction consistent with such qualification. However, the closing is not conditioned upon the receipt of an opinion of counsel or a ruling from the Internal Revenue Service (“IRS”) that the Transaction will so qualify, and neither K-C nor the Company intends to request a ruling from the IRS regarding the U.S. federal income tax consequences of the Transaction. Consequently, no assurance can be given that the Transaction will so qualify, that the IRS will not challenge such qualification, or that a court would not sustain such a challenge. If the Transaction were to fail to qualify as a “reorganization” within the meaning of Section 368(a) of the Code, a holder of the Company’s common stock generally would recognize gain or loss for U.S. federal income tax purposes upon the exchange of the Company’s common stock for K-C common stock in the Transaction. This would be in addition to income with respect to the Cash Consideration, which generally would constitute taxable income to a holder of the Company’s common stock in an amount equal to the lesser of the amount of such cash and the holder’s realized gain in its K-C common stock if the Transaction qualified as a “reorganization” within the meaning of Section 368(a) of the Code.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
There were no sales of equity securities by the Company during the fiscal nine months ended September 28, 2025.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
During the fiscal three months ended October 1, 2023, our Board authorized a share repurchase program, under which we are authorized to repurchase up to 27,000,000 shares of our outstanding common stock in open market or privately negotiated transactions. The program has no expiration date and may be suspended or discontinued at any time. The intent of this repurchase program is to offset dilution from the vesting or exercise of equity-based awards under the Kenvue 2023 Plan (as defined in Note 7, “Stock-Based Compensation,” to the Condensed Consolidated Financial Statements included herein).
The following table represents our purchases of common stock during the fiscal three months ended September 28, 2025:

(Shares in Thousands) |  |  |  |  |  |  |  |
Period |  | Total Number of Shares Purchased |  | Average Price Paid Per Common Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs
June 30, 2025 – July 27, 2025 |  | 11 |  |  | $ | 20.51 |  |  | 11 |  |  | 10,115 |
July 28, 2025 – August 24, 2025 |  | 762 |  |  | $ | 21.46 |  |  | 762 |  |  | 9,353 |
August 25, 2025 – September 28, 2025 |  | 2,740 |  |  | $ | 19.80 |  |  | 2,740 |  |  | 6,613 |
Total number of shares purchased |  | 3,513 |  |  |  |  |  |  |

Item 5. Other Information
Insider Trading Arrangements and Policies
During the fiscal three months ended September 28, 2025, none of the Company’s directors or officers (as defined in Rule 16a1(f) under the Exchange Ac t) adopted or terminated an y contract, instruction, or written plan for the purchase or sale of the Company’s securities intended to satisfy the conditions of the affirmative defense provided by Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
63

Item 6. Exhibits

Exhibit Number |  | Exhibit Description
2.1 |  | Agreement and Plan of Merger, dated as of November 2, 2025, by and among Kenvue Inc., Kimberly-Clark Corporation, Vesta Sub I, Inc., and V esta Sub II, LLC., filed as Exhibit 2.1 to the Current Report o n Form 8-K filed by Kenvue Inc. with the SEC on November 3, 2025, and incorporated herein by reference
3.1 |  | Amended and Restated Certificate of Incorporation of Kenvue Inc., effective as of May 3, 2023, filed as Exhibit 3.1 to the Current Report on Form 8-K filed by Kenvue Inc. with the SEC on May 8, 2023, and incorporated herein by reference
3.2 |  | Amended and Restated Bylaws of Kenvue Inc., effective as of May 3, 2023, filed as Exhibit 3.2 to the Current Report on Form 8-K filed by Kenvue Inc. with the SEC on May 8, 2023, and incorporated herein by reference
10.1 |  | Offer letter between Kirk Perry and Kenvue Brands LLC, dated July 13, 2025, filed as Exhibit 10.1 to the Current Report on Form 8-K filed by Kenvue Inc. with the SEC on July 14, 2025, and incorporated herein by reference†
10.2 |  | Restricted Share Unit Award Agreement for July 31, 2025 grant to Kirk Perry under Kenvue Inc’s. Long-Term Incentive Pl an*†
10.3 |  | Nonqualified Stock Option Award Agreement for July 31, 2025 grant to Kirk Perry under Kenvue Inc’s. Long-Term Incentive Plan*†
10.4 |  | Offer Letter, dated as of November 2, 2025, by and between Kenvue Brands LLC and Kirk Perry, filed as Exhibit 10.1 to the Current Report on Form 8-K filed by Kenvue Inc. with the SEC on November 3, 2025, and incorporated herein by reference†
10.5 |  | Amended and Restated Executive Severance Pay Plan of Kenvue Inc. and U.S. Affiliated Companies, filed as Exhibit 10.2 to the Current Report on Form 8-K filed by Kenvue Inc. with the SEC on November 3, 2025, and incorporated herein by reference†
31.1 |  | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2 |  | Certification of the Chief Finan cial Officer pursuant to Secti on 30 2 of the Sarbanes-Oxley Act of 2002 *
32.1 |  | Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
32.2 |  | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
101.INS |  | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | Inline XBRL Taxonomy Extension Definition Document
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
* Filed herewith
** Furnished herewith
† Indicates management contract or compensatory plan

64

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Kenvue Inc.
Date: November 3, 2025 | /s/ AMIT BANATI
| Amit Banati
| Chief Financial Officer (Principal Financial Officer)
Date: November 3, 2025 | /s/ HEATHER HOWLETT
| Heather Howlett
| Chief Accounting Officer (Principal Accounting Officer)

65